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Abstract
High concentrations of silver nanoparticles (AgNP) are increasingly present as active
ingredient in everyday consumable products for antibacterial purposes causing
increased human exposure and high risk of adverse effect development. In this thesis,
AgNP were encapsulated in dipalmitoyl phosphatidylcholine (DPPC)-based liposome
(forming Lipo-AgNP), to enhance intracellular delivery and associated cytotoxicity,
and suppress AgNP-induced inflammation.
It was noted that as a result of the encapsulation, Lipo-AgNP induced significantly
reduced cell viability of THP1 monocytes and THP1 differentiated macrophages
(TDM) at a notably lower dose than that of uncoated AgNP. The induced cytotoxicity
was shown to result in an increased level of DNA fragmentation causing interruption
at the S-phase of the cell cycle. In addition, Lipo-AgNP induced redox imbalance
through suppression of both GSH levels and ROS levels. Possibly as a consequent and
in addition to increased Bax to Bcl-2 ratio, it was found that the predominate form of
cell death upon exposure to Lipo-AgNP was caspase-dependent apoptosis. It was also
found that the encapsulation resulted in improved intracellular uptake of the
nanoparticle changing the pharmacokinetics of uncoated AgNP.
It was found that AgNP induced release of IL-1β, IL-6, IL-8 and TNF-α in THP1
monocytes all of which were suppressed by Lipo-AgNP exposure. AgNP was also
found to induce release of IL-6, IL-8 and TNF-α in TDMs while Lipo-AgNP
suppressed these cytokine releases. However, both AgNP and Lipo-AgNP suppressed
IL-1β and TNF-α release in LPS-stimulated THP1 monocytes and TDM respectively.
AgNP-induce inflammation was found to be associated with induction of STAT3
protein expression in LPS-stimulated THP1 monocytes, and non-LPS- and LPSstimulated TDMs. Whereas Lipo-AgNP may have suppressed AgNP-induced
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inflammation through STAT3, as its exposure was associated with STAT3 protein
expression levels comparable with the control untreated cells highlighting the potential
of Lipo-AgNP in treatment of bacteria induced inflammatory diseases.
These findings showed that encapsulation of AgNP in DPPC liposome enhanced
AgNP cytotoxicity by improving the intracellular delivery of the nanoparticle and also
suppressed AgNP-induced inflammation which may be linked to the suppressed ROS
generation. These processes resulted in redox imbalance within the cells causing
induction of caspase dependent apoptosis.
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1

Nanotechnology: A brief introduction

Nanotechnology is the intentional engineering and manipulation of particulate matter
into a physical state of between 1 nm and 100 nm that can be rearranged or
reassembled into nano-systems with improved function (Nasrollahzadeh et al., 2019).
The emergence of nanotechnology and its application has put Ireland in the forefront
of scientific research in the last decade (Doran and Ryan, 2019). Nanoparticles are the
ultimate result of technological modification of matter and depending on their sizes,
they are a few degrees larger than an atom consequent of molecular processing of
matter. As they possess enhanced characteristics such as auto-reactive stability and
self-reassembly, they are easily adaptable and can be modified to achieve a specific
particle with required properties with a high surface area when compared to
conventional substances (Cheng et al., 2012, Kango et al., 2013). Nanotechnology, as
a new branch of science, has gained attention in the last two decades and is rapidly
expanding from the academic arena into industry. Due to the possible advancements
that can be achieved by nanotechnology, it has been estimated that nanotechnology
will impact the global economy by about three trillion dollars by 2020, making the
field highly viable economically speaking (Roco, 2017). This could be attributed to
the unique physicochemical properties of nanoparticles at the interface of chemistry,
medicine, physics and engineering. This introduction will briefly look at the
contribution of nanotechnology in different fields with a focus in medicine and the
concept of nanoparticle enabled drug delivery systems for disease treatment. In
addition, the popularity of silver nanoparticles (AgNP) in medicine will be explored
while the imminent harmful effects its wide application portends and possible ways
by which AgNP can be modified for better application will be introduced as the main
objective of this study.

2|Page

1.1
1.1.1

Industrial application of Nanotechnology
Food industry

With the increasing awareness and demand for healthy food products, research has
been devoted into devising tools for improving food shelf life and nutrient absorption.
Nanotechnology as an enabling technology has been widely employed in achieving
these fit in recent years for food preservation and delivery of nutraceuticals (Huang et
al., 2010, Bajpai et al., 2018). Nanoparticles are added to packaging materials to act
as barrier molecules or as antibacterial agents and have displayed great promise
(Bajpai et al., 2018). One of the more widely utilised nanoparticle additives for this
purpose is that of silver (AgNP) primarily due to silver’s innate antibacterial
properties. AgNP can be added to food products in form of an edible biodegradable
casing for food products such as fruits, meat and poultry or included as an active
ingredient in the polymeric matrix of the packaging material (Carbone et al., 2016). In
fact, there are studies that have investigated the preservative effect of AgNP containing
packaging on asparagus (An et al., 2008), poultry meat (Banach et al., 2016), orange
juice (Emamifar et al., 2011), and strawberries (Zhang et al., 2018) all of which
improved shelf life by inhibiting the activities of pathogens such as E. coli, S. aureus,
moulds and yeasts. In addition to AgNP, Zinc oxide (ZnO2) and titanium dioxide
(TiO2) have been shown to be active against wide variety of food pathogens such as
S. aureus, Salmonella typhi and Klebsiella pneumoniae (Venkatasubbu et al., 2016),
while their used in preservation of food items like orange juice, strawberries, and
liquid egg albumen have been documented (Bajpai et al., 2018).
Nano-encapsulation is a well-established technique used in retaining and enhancing
the release of functional nutrients and flavour in food items. Typically these
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encapsulations are carbohydrate based delivery systems made from starch, cellulose,
chitosan and dextrin which have been modified (Fathi et al., 2014). For example,
phosphatidylcholine based liposomes have been employed in delivery of vitamin C
and this encapsulation is found to be more effective at maintaining bioavailability of
the nutrient likely through controlled release of the content when compared with free
supplements when administered orally (Davis et al., 2016). In general, nanotechnology
in the food industry has made it possible to extend the shelf life of fresh food products
in a cost effective and pragmatic manner. While nanoparticles used for improvement
of nutraceutical delivery may be relatively non-toxic, nanoparticles used in packaging
such as AgNP which may sometime leash into the main food product portend possible
toxicity issue. While it has been estimated that up to 80 µg of AgNP can be consumed
daily (Frohlich and Frohlich, 2016), there is limited and conflicting reports on toxic
effect of ingested AgNP. There some reports considering AgNP to be safe for
consumption without toxic effect and there are others that have reported significant
toxicity upon AgNP ingestion (<125 mg/body weight) with accumulation of the
nanoparticle within organs such as the liver, kidneys and small intestine (Kim et al.,
2008, Shahare and Yashpal, 2013, Park et al., 2010b). While this may be a source of
concern, it is worth considering if the level of AgNP trialled in these studies are
achievable through diet.
1.2

Cosmetic industry

There is a considerable usage of nanotechnology in the cosmetic industry with
cosmetic manufacturers now including nanomaterials in their product for variety of
reasons. In the lucrative sun screen industry, nanoparticles of zinc oxide and titanium
dioxide are routinely added to sunscreen as by virtue of their sizes, they act as efficient
filters of UV radiation without serious health hazards (Morganti, 2010) or unsightly
4|Page

“white streaking” when the cream is applied due to the reduction in particle size.
Liposomes prepared from varying lipid formulations of synthetic or natural lipids are
also widely used in cosmetics such as ethosomes and transferosomes that are used to
improve transdermal delivery of active cosmetic ingredients. The primary justification
for inclusion of liposomes in cosmetics is to enhance the transdermal delivery of
cosmetic ingredients based on the ability of the liposomal lipid bilayer to fuse with
cell membranes and alter the membrane fluidity for easy entry and delivery of
liposomal content (Verma and Pathak, 2010). In addition to these, AgNP are important
ingredients in many cosmetic products, having been shown to be effective antibacterial
agents, as active ingredients in bathing products and because of AgNP activity against
different yeast strains, they are also present in different dental products such as
mouthwash and toothpaste (Abadi et al., 2013, Prabhu and Poulose, 2012). A practical
example

is

the

already

commercialised

(https://product.statnano.com/product/4502)

and

Silvosept
Royal

mouth
Denta

rinse
Silver

toothpaste/toothbrushes (http://www.royaldenta.com/en/), which all contain AgNP as
main active ingredient. Although nanotechnology is commonplace in the cosmetic
industry, just like any other industry, the use of nanoparticles in the cosmetic industry
is not without safety concerns due to the general repeated use of many cosmetics.
1.3 Nanomedicine
Nanotechnology was first conceptualised in medicine by Dr. Richard P. Feynman in
the late 1950s, when describing the creation of molecular machines with atomic
precision for use in engineering and medicine. He described the use of molecular
mechanical machines capable of carrying out surgery or even ones that can
permanently reside in the body for the functional assistance of damaged organs
(Feynman, 1960). Nanotechnology has strongly influenced the field of medicine,
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influencing how diseases are treated particularly with use of advanced drug delivery
systems from both natural and synthetic compounds. For instance, researchers in the
Wyss institute of Harvard University developed a “nano-robot” that can specifically
target cancer cells to deliver anticancer drugs (Douglas et al., 2012). Nano-robots that
can treat cardiovascular diseases such as those that can engage in blood vessel repair
by acting as artificial platelets (Trihirun et al., 2013), or those that an treat patient with
coronary artery occlusion (Cavalcanti et al., 2006) are also in development. One of the
most important applications of nanotechnology in medicine is in drug delivery
systems, it is currently hypothesised that most conventional drugs have poor
bioavailability and aqueous solubility limiting their absorption and retention within
biological system (Khadka et al., 2014), as such significant efforts are being made to
improve the efficiency of many traditional drugs such as but not limited to
chemotherapeutics.
Many nanoparticles are thought to have improved pharmacokinetic properties due to
their physical nature and reduced size, they can target specific cells for selective action
dependent on the particle type. These particles can easily penetrate target cells and
accumulate into subcellular structures to modify cellular processes which may be
beneficial in the treatment of lifelong diseases such as diabetes, cancer and kidney
diseases (Barua and Mitragotri, 2014). As such many of these nanoparticles have
already been approved by the Federal Drug Administration in the United States for
clinical use (Table 1-1). Nanoparticles that are popularly used in research for
therapeutic purposes include encapsulated mRNA (siRNA) or DNA (in gene therapy),
inorganic metal and metal complexes or chemotherapeutic agents with pharmacologic
abilities. However, some of these nanoparticles do not easily traverse the cell
membrane, requiring delivery systems to alleviate such difficulties. Thus, different
6|Page

nanoparticle delivery systems have been developed, some of which include liposomes,
micelles, chitosan and synthetic dendrimers (Park et al., 2008, Wang et al., 2013a,
Sanyakamdhorn et al., 2013, Hasan et al., 2014). The entrapment of both hydrophobic
and hydrophilic drugs into liposomes is possible and this helps to bypass the toxicity
associated with anticancer drugs (Koudelka et al., 2010). In particular, nanoparticles
enabled delivery systems like liposomes are well established for disease treatment
such as in DoxilTM (liposomal doxorubicin) which is approved by the FDA for
treatment of Kaposi sarcoma and ovarian cancer (Table 1-1). As such, liposomal
encapsulation represents an effective route which enhances drug therapeutic effect. In
addition, modification of liposomes allows for a passive or active tumour targeting
(Figure 1-1). This effect facilitates an efficient drug payload into the malignant tumour
cells, while the non-malignant cells become minimally impacted. Encapsulation of
doxorubicin within the DPPC based liposome enhances the cytotoxicity of the drug
and at the same time suppress the toxic side effects, thus improving the antitumoural
therapeutic efficacy in comparison to conventional doxorubicin (Barenholz, 2012).

Table 1-1. List of nanodrugs approved by the FDA for clinical application
(Adapted from (Bobo et al., 2016, Ventola, 2017)

Liposomal
nanoparticle

Trade
Name
(Manufacturer)

Component

Delivery
method

Indication(s)

AmBIsome (Gilead
Sciences)
DepoDur
(Pacira
Pharmaceuticals)

Liposomal
amphotericin B
Liposomal morphine
sulphate

Intravenous
infusion
Epidural
administration

Fungal/protozoal
infections
Postoperative
analgesia

Doxil (Janssen)

Doxorubicin
HCl
liposome injection

Intravenous
infusion

Kaposi’s
sarcoma,
ovarian
cancer,
multiple myeloma

Marqibo (Spectrum
Pharmaceuticals)

Liposomal vincristine

Intravenous
injection

ALL

Nanoparticle
benefit
compared
to
conventional
formulation
Decreased
nephrotoxicity
Extended release
Increased
delivery
to
disease
site,
decreased
systemic toxicity
of free drug
Increased
delivery
to
tumour
site,
decreased
systemic toxicity
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Polymer NPs

Onivyde
(Ipsen
Biopharmaceuticals)

Liposomal irinotecan

Intravenous
injection

Pancreatic cancer

Visudyne (Bausch
and Lomb)

Liposomal
verteporfin

Intravenous
injection

Wet AMD, ocular
histoplasmosis,
myopia

Vyxeos
(Jazz
Pharmaceuticals)

Liposomal
daunorubicin
cytarabine

intramuscular,
intrathecal, or
subcutaneous
injection

AML, AML with
myelodysplasiarelated
changes

Adagen (Leadiant
Biosciences)

Pegademase bovine

intramuscular
injection

SCID

Cimzia (UCB)

Certolizumab pegol

Pills
or
intravenous
injection

Crohn’s
rheumatoid
psoriatic
ankylosing
spondylitis

Copaxone (Teva)

Glatimer acetate

Subcutaneous
injection

Multiple sclerosis

Eligard (Tolmar)

Leuprolide
acetate
and polymer

Subcutaneous
injection

Prostate cancer

Macugen (Bausch
and Lomb)

Pegaptinib

Neulasta (Amgen)

Pegfilgrastim

Pegasys
(Genentech)

Pegylated IFN alpha2a
Pegylated IFN alpha2b
Pegylated IFN beta1a

PegIntron (Merck)
Plegridy (Biogen)

Nanocrystal
nanoparticles

Intravitreal
injections
On-body
injection
Subcutaneous
injection
Subcutaneous
injection
Subcutaneous
injection

disease,
arthritis,
arthritis,

Neovascular AMD
Chemotherapyinduced neutropenia
Hepatitis B, hepatitis
C
Hepatitis C
Multiple sclerosis

Coagulation factor IX
(recombinant),
glycopegylated

Intravenous
injection

Hemophilia B

Somavert (Pfizer)

Pegvisomant

Subcutaneous
injection

Acromegaly

Zilretta
(Flexion
Therapeutics)

Triamcinolone
acetonide
ER
injectable suspension

Intra-articular
injection

Osteoarthritis
pain

Estrasorb (Novavax)

Micellar estradiol

Topical
application of
emulsion

Vasomotor symptoms
in menopause

Avinza (Pfizer)

Morphine sulfate

Oral
administration

Psychostimulant

Emend (Merck)

Aprepitant

Oral
administration

Antiemetic

Focalin (Novartis)

Dexamethylphenidate
HCl

Intravenous
injection

Psychostimulant

Invega
Sustenna
(Janssen)

Paliperidone
palmitate

Intramuscular
injection

Schizophrenia,
schizoaffective
disorder

Rebinyn
Nordisk)

Micellar NPs

and

(Novo

knee

Increased
delivery
to
tumour
site,
decreased
systemic toxicity
Increased
delivery to site of
diseased vessels,
photosensitive
release
Increased
efficacy through
synergistic
delivery of coencapsulated
agents
Longer
circulation time,
decreased
immunogenicity
Longer
circulation time,
greater
stability in vivo
Controlled
clearance
Longer
circulation time,
controlled
payload delivery
Greater aptamer
stability
Greater protein
stability
Greater protein
stability
Greater protein
stability
Greater protein
stability
Longer half-life,
greater
drug
levels
between
infusions
Greater protein
stability
Extended release
Controlled
delivery
Greater
drug
loading
and
bioavailability,
ER
Greater
absorption and
bioavailability
Greater
drug
loading
and
bioavailability
Slow release of
injectable lowsolubility drug
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NanOss
(RTI
Surgical)
Ostim
(Heraeus
Kulzer)
OsSatura
(IsoTis
Orthobiologics)
Rapamune (Wyeth
Pharmaceuticals)
Ritalin
(Novartis)

Inorganic
nanoparticles

LA

Hydroxyapatite
Hydroxyapatite
Hydroxyapatite
Sirolimus

Injectable
paste
Injectable
paste
Injectable
paste
Oral
administration

Mimics
bone
structure
Mimics
bone
structure
Mimics
bone
structure
Greater
bioavailability
Greater
drug
loading
and
bioavailability
Greater
bioavailability
simplifies
administration
Greater
drug
loading
and
bioavailability

Bone substitute
Bone substitute
Bone substitute
Immunosuppressant

Methylphenidate HCl

Oral
administration

Psychostimulant

Tricor (AbbVie)

Fenofibrate

Oral
administration

Hyperlipidemia

Zanaflex (Acorda)

Tizanidine HCl

Oral
administration

Muscle relaxant

Dexferrum
(American Regent)

Iron dextran

Intravenous
injection

Iron deficiency
CKD

in

Feraheme (AMAG
Pharmaceuticals)

Ferumoxytol

Intravenous
infusion

Iron deficiency
CKD

in

Ferrlecit
Aventis)

Sodium
ferric
gluconate complex in
sucrose injection

Intravenous
infusion

Iron deficiency
CKD

in

Iron sucrose

Intravenous
injection

Iron deficiency
CKD

in

(Sanofi-

Venofer (American
Regent)

Increased dose
Prolonged, steady
release with less
frequent dosing
Increased dose
Increased dose

AMD- Age related macular degeneration, ALL- Acute lymphoblastic leukaemia, CKDChronic kidney disease

Nanoparticles have also found favour in the medical and diagnostic imaging of internal
organs and tissues due to their interactions with mammalian cells owing to their
modifiable physicochemical characteristics such as size, shape, optical, magnetic and
electronic properties (Nam et al., 2013). Iron oxide and silica based nanoparticles have
been used to develop multifunctional imaging platforms such as MRI/optical dual
modal imaging, which possess several advantages over existing positron emission
tomography (PET) and computed tomography (CT) both of which have radiation
related concerns (Lee et al., 2015, Kim et al., 2007, Louie, 2010). Iron oxide is a
magneto-responsive metal that is also biocompatible due to its degradable nature
within biological systems. This in addition to its optical properties makes it a good
imaging material for MRI. Kim et al. (2007) described a silica based nanoparticle with
paramagnetic shell containing a luminescent core offering the possibility of using the
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magnetic field of the MRI and the optical feature of the nanoparticle core for the
multimodal imaging. The paramagnetic shell can also be functionalised by peptides or
moieties of interest offering the possibility of specifically targeting cancer cells. These
techniques, through the magnetic/optical properties of the nanoparticles and the
magnetic field of the MRI thus offer a way of detecting and monitoring changes in a
living tissue for diagnostic purposes without the need for using radioactive tracers used
during a PET or CT scan. In addition to all these, nanoparticles, in particular AgNP,
are used as coating materials in medical garments, wound bandages, medical implants
and devices as antibacterial (Chaloupka et al., 2010). Conventional disinfection only
exerts bactericidal effect that may not be effective after disinfection. On the contrary,
AgNP coatings on medical devices and clothing materials remain effective against
wide range of bacterial strains a long as the nanoparticle is retained on the material
surface. Nanotechnology seem to be playing a prominent role in medicine from use as
therapeutic agent based on the bactericidal properties to imaging and diagnostic
purposes. These innovations are possible due to the properties that are peculiar to
nanoparticles (see section 1.4) and increased nanotechnology research in the medical
field does not show any sign of slowing down.

1.4 Physiochemical properties of nanoparticles in medicine
Nanoparticles have various properties that facilitate enhanced pharmacologic
behaviour when compared with larger molecules. As such, significant efforts are being
made in research modifying the nanoparticles size, shape, surface area and surface
chemistry to maximise their benefits for medical purposes.
Different nanoparticles such as gold nanoshells, liposomes and micelles are
synthesised in various ways and the sizes and shapes of these nanoparticles can be
controlled during the synthesis process based on the intended functionality.
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Nanoparticles can agglomerate into larger sized particles during synthesis which may
enhance or indeed suppress the nanoparticle cytotoxicity depending on composition.
The surface chemistry of nanoparticles can be modified by adding reactive groups or
molecules such as antibodies to surfaces in targeted drug delivery systems (Figure
1-1).

Figure 1-1. Physicochemical properties of nanoparticles:
Nanoparticles have different physicochemical properties such as charged surfaces,
ability to agglomerate and conjugate other groups to the surfaces or controlled
synthesis that facilitate specific shapes and sizes to be obtained. These properties allow
nanoparticles to possess a more reactive nature in comparison to conventional particles
within the biological environment.

1.4.1

Size and surface area

As stated, nanoparticles are small particles with sizes ranging between 1 nm and 100
nm giving them a high surface area to volume ratio. By virtue of this property,
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nanoparticles have a high surface area of interaction per mass unit compared with more
bulky particles, making some particles that are otherwise inert such as gold, be reactive
in the nanometre range (Nel et al., 2006). A nanoparticle’s small size which is
controllable also allow them to easily infiltrate body tissues and fluids which are
otherwise hindered when in the bulk form. In essence the size and surface area of these
particles contribute to rate at which these nanoparticles are endocytosed, distributed,
retained and eliminated within biological systems (Powers et al., 2007). As
nanoparticles do not simply diffuse through the cell membrane, the extensive research
into nanoparticles movements into normal and cancer cell lines have shown they are
internalised by endocytotic means in a size-dependent fashion (Tsai et al., 2012, Jiang
et al., 2008). Nanoparticles <200 nm are known to be internalised by clathrin coated
vesicles while larger nanoparticles, usually 500 nm are known to be internalised by
caveolae mediated endocytosis (Rejman et al., 2004). In immune cells such as
macrophages however, nanoparticles are prone to phagocytosis and indeed research
has shown that nanoparticles less than 500 nm in size enter immune cells through the
phagocytotic pathway while particles with larger particle sizes of between 2 and 3 µm,
approximately around the size of bacteria cells, exhibit maximal phagocytotic uptake.
Smaller nanoparticles such as liposomes can now be engineered for maximal uptake
by mammalian cells based on their size (Chithrani et al., 2010). For example, different
lipid formulations can be used to prepare liposomes of specific sizes that can be more
easily internalised by mammalian cells. There are studies that have used extrusion
methods for instance, with a polycarbonate membrane of predetermined size to make
liposomes of suitable sizes that can be easily internalised by mammalian cells. Such
production methods of liposomes have been shown to improve the activity of
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chemotherapeutic drug due to improved drug uptake by the cells (Gosangari and
Watkin, 2012).
In addition to uptake, intracellular localisation of nanoparticles has also been shown
to be size dependent. Oh et al., (2011) showed that gold nanoparticles (AuNP) that
were 2.4 nm in size were localised in the nucleus while those larger than that up to 89
nm were localised in the cytoplasm after internalisation. Findings like these form the
basis of how to modify nanoparticles size to evade or harness the immune system and
how to localise nanoparticles in subcellular organelles of interest to maximise their
effect.
1.4.2

Surface chemistry

The surface chemistry of nanoparticles such as charge or attached chemical groups is
an important factor that determines their reactivity and ultimately can control their
function. Many nanoparticles have been modified to change their surface chemistry to
suit specific purposes. Rod shaped gold nanoparticles (AuNP) and DNA because of
its charge, cannot easily permeate or enter the cell. Both the AuNP and DNA have had
their surfaces modified by coating them with lipid layers while DNA has also been
electrostatically conjugated to cationic liposomes to facilitate their transport into the
cell which resulted in improved uptake (Chithrani et al., 2010, Fillion et al., 2001,
Dichello et al., 2017, Ewert et al., 2016). As liposomes and micelles have lipid layers
that can interact and fuse with the cell membrane through hydrophobic interactions
resulting in improved uptake, they can be used to deliver higher concentrations of
nanoparticles

intracellularly.

Silicon

nanoparticle’s

(SiNP)

are

important

semiconductors that are used in optoelectronics, but its hydrophobicity hinders its
application in biomedicine such as applications of internal imaging of tissues since the
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biological system is aqueous and SiNP are not stable in aqueous environments. Pan et
al., (2013) described a method of modifying the SiNP surface through coating it with
silicon dioxide (SiO2) to make it more hydrophilic allowing for more biocompatible
applications. ZnO2 nanoparticles are widely used in sunscreen, due to its UV
protection properties, but some studies have indicated potential cytotoxicity of the
nanoparticles making its application in cosmetic products worrisome. In order to
negate this, some researchers alter the surface properties and indeed a study has shown
that by surface coating ZnO2 with poly methyl acrylic acid (PMAA), the cytotoxicity
was reduced the nanoparticles retained their UV protection characteristics (Yin et al.,
2010).
Liposomes are made up of phospholipids which mimics the lipid bilayer of the plasma
membrane. The phospholipids component of the liposomes is amphiphilic with a polar
head and hydrophobic tail (Figure 1-2). The polar head is comprised of phosphate
group and glycerol both containing oxygen that can form hydrogen bond in aqueous
environment. The hydrophobic tail on the other hand is made up of long chain fatty
acid which aligns with the hydrophobic tail of another adjacent phospholipid, creating
a hydrophobic core that can hold non-polar hydrophobic drugs in the bilayer so
formed. The compatibility of liposomal surface chemistry with that of plasma
membrane allows adsorption of liposome to the cell membrane where the liposome is
internalised via receptor mediated endocytosis or through fusion with the plasma
membrane inducing membrane invagination and internalisation (Bozzuto and
Molinari, 2015).
The pH of the environment where the particles are delivered can also affect the
function of the nanoparticle based on its surface chemistry and this phenomenon has
been utilised to trigger drug release in the tumour microenvironment that is
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characterised with acidic pH. For example, carrageenan oligosaccharide capped AuNP
have been recently shown to significantly release epirubicin in an acidic pH inducing
cell death in HCT-116 colorectal cancer cells (Chen et al., 2019). The surface of
nanoparticles can alter their movement within aqueous biological systems and
subsequently affect their reactivity or delivery. Such surface properties facilitate their
use in variety of ways such as in biomedical sensors, coatings of medical implants and
drug delivery systems. For example, a AgNP functionalised titanium implant surface
was developed to prevent postoperative infection due to resistant strains of
Staphylococcus epidermidis and Staphylococcus aureus due to the antimicrobial
properties of AgNP (Wang et al., 2016).

Figure 1-2. Liposomal modification for drug delivery:
Liposome consists of lipid bilayer and an aqueous core which can both be used for
drug transport in disease treatment. Cholesterol is often added to the recipe for
preparing the liposome to restrict the fluidity of the phospholipid as in the plasma
membrane.
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As stated earlier, nanoparticles like AuNP and even conventional drugs are often
coated with lipid layers as in liposomes to enable compatibility with the mammalian
cell membrane, improving intracellular delivery. The liposome offers other functional
benefits due to the active phospholipid heads that can be conjugated to variety of
compounds for targeted delivery. For instance, conjugation of polyethylene glycol
(PEG) to surface of liposome has been used to improve their bioavailability by making
them undetectable to phagocytes, which eliminate them from the system (Milla et al.,
2012). PEGylation or the use of other linkers also facilitate the addition of active
groups such as folate and monoclonal antibodies to the liposomal surface for
selectively targeting specific cells (Error! Reference source not found.). Folate is often
used because of the high expression of folate receptor on cancer cells surfaces which,
the cancer cells utilise to bind folate within the body for their uncontrolled
proliferation (Marchetti et al., 2014, Carron et al., 2018). On the contrary, monoclonal
antibodies represent a more flexible approach for targeted delivery due to countless
number of unique receptors or surface antigens against which antibodies can be
developed. Conjugation of these active surface agents to nanoparticle surfaces
facilitates delivery of the nanoparticles or drugs to the tumour cells for selective cancer
cell eradication (Steichen et al., 2013).
1.4.3

Shape

As stated previously nanomaterials have tuneable sizes but their shape is also
controllable during their synthesis. The shapes of nanoparticles can be altered during
the last synthesis stage and typically involves nucleation of the nanoparticles from
seed. The nucleation process involves the fusion of nanoparticle nuclei known as the
seeds forming a template on which the nanoparticle crystals grow. Just like the size,
the shape of a nanoparticle is paramount to its biological function and reactivity.
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Generally, nanoparticles that are round or spherical in shape are easily endocytosed in
comparison to rod or tube shaped nanoparticles (Champion and Mitragotri, 2006).
This is because the shape affects endocytosis by interfering with the manner in which
the membrane wraps over the nano-construct during contact. As such, the reduced
endocytosis of nano-rods or other shapes is most likely due to the inability of the cell
to initiate the necessary actin-dependent membrane kinetics required for endocytosis.
This reason may explain why most nanoparticles of biomedical importance are
spherical in nature. On the contrary, there are reports from new studies on
nanoparticles of different shapes with potential application in drug delivery. Zhao et
al, (2017) reported that in addition to their ability to encapsulate more particles, long
rod nanoparticles have prolonged bioavailability when compared to both spherical and
short rod nanoparticles. Other shapes such as nanoflowers and nanoprisms do exist but
these structures may not be as active as nanorods and nanospheres primarily due to
their unique shapes (Wozniak et al., 2017).
1.5

Nanoparticle cytotoxicity

With the advent of nanotechnology and its growing application in almost all facets of
everyday living comes the concern on possible hazards resulting from increased
human exposure. Significant research into the toxic effect or toxicity of nanoparticle
exposure gave rise to the field of nanotoxicology. In recent years, this field has
identified that the properties of nanoparticles that confer them with suitable
pharmacologic behaviour are also responsible for their toxicity (Gatoo et al., 2014).
Several studies have investigated the cytotoxicity of different nanoparticles using
different cell lines and experimental conditions. For instance, toxicity of carbon
nanotubes have been shown to affect the diversity of soil bacteria, (Kerfahi et al.,
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2015), inhibit the growth of Daphnia magna, Chlorella vulgaris and Oryzias latipes
(Sohn et al., 2015) and result in oxidative stress, membrane damage and inflammation
in human A549 lung carcinoma cell line (Choi et al., 2009). Different findings have
shown that the mechanism of nanoparticles size dependent cytotoxicity is due to their
ability to infiltrate body tissues and subsequently enter cells to modify crucial cellular
functions, one of which is to rupture membrane of subcellular structures and induce
the overproduction of reactive oxygen species (ROS) (Fu et al., 2014). The presence
of elevated levels of ROS induces oxidative stress that affects the normal physiological
processes of the cell subsequently resulting in DNA damage, dysregulation of cell
signalling and ultimately cell death.
Nanoparticles are often surface-modified to enhance their functions. This may
inadvertently result in increased cytotoxicity of the nanoparticle due to the influence
of nanoparticle surface chemistry on its inherent toxicity. Based on localisation within
the biological system, nanoparticles with reactive surface moieties are able to react
with different intracellular or extracellular biomolecules therefore disturbing the
normal processes needed to maintain tissue or cellular homeostasis. For instance,
charged AuNP’s have been shown to be more cytotoxic compared to that of neutral
AuNP’s as they induce higher levels oxidative stress resulting in reduced
mitochondrial function and increased expression of DNA damage related genes
(Schaeublin et al., 2011). Anionic cyanoacrylic nanoparticles are known to be more
cytotoxic to macrophages compared with the cationic forms (Tomita et al., 2011).
These differences may be as a result of macrophage’s phagocytotic affinity towards
the bacterial cell membrane, which demonstrates an overall negative charge due to the
Lipid A molecule of the LPS component of the bacterial cell membrane. Contrary to
this, aminated iron oxide nanoparticles with an overall positive charge have been
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shown in a Chinese Hamster Ovary (CHO-K1) cell line to be efficiently internalised
and hence with induce higher cytotoxicity when compared to a PEGylated form
(Hanot et al., 2015). Often, nanoparticles are PEGylated to increase their
bioavailability and to reduce immunogenicity for a prolonged effect in vivo (Suk et
al., 2016). The retention of PEGylated particles in addition to the stability it confers
them with, may be a result of the slower uptake by cells resulting in the substantial
reduction in their cytotoxicity.
Coupled with the size, the shape and aspect ratio of nanoparticles play crucial role in
their cytotoxic effects in vivo. It is believed that the higher aspect ratio of nanoparticles
correlates with increased cytotoxicity due to a reduced clearance and an increased
bioavailability of nanoparticles (Shukla et al., 2015). Higher aspect ratio nanoparticles
often have cytotoxicity profile similar to that of asbestos. Such particles can induce
macrophage cell death during phagocytosis and, as was the case with asbestos fibres,
have the potential to promote cancer development (Fubini et al., 2011). In support of
this, Wozniak et al. (2017) showed that gold nano-spheres and nano-rods both of
which were under 50 nm were more cytotoxic on HeLa and HEK293T cell lines than
their nano-star, nano-flower and nano-prism counterparts that were all above 200 nm
in size. It was postulated that this was because of a more efficient internalisation of
these nanoparticles by the cells coupled with their optimum surface area for interaction
with intracellular molecules.
1.6

Nanoparticle drug delivery systems (DDS) in disease treatment

Nanoparticles used in drug delivery range from 10 to 1000 nm in size with at least
one dimension being below 100 nm in size. The small sizes of nanoparticles as well
as their surface chemistry are known to offer pharmaceutically beneficial attributes
but may also contribute to their toxic effects as discussed earlier. Smaller nanoparticles
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more effectively enter cells when compared with larger molecules but the
administration of nanoparticles with a reduced clearance may result in some of the
particles being retained within the body. In the case of a more active or cytotoxic
nanoparticle being retained rather than a bulk of the drug being eliminated during the
first pass effect, this may result in harmful effects in the targeted site due to unwanted
retention. Systemic administration of cytotoxic drugs may cause the drugs to exert
their cytotoxicity on tissues during the first pass effect before they reach the intended
tissues. 70% of globally synthesised drugs have poor aqueous solubility and hence
poor pharmacokinetic properties in vivo (Khadka et al., 2014). As a solution to this,
nanoparticle drug delivery systems (DDS) have been developed to achieve targeted
and more efficient delivery of the therapeutic substance, which would prevent damage
to surrounding organs from the effect of administered drugs that will otherwise arise
if the drugs were in the free form. Over the past few decades, research efforts into
DDS have advanced significantly with various DDS already being investigated and
developed for treatment of diseases such as cancer and neurodegenerative diseases
(Gunay et al., 2016, Iwamoto, 2013). Some of the typical nanoparticle DDS currently
in under study are discussed below.
1.6.1

Lipid based DDS

DDS made from lipids vary in formulation and sizes and are mainly of two types,
namely micelles and liposomes. Micelles are formed through the self-assembly of a
monolayer of lipid molecules in an aqueous environment into a nano-vesicle of
between 5 and 50 nm (Wang et al., 2005). They are used to successfully transport
hydrophobic molecules, trapped in the hydrophobic core, at concentrations above their
inherent water solubility. This is possible because the hydrophilic phospholipids are
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exposed to the aqueous environment while the hydrophobic tails form the core that
can interact with the drug.
Unlike micelles, liposomes are bilayer nano-vesicles similar to the cell membrane with
sizes ranging from 10 nm to several microns. The hydrophilic phospholipids of the
outer layer are exposed to the aqueous environment while that of the inner layer
encloses the aqueous core (section 1.4.2). Consequently, the hydrophobic tails of the
bilayer lie above each other and are often used to trap hydrophobic drugs while the
aqueous core is used to entrap hydrophilic drugs (Bozzuto and Molinari, 2015).
Liposomes have been one of the most useful tools in drug delivery in cancer treatment
due to their ability to transport both water soluble and insoluble drugs (Rau et al.,
2015, Casagrande et al., 2014, Guo and Huang, 2014). Conventional drugs, which are
often small molecular drugs have poor selectivity for tumour cells are not retained
within the tumour microenvironment as they diffuse back into the circulation system
causing cytotoxic side effects to normal cells. Liposomes however can improve the
delivery of such drug to the tumour microenvironment, which have tight junctions
with gaps between 100 nm and 800 nm unlike normal epithelial junctions which are 5
nm to 10 nm, via an enhanced permeability and retention (EPR) effect. Using the EPR
effect, liposomes accumulate at the tight junctions of tumour cells and extravasate the
blood vessels through to the tumour microenvironment for delivery of the
encapsulated drugs (Deshpande et al., 2013).
Liposomes generally have short half-life but advancements in drug delivery research
such as PEGylation of liposomes has allowed the development increased half-life
(Milla et al., 2012). In forming DSPE-PEG for instance, PEG is conjugated to
phosphatidyl ethanolamine of DSPE via covalent linking of the amide group of DSPE
to the carboxyl end of PEG (Marques-Gallego and de Kroon, 2014). Through PEG
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linker on the liposome surface, several other moieties can be conjugated to the
liposome as in targeted drug delivery. For example, click chemistry can be used to
couple an azide functionalised antibody to a Dibenzocyclooctyne-amine (DBCO)PEG functionalised liposome in an azide-alkyne cycloaddition reaction (Gai et al.,
2020). Thus, liposomes can now improve both the pharmacodynamic and
pharmacokinetic properties of water soluble and insoluble drugs by increasing their
delivery to target cells with potentially controlled release, thus lowering their cytotoxic
effect on surrounding cells. For instance, liposomal doxorubicin coated with PEG
(Doxil®) has been used to reduce doxorubicin cytotoxicity, improve its bioavailability
and to enhance the delivery of the anticancer drug in different cancer types (O'Brien
et al., 2004, Udhrain et al., 2007). While PEGylation of liposome result in prolonged
bioavailability by increasing the liposome hydrophilicity and reduced glomerular
filtration/excretion, it often result in reduced uptake of the liposome by cells and
degradation for drug release by the endo-lysosomal pathway (Mishra et al., 2016).
Liposomes are widely used in targeted delivery due to the flexibility of their surface
chemistry, which allows conjugation of targeting biomolecules such as peptides and
antibodies that bond with specific cell surface receptors. This feature makes it possible
to specifically target cells such as cancer/tumour cells that express or overexpress
specific receptors that recognises such molecules on the liposomes for targeted drug
delivery (Error! Reference source not found. and Figure 1-3) (Accardo et al., 2012).
Liposomes can be used to transport hydrophobic drugs in the lipid bilayer via
hydrophobic interactions with the fatty acid tail of the phospholipids while hydrophilic
molecules, such as DNA or crystalline drugs, can be encapsulated within the aqueous
core. Surface modifications are now possible on to the surface of the liposomes
allowing enhanced bioavailability as occurs with PEG. Surface coating of drugs via
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electrostatic or ionic interactions or conjugation of antibodies, chemotherapeutic
agents, peptides and other proteins can prove useful for targeted delivery are routinely
done with the aid of different linkers such as avidin-biotin complexes, PEG or peptide
linkers that are chemically conjugated to the phospholipid head and to the drug or
protein of choice (Error! Reference source not found. and Figure 1-3).
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Figure 1-3. Targeted delivery and metabolism of liposome encapsulated drug.
Adapted with modification from Deshpande et al. (2013).
In targeted drug delivery, liposomes are surface modified by conjugating them with
different groups using linkers such as PEG or chemically such as the “Click
Chemistry”(see section 1.6.1). Such groups include drugs, peptides or antibodies
specific for cell surface receptors that are overexpressed by cancer cells for example,
which facilitate binding of such groups to the receptors and prevent access to normal
cells. The liposome can be internalised through invagination of the cell membrane as
endosomes or b receptor medicated endocytosis in which case the receptor is recycled
and returned to the cell membrane. Drugs encapsulated in the liposome are released to
subcellular structures after degradation of the endosome and the liposome by the
lysozymes in the endo-lysosomal pathway.

1.6.2

Polymeric DDS

Polymer based nanoparticle DDS are made up of a repeating unit of specific polymers
and have been widely investigated for medical purposes in recent years (Nicolas et al.,
2013, Liu et al., 2014c). Some of the known polymeric DDS are PEG, chitosan, poly(lactic-co-glycolic acid) (PLGA) and polylactic acid (PLA) but PEG, PLGA and PLA
are the more widely studied while chitosan research is beginning to gain more attention
due to its biocompatibility, low immunogenicity and low toxicity (Cheung et al.,
2015). Several PEGylated drugs have been approved by FDA for clinical used making
it the most commercialised polymeric DDS (Table 1-1). PLGA and PLA are however
known to be characterised with an initial burst release of the encapsulated drug (within
24 h) irrespective of the drug localisation and this may result in high delivery of drugs
at unwanted sites, reducing drug benefits (Bouissou et al., 2006). This has led to
development of polymeric DDS with different triggers for release of entrapped drugs.
For example, some polymer-based DDS are modified to respond to subtle change in
pH or ROS generation within the biological system. The pH or ROS level within a
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tissue may signal its physiological condition, since ischemic or tumour tissue sites
have higher pH or ROS levels when compared to normal tissue. Self-assembling and
pH-sensitive poly-amine have been demonstrated to possess flexible delivery
capabilities. Doxorubicin entrapped polyamine coated with folate and ligands for HIV
transcriptional transactivator (TAT) were shown to be successful in treatment of
multidrug resistant cancer cell lines (Lee et al., 2008, Lee et al., 2005). These
polyamines are pH sensitive and release the entrapped doxorubicin in an acidic pH
environment. Since the tumour microenvironment is mostly acidic and without the
need for specific targeting molecules, this system can effectively target the tumour
microenvironment. Dextran nanoparticles containing linked arylboronic esters that are
degradable by ROS have also been used to deliver ovalbumin to murine dendritic cells
to enhance their antigen presenting abilities (Broaders et al., 2011). Because of the
varying conditions that ensues in the tumour microenvironment, polymer-based DDS
seem to be flexible and less technical way of targeting the tumour microenvironment.
1.6.3

Peptide nanoparticle DDS

Linear and cyclic peptides that are either synthesised or derived from existing
fragments of naturally occurring proteins are also important contributors to the
nanoparticle DDS that are currently available. Peptides are often used as the targets
for cell surface receptors since most proteins that bind to such receptors do so via a
specific fragment in their peptide sequence. These coupled with their ease of synthesis
and low immunogenicity makes peptides a useful tool as potential DDS. Several
peptides have been used alone or indeed as part of a surface modification to other
nanoparticles for improved drug delivery. Kim et al. (2012) used an encapsulated
peptidomimetic of epidermal growth factor receptor (EGFR) ligand in a cationic
liposome to aid in the inhibition of EGFR signalling in a lung cancer cell line.
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Somatostatins, a group of peptide hormones that are ligands highly expressed in
different cancer cells, have also been conjugated to different anticancer drugs such as
doxorubicin, methotrexate and paclitaxel to enable selective targeting of cancer cells
(Sun and Coy, 2011). RIPL peptide is a short peptide that was developed to bind
hepsin, a serine protease, that is highly expressed on the surface of hepatoma and
prostate cancer cells. Kang et al. (2014) developed a RIPL conjugated liposome to
selectively target a panel of cancer cells that overexpresses hepsin, yielding an
increased selectivity and cellular uptake compared to conventional liposomes without
the targeting peptide.
1.6.4

Background to the project

In a bid to improve on the activities of conventional drugs where possible,
nanoparticles have been a subject of different research in recent years due to their
potential pharmacologic properties (Ventola, 2012). Nanoparticles have shown
promise in a variety of treatment options ranging from treatment of cancer, kidney
disease, neurodegenerative diseases and even medical imaging for diagnostic purposes
(Murthy, 2007) and in some instances surpass the performances of conventional
treatment methods. It is now known that the use of nanoparticles alone or by
incorporating them into nanocomposites offer improved potential for targeted drug
delivery and potentially offer more effective disease treatment (Bao et al., 2013).
Nanoparticles extensively researched for their medical applications include AgNP,
AuNP, silicon/silicon oxides and iron oxide nanoparticles. Of these, AgNP have been
extensively researched for medical applications and in fact, AgNP is the most
commercialised nanoparticle at present as an active ingredient in everyday
consumable product driven by nanotechnology (Vance et al., 2015), especially in high
concentration. These diverse applications of AgNP stems from its antibacterial
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activities and indeed several mechanisms of action have been proposed for its
cytotoxic effect. In addition to this, recent investigations have now shifted to
investigate the anticancer properties of AgNP with interesting results. AgNP have
been shown to interact with the DNA inducing DNA damage. AgNP can also induce
ROS which further causes DNA single and double strand breaks in addition to DNA
adducts due to oxidation of certain nucleotides like guanine to 8-oxo-2deoxyguanosine which can base pair with deoxyadenosine resulting in mutation (Liu
et al., 2020, Tang et al., 2019, Salehi et al., 2018) (Figure 1-4). This in addition to
permeabilisation of mitochondria membrane can lead to activation of caspase
dependent cell death. However, the overall effect of both anticancer and antibacterial
applications of AgNP possesses increased toxicity risk due to increased and repeated
human exposure to the free silver ion (Ag+) released into the local environment by the
nanoparticle. Ag+ released from AgNP has been documented to cause several side
effects such as skin irritation and discolouration, hepatotoxicity, kidney damage, DNA
damage and epithelia cell damage (León-Silva et al., 2016).
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Figure 1-4. Proposed mechanism of action of AgNP. Adapted from Verano-Braga
et al. (2014) and Tang et al. (2019).
AgNPs have a dose and size dependent effect on cellular cytotoxicity which influence
the dynamic changes within the cell. AgNP can induce apoptosis via the caspasedependent mitochondrial cell death pathway facilitating cellular dynamics that can
damage the cell barrier, inactivate ATPase activity to cause inactivation of Ca2+
ATPase and Na+/K+ ATPase. This in addition to single and double strand breaks that
is caused by AgNP-induced DNA damage can excessively generate and accumulate
ROS causing permeabilisation of mitochondrial membrane and release of cytochrome
C and pro-apoptotic protein into the cytoplasm followed by activation of the caspase
cascade, and finally apoptosis.
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So, this thesis sought to mitigate the negative effects of AgNP by altering the delivery
vehicle of the AgNP to that of a liposome-based delivery. The rationale behind this
research is to improve the cytotoxicity of AgNP and suppress the AgNP-associated
inflammation such that lower concentration of AgNP will be applied commercially
lessening the dangers of human exposure. Different drugs have been encapsulated in
different DDS such as liposomes and carbon nanotubes to increase drug payload
delivery intracellular. This type of delivery has a myriad of benefits in cancer research,
one of which is the ability to modify the delivery vesicle to a targeted delivery in order
to deliver a high concentration of the drug to only tumour cells in the tumour
microenvironment. The use of DDS in drug delivery may result in lowering the
concentration of nanoparticles or drugs required to achieve a greater pharmacologic
response. This could limit the development of resistant strains of bacteria and cancer
cells while at the same time reduce the amount of nanoparticle that leaches into the
ecosystem.
This study aims as previously stated to encapsulate AgNP in a natural biosurfactant
such as dipalmitoyl phosphatidylcholine (DPPC), which is documented to have low
immunogenicity and also suppress AgNP-induced inflammation (Murphy et al.,
2015b), as a means of delivering AgNP to cancer cells for improved cytotoxic effect.
Additionally, liposomal encapsulation of conventional drug such as doxorubicin
(Doxil®) has been shown to enhance cytotoxicity of these drugs and have been
approved by the FDA (Table 1-1). Thus, this thesis aimed at and achieved the
following in attempt to improve upon AgNP cytotoxicity with minimal provocation of
inflammation,
a. Synthesised AgNP in-house, investigated and trial different ways of
encapsulating AgNP in a DPPC-based liposome
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b. Investigated the delivery efficiency of encapsulated AgNP as compared with
free uncoated AgNP in a known immune cell line/cancer cell line by evaluating
the cytotoxic effects on cellular viability.
c. Investigated the mechanism of action of encapsulated AgNP compared with
that of free AgNP looking at the signalling cascade involved in activating cell
death pathways.
d. Investigated the effect of encapsulation on AgNP induced inflammation by
investigating the release of pro-inflammatory cytokines like interleukin-1β
(IL-1β), IL-6, IL-8 and tumour necrosis-α (TNF-α).
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2

Materials and methods

2.1

Cell line

The cell line used throughout this study was THP1 (ATCC®: TIB-202TM), an acute

monocytic leukaemia cell line obtained from the blood of a one-year old leukaemia
patient (Tsuchiya et al., 1980). The cell line was differentiated into macrophages as
described in section (XXX) for macrophage studies.
2.1.1

Cell culture and exposure

THP1 (ATCC®: TIB-202TM) a suspension line derived from a human peripheral blood
monocyte from an acute monocytic leukaemia patient, was used for this study. THP1
cells were cultured in RPMI-1640 media containing 2 mM L-glutamine (Sigma
Aldrich, Ireland) supplemented with 10 % FBS and incubated at 37oC, 95 % humidity
and 5 % CO2.
For nanoparticle exposure, cells were seeded into a 96-well plate at a density of 1 x
104 cells in 100 µL of culture media for a 24- and 48-hour time period or in a 24-well
plate (VWR, Dublin, Ireland) at a density of 3 x 105 cells/ml in media containing 100
ng/ml phorbol 12-myristate 13-acetate (PMA) for a 24 h to induce maturation of the
pre-monocytes into adherent monocytic THP-1 after which the cells were rested in
PMA free media for 24 h. The cells were then treated with un-encapsulated (AgNP)
and Lipo-AgNP after seeding. For the adherent cells in 24 well plates, the culture
media containing PMA was removed from the now adhered monocytic THP1 cells
and replaced with fresh RPMI media containing different concentrations of uncoated
AgNP, PB-Lipo-AgNP and Ex-Lipo-AgNP. A positive kill control, a 10 % (v/v)
dimethyl sulfoxide (DMSO) solution was prepared in serum free media to treat the
cells while a negative control of unexposed cells was also incorporated onto the plate
for both AgNP and Lipo-AgNP exposed cells. THP1 cells were also exposed to
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varying concentrations of AgNO3 (Ag+) solution prepared by dissolving
corresponding amount of AgNO3 in ddH2O as another positive control to test possible
influence of AgNP ionisation into Ag+ on its cytotoxic effect. A minimum of three
independent experiments were conducted and for each independent experiment, six
replicate wells were employed per concentration per plate.

2.2

Other materials and reagents

Appendix A1 lists the materials and reagents used throughout this thesis.

2.3

AgNP synthesis

To synthesize AgNP, 6 ml of 1 mM of AgNO3 solution was added dropwise into an
Erlenmeyer flask containing magnetic stirrer a 350 rpm and ice cold 30 ml of 2 mM
of NaBH4. The stirring was continued until last drop when the stirrer was removed for
the solution to turn golden yellow. The obtained AgNP was characterised by UV/Vis
in a Spectramax M2 microplate reader while atomic absorption spectrophotometry
(AAS) was employed to monitor silver (Ag) concentration using a SpectrAA200
Varian Spectrophotometer (Mulgrave, VC, Australia). The samples were analysed
with a silver hollow cathode lamp at an operating current of 7.5 mA. Hydrodynamic
size of AgNP and liposomal AgNP (Lipo-AgNP) was carried out with Malvern
Zetasizer Nano ZS (Malvern Panalytical, Malvern, UK). Nanoparticles were loaded
into a pre-rinsepre-rinsed folded capillary cell up to the marked portion. For zeta
potential, an applied voltage of 15 and 50 V was used for Lipo-AgNP and free AgNP
respectively.
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2.4

X-ray diffraction (XRD) of AgNP

Powdered XRD characterisation of AgNP was conducted with a Philips diffractometer
(Phillips Inc., USA) using a monochromatic Cu-Kα1 radiation source (λ = 1.5406 Å)
operated at 40 keV, 30 mA and a 2θ angle pattern. The scanning was carried out in the
20o to 80o region and the crystalline structure was analysed by comparing the obtained
result with that of the Joint Committee on Powder Diffraction Standards (JCPDS)
library.
2.5

Liposome synthesis, AgNP encapsulation and characterisation

Liposomes were prepared with a combination of DPPC and cholesterol via a
modification of a dehydration-rehydration technique originally reported by Mugabe et
al. (2006). Liposome was prepared by probe sonication and extrusion methods. DPPC
and cholesterol were weighed in a mass ratio such that eventual rehydration of the
lipid film obtained will give a 7:3 molar ratio solution respectively. The lipids were
dissolved in a fixed amount of chloroform and mixed until the mixture becomes clear.
The resulting solution was placed in a vacuum oven set at 52oC for the chloroform to
evaporate.
2.5.1

Probe sonication method

The lipid cake formed was then rehydrated in AgNP solution at 60°C. AgNP solution
were added to the lipid at 1:300 (w/w) of AgNP:DPPC after which the solution was
vortexed briefly for 2 minutes to form multi-lamellar vesicles (MLV). The mixture
was probe sonicated at 21% amplitude, 20 sec run and 20 sec pause for 4 cycles to
form Small Uni-lamellar Vesicles (SUV). The resultant mixture was then centrifuged
at 800 x g for 10 mins at 4°C to remove any MLVs. The suspension was subjected to
DLS and zeta potential analysis for size and stability measurements respectively.
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2.5.2

Extrusion method

The lipid film was rehydrated in AgNP solution at 60oC to make the final
concentration at 1:300 (w/w) of AgNP:DPPC. The solution was placed in the shaker
at 60oC on 140 rpm for another 20 mins after which it was vortexed briefly for 2 mins
to form multi-lamellar vesicles (MLV). This was then extruded through a 100 nm
“Nanosizer” polycarbonate extruder purchased from T&T Scientific (Knoxville,
USA). The suspension was subjected to DLS and zeta potential analysis for size and
stability measurements respectively.
2.6

Dynamic light scattering (DLS) analysis and Zeta potential analysis

To measure the hydrodynamic diameter of the nanoparticle in solution, the DLS
analysis of both AgNP and Lipo-AgNP was carried out with Malvern Zetasizer Nano
ZS (Malvern Panalytical, Malvern, UK). The zeta potential measurement of the
nanoparticles was also measured with Malvern Zetasizer Nano ZS instrument set at
25°C for all the samples. Nanoparticles were loaded into a pre-rinsed folded capillary
cell up to the marked portion (usually filled with 1 ml of sample). An applied voltage
of 15 and 50 V was used for Lipo-AgNP and uncoated AgNP respectively and a
minimum of three different measurements were made for each sample.
2.7

Temperature-dependent size measurements, stability tests and pHdependent drug release study

To check the effect of incubation conditions on the nanocapsules, both probesonicated (PB-Lipo-AgNP) and Ex-Lipo-AgNP were subjected to temperature
dependent size stability tests. A solution of Lipo-AgNP in 10% foetal bovine serum
(FBS) supplemented RPMI-1640 was prepared and subjected to DLS size
measurements over a temperature range of 20oC to 38oC with 1oC increments of
temperature.
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For nanoparticle stability determination, variations in nanoparticles mean size and zeta
potential of both Ex-Lipo-AgNP and PB-Lipo-AgNP were measured at a specific
interval over a period of 6 months at both 4oC (storage temperature) and 24oC (room
temperature). 5 ml of PB-Lipo-AgNP and Ex-Lipo-AgNP were incubated at 4oC and
24oC and 1 ml sample was taken at each time point for analyses at specific time
interval.
For pH dependent AgNP release from the nanocapsules, 1 ml of the encapsulated
AgNP was added into a FLOAT-A-LYZER G2 CE dialysis tube with a 1,000 KDa
MW cut off (Spectrum Labs, Breda, Netherlands). The dialysis tube was placed in 6
ml of either an acetate buffer (pH 6.5) or a phosphate buffer saline (PBS) at pH 7.45.
The ratio between the inside and outside volumes were maintained as thus to facilitate
easy movement of the AgNP as recommended by Shen and Burgess (2013). The tube
was then placed on a shaker running a 300 rpm at 37oC. To measure the amount of
AgNP released, 200 µl of Lipo-AgNP sample was taken from the dialysis tube at
specific time interval for 24 h and the absorbance was measured in the SpectraMax
M2 microplate reader at 405 nm. After absorbance measurement, the measured sample
was replaced with a fresh buffer to avoid change in volume and sink condition.
2.8

Scanning electron micrograph (SEM) and scanning transmission electron
micrograph (STEM) analysis

SEM micrographs were obtained for both AgNP and Lipo-AgNPs. Briefly, both PBLipo-AgNP and Ex-Lipo-AgNP were microscopically analysed using Hitachi SU6600 field emission SEM (Hitachi, Maidenhead, UK) with accelerating voltage of 25
kV and 8 mm working distance. At 24 h before analysis was carried out, 5 μl of sample
was drop-cast to air dry onto a 5 x 5 mm pure silicon wafer substrate (Ted Pella Inc.,
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Redding, California, USA) for SEM or carbon formvar copper grid (Agar Scientific
Ltd., Stanstead, UK) for STEM, before micrographs were obtained.
2.9

Estimating encapsulation efficiency of the liposome

To estimate the encapsulation efficiency, both probe-sonicated and extruded LipoAgNP were centrifuged at 20,000 x g for 1 h and the supernatant was harvested. The
supernatant was then analysed by atomic absorption spectrophotometry to estimate the
concentration of silver in the solution. The encapsulation efficiency (E) of the
liposome was then calculated using the formula below
E=

!"#$% '()* $++,+ #" %-."/"0,1'()* -2 /3.,42$#$2#
!"#$% '()* $++,+ #" %-."/"0,

X 100

2.10 Cell viability
Cellular viability was evaluated with the Alamar Blue assay (AB). Briefly, a 10 %
(v/v) AB solution in serum free media was prepared and kept warm in a water bath at
37°C. The plate containing treated monocytic cells is suspension in 96 well plates was
centrifuged in a Heraeus Megafuge 16R (Thermofischer) at 500 x g and 20°C for 5
min and the exposure media removed after which 100 µL of the 10% AB solution was
added to each well. The plates were then incubated for 3 h after which the resulting
florescence of the converted AB dye was measured at 540 nm and 595 nm excitation
and emission wavelengths respectively using SpectraMax® M3 Multi-Mode
Microplate Reader and compared to the relative controls. For the adherent cells, the
exposure media were removed, and the cells were rinsed with pre-warmed sterile 1 x
phosphate buffer saline (PBS) after which 1.5 ml of AB solution was added onto the
cells and incubated at 37oC for 2 h. this was followed by absorbance measurement as
done for the suspension cells.
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2.11 Flow cytometry
Flow cytometry is a revolutionary technique used in measuring multiple features of a
single cell based on specific physical characteristic such as the size and granularity or
internal complexity as the cell flows or moves amidst population of cells through the
measuring device.
For flow cytometry analysis THP1 cells were seeded and cultured in T25 flasks at 2 x
105 cells/mL and were subsequently treated with Lipo-AgNP and AgNP for 24 h. After
exposure, cells were harvested into 15 mL tubes and were centrifuged at 300 x g for 5
min at 22oC to form pellets. The pellets were resuspended in 2 mL pre-warmed 1 x
phosphate buffer saline (PBS) and centrifuged as above and the process was repeated.
Prior to staining the pellet was finally resuspended in 1 mL binding buffer a 0.1 %
NaN3 and 1 % bovine serum albumin (BSA) solution in 1 x PBS.
For live-dead staining the cells were double stained by adding 5 µL of 1 µM calceinAM stain and 10 µL of 10 μg/mL PI. The cells were then incubated in the dark at RT
for 20 min and analysed with a BD Accuri C6 flow cytometer.
For cell cycle analysis, cells were harvested as above and rinsed in warm sterile PBS.
The cells were then fixed with ice cold 70 % ethanol. After ethanol fixation, the cells
were incubated at 4oC for up to 4 h. Prior to any staining, the cells were washed twice
in PBS and centrifuged at 800 x g for 5 min and the cell pellet treated with 50 µL of a
100 μg/mL ribonuclease A to ensure only DNA was stained. The cells were then
stained with 400 µL of 50 μg/mL PI and incubated for 10 min before analysing using
BD Accuri C6 flow cytometer.
Finally, for Caspase3/7 analysis, as before the THP1 cells treated with AgNP and
Lipo-AgNP were harvested and centrifuged at 300 x g for 5 min to remove exposure
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solutions. As a positive control, THP1 cells were exposed to 1 µM solution of
doxorubicin, which is a known activator of the executioner caspases (Ueno et al., 2006,
Yang et al., 2001). The cells were washed in PBS once and then resuspended in
binding buffer. The cells were then stained with 500 nM CellEvent caspase 3/7
detection reagent and incubated at 37oC for 30 min. The cells were then stained with
1 μM SYTOX AAdvanced dead cell stain and incubated for 5 min prior to being
analysed on a BD Accuri C6 flow cytometer.
2.12 Confocal microscopy
Confocal microscopy uses a laser technology in contrast with normal light used by a
widefield microscope where light from mercury or xenon source is shone on the whole
sample for viewing. For confocal microscopy, image of a specimen is captured by
scanning a focused beam of light from a laser source across the specimen (Paddock,
2000). The light path in the confocal microscope is similar to that of the reflected-light
wide-field epifluorescence microscope but the confocal microscope has a pin hole in
front of the light source as well as a photodetector (Figure 2-1). This approach has
allowed for automated capturing the three-dimensional data for images of cells and
subcellular structure in form of Z series even in multiple labelled samples.
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Figure 2-1. light path of laser scanning confocal microscope.

THP1 cells were seeded onto a confocal dish (VWR, Dublin Ireland) at density of 3 x
105 cells/ml. The cells were also stimulated with 100 ng/ml of PMA for 24 h and
subsequently treated with RPMI media containing 2 µg/ml of either PB-Lipo-AgNP
and Ex-Lipo-AgNP for 24 h. Dish containing cells exposed to 0.5 nM doxorubicin
were incorporated as positive kill control. After exposure, the media were discarded,
and the cells were rinsed with pre-warmed sterile PBS. The cells were stained with 50
µl of 1 µM calcein-AM and 50 µl of 10 μg/ml PI. The cells were then incubated in the
dark at RT for 20 min and rinsed with warm PBS afterwards. Prior to imaging, 1 ml
of warm PBS was added onto the cells and imaging was carried out with Zeiss LSM
40 | P a g e

510 Confocal Laser Scanning Microscope using a Plan-Neofluor oil immersion lens
at 40 X magnification and 1.3 numerical aperture.
2.13 Reactive Oxygen Species (ROS) Assay by spectrophotometric method
ROS generation in the THP1 cells as a result of particle exposure was measured with
a 6-carboxy-2’,7’–dichlorofluorescin diacetate (carboxy-DCFDA) assay. In the assay
carboxy-DCFDA a non-fluorescent dye is metabolised by esterase into H2DCFDA
which is further oxidised by ROS generated in the cell to a green fluorescent DCFDA
dye. To quantify ROS generation the THP1 cells were seeded into T75 flask at 5 x 105
cells/mL in RPMI media containing 2 % FBS and the cells were loaded with 10 μM
of carboxy-DCFDA dye and incubated for 30 min under normal culture condition. The
loaded cells were then centrifuged at 300 x g for 5 min and the medium containing
excess carboxy-DCFDA was removed. The loaded cells were then washed twice in
warm sterile PBS and then re-suspended in normal culture media. The cells were then
seeded into Corning 96-well solid black plates at 2 x 105 cells/mL and treated with
AgNP or Lipo-AgNP at 0.3 μg/mL.
ROS generation in the THP1 differentiated macrophages (TDMs) consequent of
particle exposure was monitored using 6-carboxy-2’,7’–dichlorofluorescin diacetate
(carboxy-DCFDA) assay. This assay utilises esterase metabolism of carboxy-DCFDA
a non-fluorescent dye, into H2DCFDA which is further oxidised to a green fluorescent
DCFDA dye by ROS generated in the cell. To quantify the ROS generation, media on
the TDMs seeded onto 24-well plate above were aspirated and replaced with RPMI
media containing 2 % FBS. The cells were loaded with 10 μM of carboxy-DCFDA
dye and allowed to incubate for 30 min under above culture conditions. After this, the
culture media containing carboxy-DCFDA were removed and the cells were rinsed in
pre-warmed sterile PBS. The cells were then incubated in media containing 2 µg/ml
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AgNP or Lipo-AgNP for specific time points to be analysed. Before ROS
quantification, cells were rinsed once again in PBS and the media was replaced with
PBS. ROS generation was then quantified by the fluorescence of the oxidised carboxyDCFDA, by monitoring the dyes emission at 535 nm by 485 nm excitation on a
Spectramax M3 multiplate reader, using multi-well scan at five different points per
well or flow cytometry.
2.14 Cell culture and THP1 differentiation into monocytic THP1 and TDMs for
inflammation studies
THP1 (ATCC®: TIB-202TM) cells were used here were cultured as described in section
2.1.1 The cells were stimulated with 100 ng/ml (162 nM) PMA for either 24 h or 72 h
to induce differentiation into matured monocytic THP1 or TDMs respectively. The
PMA containing media was then replaced with fresh RPMI media and the cells left to
incubate for another 24 h (Chanput et al., 2014).
2.14.1 Cell exposure
After this, the culture media containing PMA was removed from the now adhered
monocytic THP1 cells or TDMs and another fresh RPMI media containing 30 µg/mL
of polymyxin B was replaced for 1 h to inhibit any LPS that might be present in any
reagent used. Polymyxin B is known to inhibit LPS induced inflammatory response
and the concentration used here was found to inhibit up to 10 µg/mL LPS
contamination (Xiao-Xiao et al., 2017). After incubation with polymyxin B, the cells
were then treated with different concentrations of uncoated AgNP and Lipo-AgNP.
As a positive control for inflammatory response, cells primed with 10 µg/mL LPS
from E. coli 0111:B4 were incorporated on the plate while a negative control of
unexposed cells were both incorporated onto the plate. The cells were incubated in
treatment for specified period and were stimulated with 5 mM ATP for 1 h prior to
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collection of the supernatant. In some instances, cells exposed to 20 µM of Ac-YVADCMK, a caspase-1 inhibitor (ICEinh), were also incorporated onto the plate. Cells were
exposed to caspase-1 inhibitor to ensure changes in IL-1β secretion is due to AgNP
and not caspase-1. A minimum of three independent experiments were conducted and
for each independent experiment, four replicate wells were employed per
concentration per plate.
2.14.2 Cell viability
Cell viability of nanoparticle exposed TDMs was analysed by Alamar Blue assay
(AB). A pre-warmed solution of AB (10% v/v) in serum free media was prepared and
the exposure media on the TDMs were removed, after which the cells were rinsed with
pre-warmed sterile 1 x phosphate buffer saline (PBS). Then, 1.5 ml of AB solution
was added onto the cells and the plates were incubated at 37oC for 2 h. The florescence
of the converted AB dye was measured at 540 nm excitation and 595 nm emission and
wavelengths in a SpectraMax® M3 Multi-Mode Microplate Reader.
2.15 Cytokine release by sandwiched enzyme linked immunosorbent assay
(ELISA)
Sandwich ELISA is used to measure the quantity of specific antigens between two
layers of antibodies known as the capture antibody, conjugated to the surface of a glass
plate for instance and a detection antibody which is conjugated to a fluorophore for
fluorescence detection. For cytokine release assay, RPMI culture media from THP1
promonocytes, monocytic THP1 and TDMs exposed to AgNP or Lipo-AgNP post
priming with LPS and ATP challenge were collected at different time points after
which IL-1β, IL-6, IL-8 and TNF-α levels in the culture supernatant were carried out
by sandwich ELISA following manufacturer’s instructions. For each of the cytokine
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assayed, a standard of pure sample with known concentration (as supplied by the
manufacturer) was used (see Appendix 1). Absorbance was measured at 450 nm
2.16 Cell lysate collection
To collect cell lysate for protein expression analysis, culture media was aspirated from
the cells after which the cells were rinsed in ice cold 1X PBS while the plate was kept
on ice. The cells were lysed with 100 µl of RIPA buffer containing protease inhibitor
cocktail (as supplied by MerK, Dublin Ireland) per 3.5 x 105 cells and the cells were
scrapped off and pipetted up and down gently to break up intact cell membranes.
Protease inhibitor was required to prevent degradation of the protein content of the
lysate prior to sandwich ELISA, as intracellular proteases will be extracted alongside
proteins of interest. The lysate was transferred into a 1.5 ml Eppendorf tube and
centrifuged at 13,000 xg for 10 mins at 4oC. The supernatant was transferred into
another 1.5 ml Eppendorf tube and kept on ice to be analysed by ELISA as soon as
possible or stored at -80oC until analysis.
2.16.1 Cell culture and exposure
THP1 (ATCC®: TIB-202TM) cells were used in this study and were cultured in RPMI1640 media supplemented with 2 mM L-glutamine and 10 % FBS. The cells were
incubated at 37oC, 95 % humidity and 5 % CO2. For nanoparticle exposure, cells were
seeded in a 24-well plate (VWR, Dublin, Ireland) at a density of 3 x 105 cells/ml of
culture media and 1.5 ml of culture media per well. The cells were stimulated with
100 ng/ml (162 nM) PMA for 72 h TDM. The PMA containing media was then
replaced with fresh RPMI media and the cells left to incubate for another 24 h
(Chanput et al., 2014).
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For cell exposure, culture media on cells were aspirated and the cells were rinsed in
pre-warmed sterile 1X PBS solution. After this, the cells were incubated in RPMI
media containing different concentration of either of AgNP or Lipo-AgNP ranging
from 0.3 to 10 µg/ml. A negative control of unexposed cells was incorporated on the
plate while a positive kill control of a 10 % (v/v) dimethyl sulfoxide (DMSO) solution
and an internal positive control of AgNO3 were o the plate. AgNO3 was incorporated
to assess the effect of Ag ionisation in AgNP on cell viability.
2.17 Reduced glutathione (GSH) assay
To measure the GSH levels, TDMs prepared as for ROS generation were exposed to
both AgNP and Lipo-AgNP under the same conditions as above for 4 h. After
exposure, the cells were rinsed in pre-warmed sterile PBS and incubated in RPMI
media containing 10 µM of ThioltrackerTM violet dye for another 30 mins in the dark
under incubation conditions used above. The cells were rinsed again in pre-warmed
sterile PBS after which they were covered in warm PBS. GSH level of in the cells
were measured using Multi-well scan setting on a Spectramax M3 multiplate reader at
405 nm excitation and 530 emission wavelengths.
2.18 Flow cytometry of TDMs
Flow cytometry analysis was used for both ROS generation and nanoparticle uptake.
For ROS generation, TDMs already treated with carboxy-DCFDA were exposed to
nanoparticles as above, rinsed in PBS and then gently scrapped off. The scrapped cells
were resuspended in PBS containing 1% BSA and this method was subsequently used
to detach the cells before analysis.
For nanoparticle uptake, RPMI media from TDMs cultured as described above were
aspirated and cells rinsed in PBS. The cells were then incubated in media containing
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2 µg/ml and the exposure media was removed at specific time points after which the
cells were rinsed in PBS and detached as described above before flow cytometry
analysis
For live-dead staining, the TDMs were double stained by adding 5 µL of 1 µM calceinAM stain and 10 µl of 10 μg/ml PI per 1 ml of RPMI media. The cells were then
incubated in the dark at RT for 20 min after which they were detached by scrapping
and processed as above for analysis by flow cytometry.
For γH2AX activation analysis, unexposed TDMs and TDMs exposed to 2 µg/ml
AgNP and Lipo-AgNP for 24 h after which the culture media on the cell was
discarded. The cells were detached by gently scrapping off from the plate as described
above and were washed in pre-warmed sterile PBS followed by centrifugation at 300
x g for 5 mins to pellet the cells while the supernatant was discarded. The pellets were
washed as before and then fixed in ice cold 70% (v/v) ethanol for alcohol fixation at 20oC for 2 h. The cell suspension was centrifuged at 500 x g for 5 mins to discard the
ethanol, the cells washed as previously three times in flow buffer made up of PBSBSA containing 0.1% sodium azide (NaN3) using 800 x g centrifugation speed. The
cells were permeabilised by resuspension in 0.25% PBS-Triton-X100 (PBS-T) for 5
min at RT. PBS-T was completely removed by centrifugation at 400 x g for 5 min as
above. The cells were then blocked by resuspension in 2% (w/v) PBS-BSA and
incubation at RT for 30 min.
To immunostain the cells with anti- -H2AX antibody, the blocking solution was
removed by centrifugation as described above. The cells were resuspended in flow
buffer containing the antibody at 1:100 and incubated at 37oC for 30 mins. The cells
were ashed to remove excess unbound antibodies as above using PBS. The cells were
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resuspended in fresh flow buffer solution analysed by flow cytometry in BD Accuri
C6 flow cytometer.
Finally, for Caspase3/7 analysis, as before the TDMs were exposed to 2 µg/ml of either
of AgNP or Lipo-AgNP for 24 h. The cells were harvested as above and then
resuspended in flow buffer of 1X PBS containing 0.1% sodium azide (NaN3) and 1%
BSA. The cells were then stained with 500 nM CellEvent caspase 3/7 detection reagent
and incubated at 37oC for 30 min. After this, the cells were stained with 1 μM SYTOX
AAdvanced dead cell stain and incubated for 5 min prior to being analysed by flow
cytometry. All analyses were performed on a BD Accuri C6 flow cytometer.
2.19 Cell lysate collection and Sandwiched Enzyme Linked Immunosorbent
Assay (ELISA)
To collect cell lysate for protein expression analysis, culture media was aspirated from
the cells after which the cells were rinsed in ice cold 1X PBS while the plate was kept
on ice. The cells were lysed with 100 µl of RIPA buffer containing protease inhibitor
cocktail per 3.5 x 105 cells and the cells were scrapped off and pipetted up and down
gently to break up intact cell membranes. The lysate was transferred into a 1.5 ml
Eppendorf tube and centrifuged at 13,000 xg for 10 mins at 4oC. The supernatant was
transferred into another 1.5 ml Eppendorf tube and kept on ice to be analysed by
ELISA. Sandwich ELISA of the collected lysate for Bax and Bcl-2 protein expression
from TDMs exposed to AgNP or Lipo-AgNP was carried out following the
manufacturer’s instructions. Absorbance was measured at 450 nm.
2.20 Statistical analysis
Statistical analysis of acquired data was carried out with GraphPad Prism version 7.
Data was analysed by Two-way analysis of variance (ANOVA) with Sidak or Turkeys
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multiple comparisons test to detect significance in effects between exposure groups.
Statistically significant differences in tests were indicated for p value < 0.05.
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Evaluation of silver nanoparticle encapsulation in DPPC-based liposome by
different methods for enhanced cytotoxicity”. Yusuf A. and Casey A. 2019.
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Biomaterials, DOI: 10.1080/00914037.2019.1626390

Silver nanoparticles (AgNP) are a widely used nanoparticle for its antibacterial
activities and many of the already commercialized products contain AgNP in high
concentrations as the active ingredient. For example, AgNP is widely used as
antibacterial coating on medical garments and surgical equipment and even on food
materials to prolong shelf life by preventing food degradation consequent upon
bacterial metabolism and growth (Polivkova et al., 2017, Carbone et al., 2016). In
addition, AgNP are currently being investigated by different studies as a
chemotherapeutic in cancer treatment (Asharani et al., 2012, Juarez-Moreno et al.,
2016, Foldbjerg et al., 2011, Foldbjerg et al., 2012). Unfortunately, with the rise in the
biomedical applications of AgNP, development of adverse conditions due to repeated
human exposure to AgNP is imminent either from direct contact with products
containing AgNP or AgNP that has leached into the ecosystem. AgNP has been
reported to cause several adverse effects such as skin irritation and discolouration,
hepatotoxicity, kidney damage, DNA damage and epithelia cell damage (León-Silva
et al., 2016).
Adverse reactions of conventional drugs are not uncommon and improvement on the
delivery mechanisms has been a major way to limit these setbacks. For AgNPs
however, there has been little or no research into how to improve upon the delivery
mechanism to enhance their antibacterial or anticancer activities. The applications of
liposomes in drug delivery systems (DDS) have been studied for more than two
decades and there have been significant improvements in the formulations and
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methods by which liposome are prepared. For instance, phosphatidylcholine (PC)
based lipids are highly used in liposome preparation likely due to the fact that PC
makes up about 80% of the surfactants found on epithelial lining of human airways
and lungs. Interestingly, the majority of the PC in the human airways is present in the
form of dipalmitoyl phosphatidylcholine (DPPC), and this makes up about 60% of the
natural surfactants found in the human airways and lungs (Agassandian and
Mallampalli, 2013). Consequently, DPPC is highly unlikely to elicit immune response
when incorporated in a liposomal formulation compared to the other derivatives.
Liposomes are designed to mimic the lipid bilayer of the cell membrane and while the
natural bilayer of the cell membrane is made up different phospholipids, they also
contain cholesterol molecules that help restrict the movement of the fluid phospholipid
molecules. In the same manner, it has been shown that cholesterol, when incorporated
in liposomal formulations at the right concentration can produce such rigidity to
protect the liposomal content (Briuglia et al., 2015). In this study, AgNP synthesised
by chemical reduction of silver nitrate (AgNO3) using sodium borohydride (NaBH4)
was encapsulated in a DPPC/cholesterol liposome to both stabilize and improve the
uptake of the AgNP in vitro for enhanced cytotoxicity. Two simple encapsulation
methods were trialled AgNP, followed by nanoparticle characterization and evaluation
of cytotoxicity on a THP1 cell line, a monocytic cell line which acts as first line of
defence against nanoparticle during exposure (Wu et al., 2017)..
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3.1

Results

3.2 DLS characterisation
Results of the DLS characterization of AgNP is summarized in Table 3-1 for
dispersions in water (ddH2O) and RPMI-1640 culture media. DLS analysis of AgNP
shows an increase in mean particle size (MPS) of AgNP when dispersed in ddH2O to
RPMI-1640 media from 21.14 nm to 79.15 nm with polydispersity index (PDI) 0.230
to 0.566 respectively. The zeta analysis for AgNP in ddH2O was -26.5 mV which
dropped to -7.90 mV in RPMI-1640 media. There was also change in AgNP colour
from golden yellow in ddH2O to dark grey when dispersed in RPMI-1640 media which
is likely due to agglomeration of the nanoparticle.
Table 3-1. Size and Zeta potential of uncoated AgNP, PB-Lipo-AgNP and Ex-LipoAgNP in ddH2O and RPMI-1640
ddH2O

Uncoated
AgNP

PB-LipoAgNP

Ex-LipoAgNP

media

Peak 1 (%)

Peak 2 (%)

Peak 1 (%)

Peak 2 (%)

DLS
Intensity
PSD (nm)

21.14±9.48

-

79.15±66.67

-

Zeta (mV)

-26.50

-

-7.90

-

PDI

0.230

-

0.566

-

DLS
Intensity
PSD (nm)

143.7±64.18
(98.7)

5005±605.6
(1.3)

268.7±186.9
(80.4)

2555±1325
(19.6)

Zeta (mV)

-25.9

-0.96

PDI

0.305

0.437

DLS
Intensity
PSD (nm)

140.1±47.49 (100) N/A

138.9±54.93
(86)

Zeta (mV)

-31.9

-0.61

PDI

0.105

0.421

3928±1081 (14)
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3.3

SEM/STEM and spectra analysis of AgNP

SEM analysis of the AgNP showed a spherical nanoparticle with average size of 14.3
± 1.9 nm (Figure 3-1A). The UV-Vis spectra of the different AgNP concentration
ranging from 0.625 to 10 µg/ml are depicted in Figure 3-1B, showing a characteristic
peak absorption (λmax) corresponding to the surface plasmon resonance (SPR) of 20
nm AgNP at around 400 nm, which was the approximate size obtained by DLS. The
peak flattening corresponds to decrease in concentration of AgNP, explained by the
reduction in the amount of AgNP particles that absorbs UV light at the wavelengths
indicated.
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Figure 3-1. SEM/STEM and UV-Vis Spectra analysis of AgNP
(A) SEM and of AgNP with STEM image inset (B) UV spectra analysis of 0.625 to
10 µg/mL of AgNP measured at 22.6oC.
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3.4

Liposome characterisation

PB-Lipo-AgNP size increased from 143.7 when in ddH2O to 268.7 nm after dispersion
in RPMI-1640 media (Table 3-1). A second peak of larger sized particles was observed
in both ddH2O (1.3%) and RPMI media (19.6%) likely due to agglomeration. The PDI
of PB-Lipo-AgNP also increased from 0.305 to 0.437 after resuspension in RPMI1640 media but there was a reduction in zeta potential from -25.9 mV in ddH2O to 0.96 after dispersion in RPMI-1640 media.
For Ex-Lipo-AgNP, there was a small decrease in size from 140.1 nm in ddH2O to
138.9 nm (half that of PB-Lipo-AgNP) when dispersed in RPMI-1640 media. Unlike
the PB-Lipo-AgNP, extrusion produced Lipo-AgNP that was 100% uniform in size in
ddH2O, however, a second peak was found at 3.9 µm for 14% of the particles in RPMI
media (Table 3-1). In contrast, Ex-Lipo-AgNP had a PDI of 0.105 in ddH2O but this
increased to 0.421 in RPMI-1640 media. There was also a reduction in zeta potential
of Ex-Lipo-AgNP from -31.9 mV in ddH2O, higher than that of PB-Lipo-AgNP to 0.61 mV in RPMI-1640.
An overlay of DLS size values of the uncoated AgNP in ddH2O was carried out with
the size values of the PB-Lipo-AgNP obtained with the same AgNP solution both in
ddH2O and in RPMI media (Figure 3-2C). Overlap in AgNP size value with that of the
PB-Lipo-AgNP dispersed in ddH2O was observed, indicating some of AgNP had not
been encapsulated within the PB-Lipo-AgNP. In addition, a shift in the major peak of
the PB-Lipo-AgNP was observed for a 120 nm increase in size from dispersion in
ddH2O to RPMI, accounting for 20% of the total nanoparticle. Ex-Lipo-AgNP
exhibited no overlap with AgNP in both dispersion media, indicating both
nanoparticles have distinct populations (Figure 3-2D). In addition, there was only a
single peak observed for Ex-Lipo-AgNP dispersed in ddH2O indicative of uniform
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nanoparticle although there was a slight shift in the major peak to the left as the size
reduced by 1.2 nm while a second peak was also visible, accounting for 14% of the
total nanoparticle likely due to agglomeration in RPMI.

Figure 3-2. SEM/STEM of PB-Lipo-AgNP and Ex-Lipo-AgNP:
(A) SEM with STEM (inset) of PB-Lipo-AgNP, and overlay of AgNP size value with
PB-Lipo-AgNP (B) SEM with STEM (inset) Ex-Lipo-AgNP and overlay of AgNP
size value with Ex-Lipo-AgNP
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3.5 UV-Vis spectra analysis of encapsulated AgNP and encapsulation
efficiency
Different concentrations of PB-Lipo-AgNP and extruded AgNP, were analysed by
UV-Vis spectra to investigate whether the AgNP has been successfully encapsulated
(Figure 3A and B). PB-Lipo-AgNP showed a similar spectra characteristic with AgNP
especially at 10 µg/ml but there was a red shift in the AgNP peak at around 410 nm,
observable for both 5 µg/ml and 10 µg/ml. There was considerable peak flattening at
concentration ≤ 5 µg/ml (Figure 3-3A). It was observed that PB-Lipo-AgNP was
cloudy with lipids and retained the golden yellow colour of AgNP showing presence
of free AgNP (Figure 3-2A inset). On the contrary for Ex-Lipo-AgNP, the peak
absorbance was barely observed even at 10 µg/ml and there was also a red shift in the
peak at around 410 nm (Figure 3-2B). Ex-Lipo-AgNP solution was clear and did not
retain the golden yellow colour of AgNP (Figure 2B inset), likely because of the
refraction due to the lipid layer of the liposome. PB-Lipo-AgNP also had higher
absorbance compared to Ex-Lipo-AgNP (at 10 µg/ml) which has similar baseline with
uncoated AgNP (Figure 3-3C), indicating no agglomeration of Ex-Lipo-AgNP. The
EE was determined to be 67.8% and 86.5% for the PB-Lipo-AgNP and Ex-Lipo-AgNP
respectively, which may explain the similarities between the UV-Vis spectra of free
AgNP and PB-Lipo-AgNP since less AgNP was encapsulated.
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Figure 3-3. UV-Vis Spectra of PB-Lipo-AgNP and Ex-Lipo-AgNP
UV-Vis spectral analysis of(A) PB-Lipo-AgNP and (B) Ex-Lipo-AgNP at different
concentrations between 0.625 µg/ml to 10 µg/ml (C) combined UV-Vis spectra of 10
µg/ml AgNP, Ex-Lipo-AgNP and PB-Lipo-AgNP.
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3.6

SEM/STEM analyses of Lipo-AgNP

PB-Lipo-AgNP and Ex-Lipo-AgNP were analysed microscopically by SEM and
STEM (Figure 2A and B). As shown, PB-Lipo-AgNP formed agglomerates unlike ExLipo-AgNP. SEM analysis of Ex-Lipo-AgNP showed non-agglomerating spherical
liposomes with a well-defined structure. STEM of the PB-Lipo-AgNP (Figure 2A
inset) showed AgNP found coated on the liposome with very few nanoparticles
encapsulated within. The AgNP in Ex-Lipo-AgNP shown in the STEM (Figure 2B
inset) were all encapsulated within the liposome (grey sphere). This alludes to the EE
and spectra characteristics of both PB-Lipo-AgNP and Ex-Lipo-AgNP. Size
estimation from SEM indicated Ex-Lipo-AgNP was 162.73 ± 29.23 nm while the PBLipo-AgNP was 204.22 ± 45.39 nm representing the average of 20 particles counted
and similar to the value obtained by DLS.
3.7

Temperature-dependent size change, stability analyses and load release
profile of Lipo-AgNP

The practicability of the Lipo-AgNP to retain their contents in in vitro experiments
was tested under incubation conditions. Sizes of both PB-Lipo-AgNP and Ex-LipoAgNP with respect to temperature changes was monitored using DLS in RPMI-1640
media containing 10% FBS over 6 h at 20 mins interval for a degree rise in
temperature. The initial size of PB-Lipo-AgNP doubled that of Ex-Lipo-AgNP
confirming the values in Table 3-1. PB-Lipo-AgNP size reduced from 334 nm at 20oC
to 150.2 nm, a 55% reduction in size at 37oC. For Ex-Lipo-AgNP, a reduction from
174.7 nm at 20oC to 113.1 nm at 37oC, a 35.3% reduction in size was observed (Figure
3-4B). This reduction in size could be as result of loss of liposomal content due to

increase in temperature.
Stability analyses of the liposomes over a 6-month period is shown in Table 3-2. After
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6 months of incubation, the MPS and zeta potential of PB-Lipo-AgNP increased by
10.3 nm and 5.1 mV respectively at 4oC. Compared to 4oC, PB-Lipo-AgNP at 24oC
exhibited a higher reduction in MPS and zeta potential of 19 nm and 4.3 mV for the 6
months in addition to the sedimentation of the lipids that was observed. On the
contrary, Ex-Lipo-AgNP showed slight increase in size as well as zeta potential over
the 6-month period. At 4oC, an overall 3.2 nm and 2.0 mV MPS and zeta potential was
observed, which was comparable to that observed at 24oC (5.9 nm and 2.5 mV MPS
and zeta potential respectively), and lower to that of PB-Lipo-AgNP for the same time
points.
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Figure 3-4. Stability kinetics of probe-sonicated and extruded Lipo-AgNP
Temperature dependent changes in the sizes of (A) PB-Lipo-AgNP and (B) Ex-LipoAgNP dispersed in RPMI-1640 culture medium were analyzed by DLS. Values are
mean ± SD from average of three independent measurements.
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Table 3-2. Stability of PB-Lipo-AgNP and Ex-Lipo-AgNP over a 6-month period
Temp

Initial size
(nm)

Initial
Zeta
(mV)

4oC
PB-LipoAgNP
Ex-LipoAgNP

o

24 C

143.7±64.
18

24oC

Size (nm)
149.44±9.7

-25.9
153.27±9.61

4oC
140.1±47.
49

Month 1

142.23±3.4
-31.9
141.33±1.72

Month 3
Zeta
(mV)
-25.5
-24.1
-30.5
-30.9

Size (nm)
151±13.3
156.26±8.
9
144.4±2.5
145±1.98

Month 6
Zeta
(mV)
-24.3
-23.1
-30.0
-30.7

Size (nm)
154±20.3
161.34±14
.5
143.33±1.
3
146±2.4

The load release profile of both Lipo-AgNPs was carried out to evaluate AgNP release
from the nanocapsule using dialysis. Due to the large volume of fluid outside the
dialysis tube and the effect this will have on the absorbance of minute quantity of
released nanoparticles from the dialysis tube, the absorbance of the sample inside of
the dialysis tube was measure instead, as drop in absorbance will corresponds to the
amount of AgNP released into the buffer. As shown in Figure 3-5A, PB-Lipo-AgNP
appeared to have initial burst release of AgNP as more than 25% of the encapsulated
AgNP was released within the first 2 h at pH 6.5. Afterwards, a release of 29% to 30%
at 4 and 6 h respectively was observed. Unlike PB-Lipo-AgNP, the extruded AgNP
showed a steady release from 2 h up till 6 h, releasing only 15% of the encapsulated
AgNP at 6 h, a significantly lower release to that of PB-Lipo-AgNP. Both
nanocapsules exhibited similar release at 24 h with PB-Lipo-AgNP releasing 80% of
encapsulated AgNP while Ex-Lipo-AgNP released 74%. At physiological pH of 7.45,
PB-Lipo-AgNP exhibited lower release rate of AgNP from 2 h to 6 h releasing 0.8%
to 12.5% respectively. In the same time point, Ex-Lipo-AgNP only released 0.7% to
3.5% respectively, a significantly lower release than that of PB-Lipo-AgNP. At 24 h,
Ex-Lipo-AgNP released 70%, a significantly lower release compared with PB-LipoAgNP exhibiting 79% AgNP release (Figure 3-5B).
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Figure 3-5. pH dependent drug release profile of PB-Lipo-AgNP and extruded
Lipo-AgNP
Encapsulated AgNP in (A) acetate buffer at pH 6.5 or (B) PBS at pH 7.45 and at
specific time interval, 200 µL of the sample was taken out for absorbance
measurement. Data is presented as mean ± SD of 3 independent experiments * p <
0.05, ** p < 0.01, **** p < 0.0001.
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3.8

Cell viability

To evaluate if the stability of Ex-Lipo-AgNP translates to enhanced cytotoxicity,
THP1 cells were first stimulated with 100 ng/ml PMA to induce adherence of the cell
line prior to exposure to facilitate easy removal of uninternalized liposome and prevent
cell loss during wash steps. After 24 h of exposure to the nanoparticles, viability of
the PMA-stimulated THP1 cells was evaluated by their ability to convert the nonfluorescent resazurin in AB dye into a fluorescent resorufin. As shown in Figure 3-6A,
Ex-Lipo-AgNP induced significant reduction in cell viability at concentration ≥ 1.25
µg/ml while uncoated AgNP and PB-Lipo-AgNP induced significant reduction in the
THP1 cell viability at 5 µg/ml. It was observed that Ex-Lipo-AgNP at concentrations
of 1.25 and 2.5 µg/ml were significantly more cytotoxic on THP1 cell than the PBLipo-AgNP at the same concentration.
A flow cytometry cell viability study was carried out to confirm AB assay findings.
THP1 monocytes exposed to AgNP, PB-Lipo-AgNP and Ex-Lipo-AgNP were stained
with calcein-AM and PI. Calcein-AM is a non-fluorescent stain hydrolysed by esterase
activity of viable cell into a fluorescent calcein derivative that is maintained within
cell with intact cell membrane (Uggeri et al., 2000), while PI only permeates
compromised membrane of dead cells. As expected, Ex-Lipo-AgNP induced
significantly more cell death compared to free AgNP and PB-Lipo-AgNP (p < 0.001).
A significantly higher proportion of early apoptotic cells positive for both calcein and
PI (9.7%) and late apoptotic cells that are only positive for PI (26.4%) was observed
in Ex-Lipo-AgNP exposed cells compared to unexposed control cells, free AgNP and
PB-Lipo-AgNP exposed groups (Figure 3-6B). In addition to this, PB-Lipo-AgNP
exposure resulted in higher proportion of cells identified as cellular debris (22.6%)
compared to Ex-Lipo-AgNP (1.1%) which was similar to that in untreated controls
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and free AgNP exposed cells (0.2%) (p < 0.001). This cell population are likely due
to PB-Lipo-AgNP identified as cellular debris due to the larger and ununiform sizes.
To further confirm the effect of the Lipo-AgNPs on cell viability, confocal microscopy
was used to analyse calcein-AM and PI stained PMA-stimulated THP1 cells exposed
to nanocapsules containing equivalent amount of 2 µg/ml AgNP for 24 h. THP1 cells
that were exposed to either of PB-Lipo-AgNP or Ex-Lipo-AgNP appeared to have
spotted calcein fluorescence (Figure 3-7A and B). This was unlike the control-untreated
THP1 cells which appeared to have uniform calcein stain throughout the cytoplasm.
In addition, only Ex-Lipo-AgNP induced significantly higher cytotoxicity on THP1
cells compared with control-untreated or PB-Lipo-AgNP exposed cells (p < 0.01)
(Figure 3-7A and B). Similarly, only Ex-Lipo-AgNP resulted in significantly higher PI
fluorescence when compared to both PB-Lipo-AgNP exposed and control-untreated
cells (p < 0.001). Thus, verifying the result of the AB and flow cytometry assays.
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Figure 3-6. Cell viability of PMA-stimulated THP1 cells post-exposure to AgNP
nanocapsules
(A) AB assay determining viability of THP1 cells exposed to 0.3 to 5 µg/mL AgNP,
PB-Lipo-AgNP and Ex-Lipo-AgNP for 24 h (B) THP1 monocytes cell viability by
flow cytometry after exposure to 2 µg/ml of AgNP, PB-Lipo-AgNP and extruded
Lipo-AgNP. Calcein was assessed on FL-1 channel while PI was assessed in the FL3 channel. Data is presented as mean ± SD of the 3 independent experiments and
similar values were obtained. ***p < 0.001 and ****p < 0.0001
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Figure 3-7. Cell viability by confocal microscopy
(A) Confocal microscopy assessment of PMA-stimulated THP1 cell viability after
exposure to 2 µg/ml of AgNP, PB-Lipo-AgNP and extruded Lipo-AgNP. Calcein
fluorescence is shown in green and PI fluorescence in red (B) fluorescence intensities
quantified by ImageJ software from 50 different cells. Data is presented as an abstract
value and as mean ± SD of 3 independent experiments. *p ≤ 0.05 and **p < 0.01.
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3.9

Discussion

AgNP can be synthesized from AgNO3 by different methods such as using reducing
agents like citrate or NaBH4 with further stabilization of the nanoparticle with
compounds such as polyvinyl alcohol (PVA) (Becaro et al., 2015, Cheon et al., 2015,
Dong et al., 2009). A citrate-based reduction is most commonly used in the synthesis
of AgNP because of its reducing and stabilizing functionality. However, reduction of
AgNO3 with citrate results in formation of AgNP in complex with the citrate ions
which prevents the release of elemental silver (Djokic, 2008), limiting its effects. It is
reported here that the encapsulation of AgNP in a DPPC based liposome through
different methods enhances its associated cytotoxicity. The AgNP synthesis employed
here was designed to yield elemental AgNP through reduction of AgNO3 by NaBH4
as in the equation below;
AgNO3 (aq) + NaBH4 (aq) à Ag0 (s) + ½ B2H6 (g) + ½ H2 (g) + NaNO3 (aq)
One of the aims of this study was to encapsulate AgNP in a DPPC liposome, as DPPC
is a natural biosurfactant in human airways. Thus, it is hoped that such a system will
result in a very low capability of inducing adverse immune responses. SEM images of
PB-Lipo-AgNP indicated a high agglomeration while that of Ex-Lipo-AgNP indicated
a uniform spherical nanoparticle. In addition, DLS analyses indicated higher average
size for PB-Lipo-AgNP compared to Ex-Lipo-AgNP both in ddH2O and RPMI media.
It is believed that PB-Lipo-AgNP increased size could have significant impact on
cellular response. It is known that larger nanoparticles have reduced bioavailability as
they are quickly eradicated by the reticulo-endothelial system (Maruyama, 2011),
making PB-Lipo-AgNP less practical for in vitro applications as a drug delivery
system. PB-Lipo-AgNP exhibited a lower zeta potential -25.9 mV while that of ExLipo-AgNP was -31.9 mV. Nanoparticles with zeta potential value between -30 and
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+30 mV are considered less stable owing to the increased agglomeration potential due
to reduced repulsion between the particles (Shieh et al., 2012), indicating the Ex-LipoAgNP is more stable. In addition to this, the PDI of PB-Lipo-AgNP was found to be
higher than that of Ex-Lipo-AgNP in ddH2O, indicating that Ex-Lipo-AgNP are of
more uniform size compared to PB-Lipo-AgNP.
The UV-Vis spectra analysis of free AgNP conformed with reported SPR
characteristic of a 20 nm AgNP which is at 400 nm (Zuber et al., 2016), in a way
confirming the DLS size of 21 nm. UV-Vis spectra analysis of both PB-Lipo-AgNP
and Ex-Lipo-AgNP also allude to the success of the encapsulation process. PB-LipoAgNP and AgNP had a similar spectra profile with same λmax although PB-LipoAgNP spectra exhibited a broadened peak with a raised baseline and a red shift in the
λmax, which are indicative of agglomeration/size increase. The λmax also indicates
free AgNP that are not successfully encapsulated absorbing UV emission to produce
the observed spectrum. In support of this, an overlap in the DLS size value of AgNP
with the ddH2O dispersed PB-Lipo-AgNP observed indicates that the PB-Lipo-AgNP
particles in the overlap region is more likely to be uncoated AgNP. Contrastingly, ExLipo-AgNP spectra depicted a flat peak with same baseline as free AgNP which hints
at non-agglomeration of the nanoparticle. The spectra observed at 10 µg/ml was
similar to that of 1.25 µg/ml of free AgNP indicating less free AgNP that are able to
absorb at the UV-Vis wavelength. This observation is also supported by non-overlap
of the AgNP and Ex-Lipo-AgNP DLS size values.
Interaction between nanoparticles and culture media proteins is not uncommon based
on their surface reactivity. This interaction was monitored through the size and zeta
potential of the liposomes in RPMI-1640 medium. There was increase in the size of
PB-Lipo-AgNP and drastic reduction in its zeta potential. The dramatic increase in
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PB-Lipo-AgNP size in RPMI-1640 could be due to the AgNP on the surface
interacting with the proteins in the culture medium as also observed for free AgNP.
This is in agreement with the findings of Sabuncu et al. (2012) who also reported an
increase in gold nanoparticle size and decrease in the zeta potential when dispersed in
foetal calf serum (FCS) supplemented DMEM culture. This is supported by the DLS
overlay of PB-Lipo-AgNP in ddH2O and RPMI which indicates increase in size of the
nanoparticle from dispersion in ddH2O to RPMI medium. On the contrary, there was
a considerable drop in the zeta potential of Ex-Lipo-AgNP, with only a small increase
in the percentage of nanoparticles with increased size (14%). This could mean that ExLipo-AgNP do not readily react with proteins in the culture medium, resulting in no
net increase in the size after dispersion in FBS containing RPMI-1640 medium.
Interestingly, the charges on the protein amino acids may have a masking effect on
Ex-Lipo-AgNP zeta potential. The spectra characteristic of Ex-Lipo-AgNP was less
similar to that of AgNP, although with a red shift in λmax at 410 nm. Taken together
with the similar baseline as free AgNP and the low absorbance at λmax which is about
50% less than that of free AgNP and PB-Lipo-AgNP, the shift is likely due to the
increase in size contributed by the liposome. This also shows that the AgNP is bound
to the liposome assuming a larger size than prior to encapsulation such that less AgNP
particles are available to interact with proteins in the RPMI media and absorb UV
emission. In a study investigating the use of AgNP as biosensor, a red shift in the
spectra of a 19 nm AgNP was reported to be consequent upon the binding of the
nanoparticle to protein ligands present on the biosensor platform (Liao et al., 2009),
explaining why there was no considerable change in the Lipo-AgNP size in the media.
In temperature dependent study, it was noted that the PB-Lipo-AgNP size decreased
by more than half at 37oC whereas Ex-Lipo-AgNP only decreased in size by about a
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quarter of the original size. The reason for reduction in their sizes with increased
temperature is not known, but this could be as a result of the increased fluidity of the
lipid bilayer at temperature close to the transition temperature. Increased fluidity could
result in the movement of the liposomal water content out of the liposome into the
more concentrated culture medium by osmosis. A previous report indicated liposome
often lose their aqueous content when dispersed in medium of high osmolarity
(Monteiro et al., 2014), such that water moves from region of lower concentration to
region of higher concentration through the lipid bilayer. As such, Ex-Lipo-AgNP
appeared to be more stable with respect to its ability to retain its content at 37oC. The
stability study over a 6-month period also indicated Ex-Lipo-AgNP to be more stable
with minimal overall increase in size and zeta potential at both 4oC and 24oC compared
to PB-Lipo-AgNP which was also found to sediment unlike the Ex-Lipo-AgNP that
remained clear.
Encapsulation of AgNP in liposome here was carried out with the intent of improving
its cytotoxicity as a chemotherapeutic agent. Hence, it became pertinent to carry out
drug release studies. Considering the possible route of administration and target site
for the encapsulated AgNP, pH of 7.45 which is the physiologic pH and most culture
media (relevant for in vitro studies) and pH 6.5 which is known to be the pH of the
tumour microenvironment and inflamed tissue (Ueno et al., 2008, Huber et al., 2017,
Som et al., 2016), were considered. One of the major problems associated with drug
delivery systems is the initial burst release which is associated with an initial
hypertoxicity and suboptimal concentration of the drug at the time it reaches the target.
A good drug delivery system is expected to protect the drug against the harsh
physiological environment of immune cells, minimize the burst release and maintain
a steady release of the drug for optimal concentration to achieve maximum efficacy
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over a period. Findings in this study, showed that PB-Lipo-AgNP possesses initial
burst release at pH 6.5 and 7.45. Ex-Lipo-AgNP exhibited and maintained a steady
release of AgNP at pH 6.5 with significantly lower release compared to PB-LipoAgNP. At 24 h, the two systems have released similar concentration of AgNP. At
physiologic pH of 7.45, PB-Lipo-AgNP had already released 12.5% of the
encapsulated AgNP compared to 3.5% of Ex-Lipo-AgNP. Initial burst release has
been demonstrated for Ag+ coated with titanium dioxide used as an antibacterial for
Staphylococcus aureus (Jamuna-Thevi et al., 2011). Although it was found that this
rapid release produced an effective antibacterial effect, this effect can be quite adverse
in an in vivo model.
Initial burst release has been proposed to occur consequent upon rapid dissolution of
weakly or poorly encapsulated drugs that might be attached to the surface of the
delivery systems (Rivadeneira et al., 2014, Hua et al., 2014, Singh and Lillard, 2009,
Tan et al., 2014). This supports the deduction from UV/Vis spectra features of PBLipo-AgNP to weakly encapsulate AgNP with some free AgNP attached to the surface
of the liposome as also depicted in the STEM image. Contrastingly, the finding here
indicated that Ex-Lipo-AgNP can maintain steady AgNP release at both pH 6.5 and
7.45. The advantage is that the absence of initial burst release of Ex-Lipo-AgNP
prevents initial hypertoxicity. On the other hand, while Ex-Lipo-AgNP had
significantly less drug release at 24 h compared with PB-Lipo-AgNP at pH 7.45,
stability of Ex-Lipo-AgNP may facilitate better drug delivery with better net
cytotoxicity. In support of the finding for Ex-Lipo-AgNP however, Ruttala and Ko
(2015), showed that a liposomal anti-tumour agent with steady load release exhibited
enhanced cytotoxicity.
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The uncertainty that encapsulation of AgNP translates to enhanced and improved
cytotoxicity led to the investigation of the cytotoxicity of PB-Lipo-AgNP and ExLipo-AgNP on THP1, a leukemic cell line in the monocytic lineage. The choice of the
cell line for this study is three-folds. Firstly, THP1 is a leukemic (cancer) cell line,
allowing investigation of the cytotoxic effect of AgNP encapsulation on a cancer cell
line. Secondly, monocytes and similar immune cells act as first line of defence in
response to foreign objects including nanoparticles upon human exposure (Mrakovcic
et al., 2014, Rueda-Romero et al., 2016, Robbins et al., 2015), making the cell line a
perfect model to also study the effect of the nanoparticle on the innate immune system.
In addition to this, due to the role of monocytes in diseases such as atherosclerosis and
cancer (Lameijer et al., 2013), this cell line is a potential therapeutic targets in
treatment of these diseases.
Upon exposure of THP1 monocytes to the different nanoparticles, it was discovered
that Ex-Lipo-AgNP induced significantly higher cytotoxicity at lower concentrations
compared with PB-Lipo-AgNP and free uncoated AgNP exposed cells. In addition,
flow cytometry and confocal microscopy analyses both confirmed Ex-Lipo-AgNP to
be more cytotoxic compared to PB-Lipo-AgNP and free uncoated AgNP. There was
a significantly higher live cells and less dead cells in the control-untreated, free
uncoated AgNP, and PB-Lipo-AgNP exposed cells groups compared to Ex-LipoAgNP exposed cells. Another observation was the speckled fluorescence observed in
both PB-Lipo-AgNP and Ex-Lipo-AgNP exposed cells but not the control-untreated
cells. This is likely due to the loss of membrane integrity upon exposure to the
nanoparticles resulting in leakage of calcein from the cytoplasm. Foged et al. (2008)
have previously showed that disruption of the cell membrane can result in leakage of
calcein.
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The enhanced cytotoxicity of Ex-Lipo-AgNP in comparison to AgNP or PB-LipoAgNP may be attributed to its superior characteristics and enhanced delivery. This
may have been facilitated by the hydrophobic interaction between the lipid bilayer of
the cell membrane and that of the liposome encapsulating the AgNP. On the other
hand, the slightly enhanced cytotoxicity of the PB-Lipo-AgNP may be because of less
encapsulated AgNP and lower endocytosis due to larger size in culture media. This
reason may also explain why Ex-Lipo-AgNP enhanced delivery into the cells since its
size may have remained unchanged even when reconstituted in culture media. Lastly,
flow cytometry detected more cellular debris in PB-Lipo-AgNP exposed THP1 cells
than in other exposure groups. These debris were due to the PB-Lipo-AgNP which
were larger in size and similar to left over of apoptosed cells. Unfortunately, this
identified debris are counted as events in the cytometer, imposing a confounding effect
on the number of viable cells that will be analysed. Interestingly, Ex-Lipo-AgNP does
not exhibit such anomaly, further alluding to the stability and superior characteristic
liposome obtained through the extrusion as compared with that obtained from probe
sonication. Taken together, encapsulation of AgNP in DPPC based liposome may help
limit the concentration of AgNP used in the various biomedical applications to achieve
better cytotoxicity resulting in less human exposure and mitigation of any
development of adverse effects.
3.10 Conclusion
Stable AgNP were successfully synthesized at a suitable concentration without the
need for stabilizer. Synthesized AgNP were successfully encapsulated in liposome for
the first time by both probe sonication and extrusion methods. However, the extrusion
method produced a more stable liposome both when dispersed in ddH2O and in culture
medium. The spectra analysis confirms probe sonication produced a less successful
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encapsulation based on the similarity between PB-Lipo-AgNP and AgNP spectra
characteristics. Ex-Lipo-AgNP on the other hand had a different spectra analysis
which is believed to be as a result of the shielding effect of the liposome bilayer. In
addition, Ex-Lipo-AgNP exhibited a more controlled AgNP release compared with
the PB-Lipo-AgNP which showed an initial burst release. Cell viability studies
indicated that Ex-Lipo-AgNP exhibited higher cytotoxic effect in comparison to PBLipo-AgNP and uncoated AgNP at similar concentrations. This may have been due to
the stable characteristic of Ex-Lipo-AgNP facilitating an effective delivery of the
nanoparticle into the cell. As such, extrusion method offers a more reliable way for
encapsulating AgNP in liposome with repetitive characteristics and enhanced
cytotoxicity. This provides with potential of achieving cytotoxicity at lower
concentrations compared to those currently in application limiting possible exposures.
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4
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4

“Liposomal encapsulation of silver nanoparticles enhances cytotoxicity
and causes induction of ROS independent apoptosis” Yusuf et al. 2018

Published: May 2018, Journal of Applied toxicology 38(5):616-627.

Silver

nanoparticles

(AgNP)

are

one

of

the

most

crucial

metals

in

nanomedicine/nanotechnology. They have been investigated in the treatment of
bacterial diseases and are found to possess a striking antimicrobial activity. AgNP are
known to cause oxidative lesion that destroys bacterial cell wall, facilitating its entry
into the cell to bind to sulfhydryl groups of key proteins and bacterial DNA to disrupt
crucial metabolic processes and halt cell proliferation (Feng et al., 2000, Wigginton et
al., 2010, Grigor'eva et al., 2013). This has also led to the worldwide
commercialisation of AgNP in an array of formats with up to 24 % of nanotechnology
driven everyday consumer products worldwide containing AgNP (Vance et al., 2015).
Some of the AgNP based consumable products include but are not limited to food
packaging, antibacterial creams, coatings in antimicrobial textiles and domestic
cleaning products. AgNP are widely used in medicine for dressing wounds, in making
orthodontic materials, coating of bone prosthesis, coating of stents or catheters,
cleaning surgical equipment and in certain contraceptive devices (Blaske et al., 2013,
Correa et al., 2015, Knetsch and Koole, 2011, Samuel and Guggenbichler, 2004). In
recent years, research involving AgNP has moved beyond investigating its
antibacterial properties. The possibility of AgNP as an anticancer drug has been the
subject of research due to the emergence of drug resistant cancer cells and the
discovery that AgNP possess an inherent cytotoxic effect on cancer cells (Zhang et al.,
2016).
With increasing applications of AgNP in consumable products and in medicine there
is an increased risk of exposure to the toxic side effects of AgNP that may have leached
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into the environment. (Benn and Westerhoff, 2008) showed that a sock coated with
about 1.36 mg of AgNP can release 48 % of its coating into water by simply shaking
the sock in water or as much as 100 % in four consecutive washes. AgNP can also be
released in the same manner from shampoos, toothpaste, detergents and medical
apparels (Benn et al., 2010). It has been reported that AgNP route of entry could be
through oral, pulmonary or dermal routes. Irrespective of the entry route, AgNP
induced cell death through the generation of ROS, increased DNA damage and
impairment of mitochondrial functions (Kang et al., 2012). As such, continuous use
of AgNP at these high concentrations comes with a potential danger in the near future.
For instance, inefficient delivery of AgNP to target cells could result in systemic
toxicity as it has been previously reported that prolonged bio-distribution of AgNP
could result in systemic transport to different tissues especially to the spleen and liver
(Xue et al., 2012). As such, devising ways by which low concentrations of AgNP can
be efficiently delivered to target cells thus becomes pertinent. Generally, the
unspecific systemic activities of conventional anticancer drugs are the major limiting
factor in their application as chemotherapeutics. To subvert this negative side effect,
encapsulation of drugs in lipid bilayer has been investigated for improved delivery
with promising results (Sercombe et al., 2015). For example, doxorubicin is a potent
anticancer drug that inhibits topoisomerase II preventing accessibility of DNA
polymerase to the DNA. Regardless of its potency, there is limitation to the use of
doxorubicin in cancer treatment due to the negative side effects following its
administration such as alopecia, hepatotoxicity, cardiotoxicity and nephrotoxicity
(Tacar et al., 2013). However, liposomal encapsulation of doxorubicin has been shown
to improve its delivery in addition to alleviating the negative side effects of the drug,
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reducing the required concentration to achieve cell death (Brown and Khan, 2012,
Camacho et al., 2016, Souto et al., 2016).
Liposomes like many other nanoparticles have unique characteristics that make them
efficient drug delivery vehicles. They are suitable for transporting both hydrophobic
and hydrophilic molecules, the lipid layer of liposomes can entrap hydrophobic drugs
due to hydrophobic interactions between the fatty acid chains and the drug while the
aqueous core of the liposome can also hold hydrophilic drugs (Bozzuto and Molinari,
2015). In general, liposomes are often prepared from phospholipids which then form
the outer layer of the nanostructure that can be similar to the lipid bilayer of the cell
membrane. The lipid layer of liposomes aids the passive transport of the liposome and
its associated content into the cell. This prevents the requirement of membrane
channels or pumps normally controlling the entry of charged or polar molecules such
as peptides, metals and synthetic compounds that can be encapsulated in the lipid
vesicle. These attributes allow for dose intensification of compounds which are
encapsulated within the liposome while limiting any negative side effects associated
with excess free drug present in a non-liposome delivery method (Silverman et al.,
2013). Liposomes have controllable sizes and their surface properties are easily
modified in the synthesis process and can be tailored to any functional delivery
requirements. These properties coupled with an enhanced permeability and retention
(EPR) effect in vivo, increases their ability to accumulate in a tumour
microenvironment, which is typically composed of leaky vessels and abnormal cell
junctions (Nehoff et al., 2014, Xing et al., 2016).
In this study, AgNP were encapsulated in a liposome made of natural bio-surfactant,
DPPC to improve delivery due to increased permeabilisation into the target cells. It is
hoped that such a system will not only reduce the non-specific cytotoxic effect
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observed during AgNP treatment, but it may also reduce the concentration of AgNP
required to elicit the expected cytotoxic response. Subsequently, this may help reduce
the development of resistant strains to AgNP based drug as well as eliminate the
release of AgNP in large quantities into the ecosystem.
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4.1 Results
4.1.1

Particle characterisation

It was demonstrated in Chapter 3 that extruded Lipo-AgNP is more stable than the
probe sonicated Lipo-AgNP with more superior characteristics. Hence, the extruded
Lipo-AgNP was used in subsequent studies. A summary of the synthesised
nanoparticles characterisation using DLS is shown in Table 4-1 for different
dispersion environments. DLS analysis of AgNP showed a dramatic increase in mean
particle size when dispersed in RPMI-1640 media when compared to dispersion in
ddH2O from 21.24 nm to 79.15 nm respectively. This increase in size was
accompanied by a change in colour of the AgNP when dispersed in RPMI-1640 from
the usual golden yellow colour to dark grey colour. In contrast, there was no significant
change in the mean particle size of Lipo-AgNP when dispersed in RPMI-1640
compared to ddH2O and no colour change when dispersed in RPMI-1640 media. There
was an observable increase in polydispersity index (PDI) of the AgNP (PDI = 0.23 to
0.566) and the Lipo-AgNP (PDI = 0.105 to 0.421) when dispersed in water compared
to dispersion in RPMI-1640 media. However, no sedimentation was observed for the
AgNP when dispersed in RPMI-1640 likely due to the concentration used. There was
a measurable drop in zeta potential values for AgNP (zeta = -26.5 mV to -7.9 mV) and
Lipo-AgNP (zeta = -31.9 mV to -0.61 mV) when dispersed in ddH2O to RPMI-1640
media, indicating a less stable nanoparticle in RPMI-1640 media.
As shown in Figure 1B, EDX analysis confirmed the presence of elemental AgNP in
the sample as the strong peak at 3 keV. The other peaks observed correspond to other
elements due to sample preparation, the substrate (Si wafer) and carbon tab for
conductive support. Result from XRD characterisation of AgNP is shown in Figure
1C. The XRD pattern shows four main peaks for AgNP at 2θ values of 38.30o, 44.55o,
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64.60o and 77.55o which corresponds to (111), (200), (220) and (311) planes
respectively for the face centred cubic (fcc) structure of metallic silver. This pattern is
in agreement with that of the JCPDS file no. 04-0783 confirming the crystalline
structure of the synthesised AgNP (Luna et al., 2016). The average size of synthesised
AgNP was estimated by the Debye–Scherrer’s equation (Equation 3)
5.78

D = 9:;<= -----> Equation 3
Where D is the size of AgNP crystal in nm, λ is the wavelength of the diffractometer,
β is the full width at half maximum intensity and θ is the Bragg angle. Based on the
equation, the size of AgNP crystal was estimated to be 18.7 nm which was similar to
that of the average size as determined by DLS measurement of 21.24 nm.
Table 4-1. Size and Zeta potential of AgNP, lyophilised and extruded Lipo-AgNP
nanoparticles in ddH2O and RPMI-1640 media

AgNP

Extruded
LipoAgNP

In ddH2O

In media

Intensity PSD

Intensity PSD

DLS (nm)

21.14±9.48

79.15±66.67

Zeta (mV)

-26.50

-7.90

PDI

0.230

0.566

DLS (nm)

140.1±47.49

138.9±54.93

Zeta (mV)

-31.9

-0.61

PDI

0.105

0.421

SEM and STEM were used to evaluate the morphology of the nanoparticles and to
estimate the size distribution values of the nanoparticles in dry state. The STEM
analysis of AgNP showed all particles produced were spherical with an average size
of 14.3 ± 1.9 nm which is similar to that estimated by the XRD analysis (Figure 4-1A).
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SEM analysis of Lipo-AgNP showed spherical and uniformly extruded vesicles while
the contrasting image of the STEM showed encapsulation of the AgNP in the liposome
with an average size of 82.73 ± 29.23 nm (Figure 4-2A and B) which displays size
values less than the DLS values which considering the hydrodynamic radius of the
nanoparticles was expected (Table 4-1). To confirm the encapsulation, DLS values of
both AgNP prior to and after encapsulation were overlaid to determine if any
unencapsulated AgNP were present in the test sample (Figure 4-2C). As expected,
there was no overlap in the size values showing successful encapsulation of AgNP.
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Figure 4-1. AgNP characterisation by STEM, EDX and XRD
Characterisation of nanoparticles showing (A) STEM (B) EDX analysis of AgNP on
a Si wafer (C) XRD pattern of AgNP synthesised by chemical reduction method.
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Figure 4-2. Lipo-AgNP characterisation by SEM/STEM and DLS
Characterisation of nanoparticles showing (A) STEM (B) SEM and (C) Superposition
of AgNP DLS analysis before and after encapsulation in extruded liposome
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4.1.2

Encapsulation efficiency

Encapsulation efficiency of Lipo-AgNP was estimated based on Equation 2. A 10
µg/ml AgNP solution (representing total AgNP added) was used to rehydrate the lipid
film and the liposome was prepared as described above. The encapsulation efficiency
of the different Lipo-AgNP preparations (Lipo-AgNP-L1 to L3) are shown Table 4-2
was between 85 and 89 % of the total AgNP added prior to encapsulation.
Table 4-2. Encapsulation efficiency of Lipo-AgNP
Lipo-AgNP-L1 Lipo-AgNP-

Lipo-AgNP-

L2

L3

Total AgNP (µg/ml)

10.00

10.00

10.00

AgNP in Supernatant (µg/ml)

1.13

1.50

1.43

Encapsulation efficiency

88.7 %

85.0 %

85.7 %

4.1.3

Cellular viability study

The cell viability of THP1 cell line was evaluated by AB assay. The assay evaluates
the ability of metabolically active cells to reduce resazurin, a non-fluorescent blue dye
to resorufin, a pink fluorescent product. Reduction of resazurin is done by both
mitochondrial and cytoplasmic reducing agents such as NADPH, NADH, FMNH and
FADH as such the assay gives a broad indication of cellular viability (Rampersad,
2012). THP1 cells were exposed to varying concentrations of AgNP and Lipo-AgNP
(0.3 – 5 µg/mL) for 24 and 48 h. To evaluate possible ionisation of AgNP into Ag+,
THP1 cells were exposed to same concentration of Ag+ for 24 h. At 24 h, there was
significant reduction in THP1 cell viability treated with 2.5 μg/mL of Lipo-AgNP and
cells treated with 5 μg/mL AgNP and Lipo-AgNP when compared with the unexposed
control cells (Figure 4-3A). Interestingly, the cytotoxic effect of Ag+ was 3-fold that
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of AgNP, showing a highly significant reduction in THP1 cell viability at
concentrations 0.625 to 2.5 µg/ml and 2-fold reduction at 5 µg/ml after 24 h. Ag+
induced significant reduction in THP1 cell viability when compared with AgNP at
concentrations ≥ 0.625 μg/mL. The IC50 of AgNP, Lipo-AgNP and Ag+ at 24 h was
estimated to be 4.991 μg/mL, 3.045 μg/mL and 0.3226 µg/ml respectively. At 48 h,
there was significant reduction in cell viability for all exposure groups and
concentration when compared to control. Interestingly, it induced a significant
reduction in THP1 cell viability by 2.5 μg/mL of Lipo-AgNP compared to the AgNP
at the same concentration (Figure 4-3B). Cell viability for Ag+ was not carried out at
48 h as ≤ 20 % cell viability was already observed at 24 h. To ensure the cytotoxic
effect of Lipo-AgNP was due to the encapsulated AgNP and not the liposome, THP1
cells were exposed to empty liposome at same concentration present in 1.25 and 2.5
µg/ml or Lipo-AgNP. THP1 cell viability after 24 h exposure showed no significant
difference when compared with unexposed THP1 cells (Figure 4-4).
To verify the AB findings, the levels of THP1 cell viability after exposure were
monitored by flow cytometry. Flow cytometry is a single cell analysis method and as
a result it gives a better indication of the exact viability levels in the exposures when
compared to the AB assay. THP1 cell death was evaluated by initially staining the
cells with calcein-AM and PI 24 h after being exposed to 0.625 µg/mL of AgNP and
Lipo-AgNP. Compared to an unexposed control as with the previous viability
measurements, 10 % DMSO medium solution was used as positive control.
From the results obtained, there was no significant difference in the percentage of live
cells between the control (98.35 %) and AgNP treated cells (98.55 %) after 24 h. A
highly significant difference in the percentage of live cells treated with Lipo-AgNP
(66.75 %) was discovered in comparison with AgNP (Figure 4-5). In both control87 | P a g e

unexposed and AgNP-treated cells, only 0.5 % cell death was observed after 24 h.
Contrarily, Lipo-AgNP treatment induced cell death in 32.5 % of THP1 cells, a highly
significant increase in cell death compared with both control-unexposed and AgNPtreated THP1 cells after 24 h. This result suggests Lipo-AgNP is capable of inducing
cell death at lower dose than that established by AB assay.
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Figure 4-3. Cell viability of THP-1 cells post exposure to AgNP and Lipo-AgNP
(a) AgNP, Lipo-AgNP and Ag+ exposed cells at 24 h and (b) AgNP and Lipo-AgNP
at 48 h as determined by the Alamar Blue assay. Data is expressed as a percentage of
three independent experiments ± SEM of the 4 individual experiments and relative to
a 2D culture control. Statistically significant differences between the exposed viability
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responses and that of the control cultures are denoted by * p < 0.05, ** p < 0.01, ****
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Figure 4-4. Cell viability of empty liposome exposed cells at 24 h as determined
by the Alamar Blue assay. Data is expressed as a percentage of three independent
experiments ± SEM of the 4 individual experiments and relative to a 2D culture
control.
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Figure 4-5. Lipo-AgNP induced THP1 cell death.
Control THP1 cells, and cells treated with 0.625 μg/mL of AgNP and Lipo-AgNP and
10 % DMSO were incubated for 24 h and were washed in PBS before staining with
89 | P a g e

10 µg/mL PI and 10 nM calcein-AM. Data represent mean percentage ± SEM (n = 3).
**** p < 0.0001.
4.1.4

Cell cycle analysis

THP1 cells were exposed to 0.625 μg/mL of AgNP and Lipo-AgNP while unexposed
cells were used as control. Cell cycle analysis after 24 h of exposure showed that
exposure of THP1 cells to both AgNP and Lipo-AgNP did not affect the cell cycle
progression from G1 to S phase and there was no significant difference between the
exposed cells to control-unexposed cells. Exposure of THP1 cells to Lipo-AgNP
resulted in 21.1 % cells in the G2/M phase of the cell cycle. As expected, AgNP
treatment did not show any effect on cells in the G2/M phase having 32.65 % cells
comparable to the 30.85 % unexposed-control cells in G2/M phase. Interestingly, it
was found that Lipo-AgNP treatment resulted in 8.4 % cells in the SubG1 phase
compared with 0.65 % and 0.8 % cells for both unexposed-control and AgNP treated
cells respectively (Figure 4-6). This indicated that Lipo-AgNP at low doses caused
DNA fragmentation which was evident by the characteristic of Sub-G1 peak. The
percentage of cells in the G0/G1 and S phases remained the same in all groups,
suggesting no apparent effect of treatment on cells in all exposure groups
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Figure 4-6. Lipo-AgNP treatment induced DNA fragmentation
THP1 cell lines were treated with 0.625 μg/mL of Lipo-AgNP and AgNP while
unexposed cells and 10 % DMSO treated cells were used as controls. Data represent
mean percentage ± SEM (n = 3), *p < 0.05
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4.1.5

ROS induction

DNA fragmentation is one of the consequences of ROS generation prior to apoptosis.
To determine if the low dose Lipo-AgNP was inducing generation of ROS at sufficient
levels to induce DNA damage, ROS levels were monitored in THP1 cells exposed to
0.3 µg/mL Lipo-AgNP at varying time points indicated in Figure 4-7 alongside an
unexposed-control and uncapped AgNP in order to plot ROS generation as a function
of time. From 30 min to 5 h, there was an average of 1.5-fold induction of ROS in
cells exposed to 0.3 μg/mL of AgNP compared to control cell ROS. Cells exposed to
the same concentration of Lipo-AgNP showed mild suppression of ROS induction up
to 4 h, which significantly increased to approximately 3 folds of control ROS at 24 h.
This indicates that ROS generation was not responsible for the observed cell death in
THP1 cells exposed to 0.3 µg/mL of Lipo-AgNP.

Figure 4-7. ROS generation post exposure to AgNP and Lipo-AgNP
THP1 cell lines were loaded with 10 µM carboxy-DCFDA dye for 20 min: After which
they were exposed to 0.3 µg/mL AgNP and Lipo-AgNP for up to 4 h. Control value
was set as baseline for all time point and represented as mean ± SEM (n = 3).
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4.1.6

Caspase activation

ROS and DNA damage are known to be indicators of apoptosis and to verify this was
the mechanism of action utilised by Lipo-AgNP, the CellEvent Caspase-3/7 Green
Detection Reagent and SYTOX AADvanced Dead Cell Stain were employed. THP1
cells exposed to 0.625 μg/mL of AgNP and Lipo-AgNP were stained after 1 h, 4 and
24 h of exposure. The result showed basal caspase activities at 1 hr and 4 h in all
exposure groups with an average of 2 % of the total cell population exhibiting caspase
activities. After 24 h of exposure, the level of caspase activation remained the same
for control-unexposed cells and AgNP-treated cells. Conversely, 33 % of total THP1
cells exposed to Lipo-AgNP were positive for caspase activation at 24 h (Figure 4-8).
This result suggested the cell death observed in Lipo-AgNP exposed cells was likely
a consequence of caspase-3/7 activation.

Figure 4-8. Lipo-AgNP activates caspase-dependent apoptosis in THP1 cells after
24 h
THP1 cells that were unexposed, treated with 0.625 μg/mL of AgNP, 0.625 μg/mL of
Lipo-AgNP and 1 μM Doxorubicin were stained with 500 nM CellEvent™ for 30 min
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and co-stained with 1 µM Sytox AADvanced during the last 5 min. Data is represented
as mean ± SEM (n = 3), **** p < 0.0001.

4.2 Discussion
Currently AgNP are the main active ingredient in multiple nano-enabled commercial
products worldwide, primarily due to their antimicrobial activities. Despite this,
several studies have investigated and identified the cytotoxicity related hazards
associated with AgNP (Connolly et al., 2015, Nowrouzi et al., 2010, Zhang et al.,
2014). Interestingly, the increasing investigation of AgNP cytotoxicity has now moved
beyond antibacterial applications and recent studies are investigating the potential of
AgNP as anticancer drugs. This shift is partially due to the evolution of multidrug
resistant cancer cells similar to that of antibiotic resistant bacteria. Foldbjerg et al.
(2012) noted that AgNP at an EC20 of 12.1 μg/mL showed potential anticancer
properties such as induction of ROS, modulation of cell division and growth
regulatory gene expressions such as cyclin B1 and histone H1B and the arrest of cells
in the G2/M phase. Lin et al. (2014) showed that 10 μg/mL of AgNP produced
enhanced cytotoxicity in HeLa and B16 mouse melanoma cell lines that have
undergone chemotherapeutic or genetically induced autophagy inhibition by
preventing formation of anti-apoptotic autophagosomes normally induced by AgNP
in these cell lines. Asharani et al. (2012) showed that 400 μg/mL of AgNP induces
activation of γH2AX foci, suppresses expression of key cell cycle proteins such as
p21, p53 and cyclin B, and induces expression of DNA damage response genes RPA1
and FEN1. Several other studies evaluating the antibacterial properties and mechanism
of action of AgNP have shown the minimum inhibitory concentration of AgNP from
10 μg/mL to as high as 180 μg/mL for different bacteria strains (Bao et al., 2015,
Guzman et al., 2012, Amato et al., 2011, Maiti et al., 2014, Hsueh et al., 2015).
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Nonetheless, all of these studies have investigated AgNP activities at high
concentrations which are likely to be detrimental to human health, thus limiting the
potential therapeutic applications. Hence, this necessitates development of delivery
systems capable of delivering AgNP intracellularly at a lower concentration to achieve
the desired pharmacological response.
In this study, an in-house synthesised AgNP was encapsulated to improve the in vitro
delivery of the AgNP to enhance their in vitro effects and simultaneously reduce the
dose required. Nanoparticles are found in bodily tissues and fluid after entering the
body through different routes such as oral, intravenous, transdermal or inhalation
(Yildirimer et al., 2011). The use of THP1 in the study was to mimic such presence in
the blood system as a result of relocation in a diseased condition and as an enhanced
delivery mechanism for cancer. There are multiple reports on the effect of nanoparticle
size on drug delivery and cellular internalisation. Nanoparticles of larger sizes (< 500
nm) are, in addition to hepatic uptake, more prone to clearance by the
reticuloendothelial system resulting in reduced bioavailability and pharmacological
potential (Alexis et al., 2008, Omar Zaki et al., 2015). Both the DLS and SEM/STEM
characterisation showed the sizes of the AgNP and Lipo-AgNP to be below 30 nm and
200 nm respectively. In general, DLS values were slightly higher than that of the SEM
values and this was as expected as the DLS is an intensity measurement that tracks the
hydrodynamic radius of the solvated nanoparticle while SEM/STEM imaging is a
physical snapshot of the dry particles with no influence from surrounding solvent. As
such, the hydrodynamic radius which includes the aqueous layer tends to be slightly
larger than dry particle radius. The XRD pattern analysis using the Debye-Scherrer
equation estimated a size of 18.7 nm and peak pattern that is characteristic of an fcc
crystalline structure. This finding is in agreement to those of other studies further
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confirming the sample as metallic silver (Anandalakshmi et al., 2016, Bindhu and
Umadevi, 2015). However, there are two peaks around 26o and 30.7o that are not
characteristic of silver. These peaks may be generated by the NaBH4 reducing agent
used in chemical reduction of AgNO3 and it is similar to those reported in other studies
for NaBH4 (Su et al., 2012, Agnihotri et al., 2014).
Several studies have noted particle size changes of AgNP in cell culture environments;
as such the size distributions of AgNP and Lipo-AgNP in culture media were
monitored and compared to those in water. AgNP size increase from 21.14 nm to 79.15
nm was observed in media compared to when dispersed in water. This size increase
was presumed to be an indication of nanoparticle agglomeration in the solution. In
contrast, this was not the same for Lipo-AgNP where there was a slight reduction in
recorded sizes (140.1 nm in water and 138.9 nm in media). Previous studies have
reported an increase in AgNP size in culture media and this increase in size has been
proposed to be due to association of AgNP with proteins (Hansen and Thunemann,
2015, Shannahan et al., 2013, Murphy et al., 2015a, Mukherjee et al., 2012). The
interaction of AgNP with protein in culture media was most likely prevented by LipoAgNP due to the presence of the protective lipid layer, preventing the encapsulated
AgNP from directly interacting with biomolecules in the milieu of the culture media.
Additionally, there was an increase in PDI values for AgNP in both water and RPMI1640, the difference in these PDI values for AgNP was higher than that of Lipo-AgNP.
PDI value increases indicate an increased non-uniformity of the nanoparticles when
they were dispersed into the culture media. These findings suggest encapsulation and
formation of the Lipo-AgNP suppresses the changes in morphology of AgNP in
culture media and ultimately improves their stability in comparison to standard AgNP.
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After dispersion, cellular viability levels of THP1 cells exposed to varying
concentration of AgNP and Lipo-AgNP (0.3-5 µg/mL) for 24 h and 48 h were
monitored with the AB assay. The results showed a dose-dependent reduction in cell
viability with a greater level of cytotoxicity observed for the Lipo-AgNP treated cells.
A significant THP1 cell viability reduction was observed at 2.5 μg/mL Lipo-AgNP
treatment (p < 0.05) and interestingly not for AgNP of the same concentration after 24
h. In contrast, there was a significant reduction in cell viability of THP1 cells treated
with 2.5 μg/mL Lipo-AgNP compared to AgNP of the same concentration at 48 h (p
< 0.0001), suggesting Lipo-AgNP were more cytotoxic than AgNP. AgNP only
induced significant reduction in cell viability at 5 μg/mL and ≥ 2.5 μg/mL at 24 and
48 h respectively when compared to control. This finding is in agreement with those
of other studies that investigated dose-dependent cytotoxicity of AgNP on different
human cell lines. (Jiang et al., 2013) reported significant reduction of Chinese Hamster
Ovary (CHO-k1) cell viability at concentrations ≥ 5 μg/mL at 24 h using MTT assay.
(Juarez-Moreno et al., 2016) in their study reported similar AgNP IC50 to that of this
study in addition to significant reduction in cell viability at AgNP concentration ≥ 1.25
μg/mL for eight different human cancer cell lines where viability was monitored with
the MTT assay. Variations in the cytotoxicity of AgNP in these cell lines could be
attributed to the difference in sensitivity of the cell lines to the nanoparticle but also
differences in assays employed to monitor viability. Interestingly, (Murphy et al.,
2016) who used THP1 cells reported dose dependent cytotoxicity of AgNP (50-70 nm
size) with significant difference from ≥ 1.9 µg/mL. This contrasted with the finding
heres and could be due to polyvinyl pyrrolidine (PVP)-coated AgNP used in the study,
which may have its own inherent toxicity. Of course, it may be because of a difference
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in particle sizes, which have been previously shown to mediate cytotoxicity
irrespective of capping agent used (Gliga et al., 2014).
AgNP ionisation into Ag+ has been widely proposed as its mechanism of action in
inducing cytotoxicity (Hsueh et al., 2015, Lansdown, 2010). As such, the cytotoxicity
of Ag+ on THP1 cells was investigated and findings indicated that Ag+ at
concentrations between 0.625 and 2.5 µg/ml reduced THP1 cell viability by more than
3-folds while 2-fold reduction in cell viability was observed for THP1 exposed to 5
µg/ml Ag+ when compared with AgNP at the same concentrations. This finding is in
agreement with that of (Foldbjerg et al., 2009) who used flow cytometric analysis to
determine viability of THP1 cells after exposure to AgNP and Ag+. Their findings
showed at least 2-fold reduction in THP1 cell viability after exposure to ≥ 0.625 µg/ml
Ag+. There was a similar concentration-dependent cytotoxicity profile for both AgNP
and Ag+ although Ag+ had higher toxicity. Taken together, ionisation of AgNP into
Ag+ is likely responsible for the cytotoxic effect of AgNP. The lower cytotoxic effect
of AgNP may be as a result of its slow ionisation rate as it has been reported that AgNP
ionisation rate correlates with its concentration (Maurer-Jones et al., 2013). This is
also supported by the reduction in Ag+ cytotoxic effect to 2-fold relative to that of
AgNP at 5 µg/ml. This may be consequent upon increased ionisation of AgNP with
increased concentration. In addition, the steady reduction in THP1 cell viability after
48 h of exposure to 0.625 to 2.5 μg/ml of AgNP also supports this notion.
To verify the results of the AB assay, flow cytometry, which is a more sensitive
technique, was employed to evaluate cell viability after exposure to THP1 cells with
AgNP and Lipo-AgNP. Calcein-AM and PI staining of THP1 cells after 24 h of
treatment with 0.625 μg/mL Lipo-AgNP showed induction of significant amount of
death in the cells (p < 0.0001). Conversely, AgNP treatment showed a comparable
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outcome to control-unexposed cells with little or no cell death observed, verifying the
AB assay results that the Lipo-AgNP exhibited a higher level of cytotoxicity that the
AgNP alone.
Several studies have shown that AgNP can initiate cell cycle arrest at different phases
of the cell cycle including the G0/G1, S and G2/M phases (Asharani et al., 2012, De
Matteis et al., 2015, Eom and Choi, 2010). As such the effect of a low dose LipoAgNP on THP1 cell cycle was monitored. the finding here showed normal progression
of THP1 cells from the G1 to the S-phase for all exposure and control groups. On the
contrary, Lipo-AgNP exposure resulted in significant reduction in G2/M cell
population compared with the control and AgNP treated cells (p < 0.05). In the Sphase, cells that have successfully passed through the G1/S checkpoint replicate their
DNA in preparation for progression into the G2/M phase where they divide during
mitosis (Takeda and Dutta, 2005). DNA damage in the S phase results in activation of
ataxia-telangectasia mutated (ATM) and ataxia-telangectasia related (ATR) kinases
which in turn activate CHK2, γH2AX and the BRCA genes to slow down replication
through abrogation of origin firing and signal DNA damage for repair. Increased DNA
damage however results in induction of apoptosis by ATM, ATR and CHK2 activation
of p53 (Norbury and Zhivotovsky, 2004, Willis and Rhind, 2009). A population in the
Sub-G1 upon Lipo-AgNP exposure was noted and such populations are known to be
cells with fragmented DNA that are undergoing or have undergone apoptosis. A
genomic DNA fragmenting effect of AgNP has indeed been previously demonstrated
by Awasthi et al. (2013) and may be occurring in this study after exposure to LipoAgNP. The proportion of cells observed in the sub-G1 recorded as a result of LipoAgNP exposure matches the reduction in the G2/M phase. This may indicate the cells
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were forced out of the cell cycle due to the increased DNA damage because of LipoAgNP exposure and died via apoptotic mechanisms.
The cell induces apoptosis for many reasons, one of which is to maintain genome
integrity by killing cells with high amount of DNA damage. ROS induction is often
used to activate the signalling cascade that result in apoptotic induction in such cell.
ROS are known to disrupt the mitochondrial membrane which results in the release of
cytochrome c. Release of cytochrome c activates the proapoptotic Bcl2 proteins Bax
and Bak which in turn activate executioner caspases 3 and 7 (Quast et al., 2013). There
are reports in literature indicating that AgNP cause apoptosis by inducing increased
generation of ROS. Indeed Kang et al. (2012) and Foldbjerg et al. (2011) reported a
dose and time-dependent ROS induced apoptosis in dendritic cell line (DC2.4) and
A549 lung cell lines respectively as a result of AgNP exposure. Awasthi et al. (2013)
also reported a dose-dependent ROS generation and induction of apoptosis in CHO
cell lines. To monitor if this was occurring here as a result of the Lipo-AgNP exposure,
ROS generation was monitored in THP1 cell lines. The cells were treated with a low
concentration of AgNP and Lipo-AgNP (0.3 µg/mL) for up to 4 h to evaluate the onset
of ROS generation. It was noted that AgNP exposure did induce ROS, but nonsignificant levels of ROS with respect to the controls, most likely because the
concentrations considered were not cytotoxic to the cells. In contrast to above studies,
this study showed that Lipo-AgNP did not induce ROS generation to cause THP1 cell
death. In fact, there was an observable suppression of ROS induction. The variation in
these studies can likely be due to several factors which include but not limited to
difference in cell lines, size and surface characteristics of the AgNP used.
Literature indicates cell death as a result of AgNP exposure is typically due to ROS
generation with subsequent DNA damage to the cells followed by apoptosis. But
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findings of this study suggested ROS was not involved in the induction of observed
cell death when studying the Lipo-AgNP. One of the downstream factors activated by
p53 signalling after sensing DNA damage is caspase 3. Different studies have shown
that activation of p53 in response to DNA damage results in p53 transcriptional
upregulation of Puma and Noxa, inhibitors of Bcl-2, Bcl-xl and Mcl-1. Inhibition of
this Bcl proteins result in Bax and Bak activation which ultimately result in
cytochrome c release and activation of the executioner caspases (Ashkenazi, 2008).
To explore the possibility of ROS independent induction of apoptosis, activation of
caspases 3/7 in THP1 cells treated with same low dose AgNP and Lipo-AgNP at 1 hr,
4 h and 24 h to monitor onset of activation was investigated. For all cell groups, there
was no significant activation of caspases 3/7 at 1 h and 4 h. On the other hand, there
was significant induction of caspases 3/7 in THP1 cells treated with 0.625 μg/mL of
Lipo-AgNP after 24 h (p < 0.0001).
Previous studies have linked AgNP mechanism of action to increased generation of
ROS, which causes depolarisation of mitochondrial membrane potential and
subsequent rupture of the membrane for release of cytochrome c (Kang et al., 2012,
Foldbjerg et al., 2011, Jiang et al., 2013). This has been proposed to be achieved by
the intracellular oxidation of AgNP to Ag+ by the acidic environment in the lysosome
(De Matteis et al., 2015). Endocytosis of AgNP is believed to result in the
compartmentalisation of the nanoparticle in an endosome, which is metabolised in the
endolysosomal pathway thus leading to its oxidation and generation of ROS. the
finding heres have interestingly opened an alternative pathway to ROS-dependent
apoptosis induction by AgNP. In this study, it was shown that encapsulation of AgNP
in liposomes was able to achieve greater cytotoxicity at low dose compared to what
was achievable at high doses, in a ROS-independent way. This may be attributed to
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the improved delivery of AgNP into the cells via the liposome since the lipid layer can
easily traverse the lipid bilayer of the cell membrane due to the hydrophobic
interactions when compared to un-encapsulated AgNP. Lipo-AgNP may also suppress
the ionisation of AgNP as part of its mechanism to prevent ionisation-dependent
generation of ROS. Conventional drugs encapsulated in liposome are known to have
an increased bioavailability, enhanced permeability and retention (EPR) effect
(Maeda, 2012). These characteristics enhance the pharmacokinetics of Lipo-AgNP in
the cells resulting in efficient delivery of AgNP into the cell. Lysosomal breakdown
of the lipid layer will result in overwhelming delivery of AgNP into the cytoplasm and
subsequently in the nucleus allowing interaction between AgNP and the DNA causing
DNA damage and halted replication (Li et al., 2013a, Pramanik et al., 2016). The DNA
damage could be responsible for the activation of executioner caspases consequent
upon activation of p53. Taken together, this suggests a “Trojan Horse” effect
mechanism for Lipo-AgNP due to the sudden leakage of AgNP into the cytoplasm and
subsequently the nucleus after degradation of the liposome. This stealth mechanism
nonetheless, is in contrast with the type previously described for AgNP in other studies
where AgNP is phagocytosed, ionised and released to enhance generation of ROS
which in turns stimulate inflammatory responses that can mediate cell death (Park et
al., 2010a).
The cytotoxicity induced by Lipo-AgNP independent of ROS generation offers some
advantages if properly harnessed. ROS is known to induce cellular senescence in
neighbouring cells and this is accompanied by up-regulation of stress and
inflammatory genes through secretion of pro-inflammatory molecules like nuclear
factor kappa B (NF-κB) (Correia-Melo et al., 2014). In addition, ROS mediated
necrosis of cells could result in release of cytoplasmic wastes that can cause
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exaggerated and unscheduled inflammatory responses, which may promote tumour
development (Vakkila and Lotze, 2004). As such, these secondary effects can be
prevented by coating AgNP surface in a protective layer as demonstrated in this study.
4.3

Conclusion

In this chapter, the encapsulation of AgNP in a liposome has been demonstrated to
enhance AgNP cytotoxicity at low concentrations through increased DNA damage
with suppression of ROS. This contrast with several other studies that have shown that
AgNP cytotoxic effect can only be achieved through generation of ROS. It is
postulated that the encapsulation of AgNP in liposomes could eliminate the negative
side effects of ROS making it possible to achieve a greater level of cytotoxicity that
would otherwise only be possible at high concentrations. As such, Lipo-AgNP could
reduce the concentration of AgNP required thereby increasing any potential biological
activity with reduced associated side effects typically caused from high dose
exposures.
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5
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5

“Liposomal encapsulation of silver nanoparticles (AgNP) improved
nanoparticle uptake and induced redox imbalance to activate caspasedependent apoptosis.” Yusuf et al. 2018

Published: Journal of Apoptosis, 2020
While macrophages are an essential component and are key players in the innate and
adaptive immune system, they also play a central role in maintenance of tissue
homeostasis and developmental processes in defining physiological and pathological
conditions. Due to this, macrophages have been widely studied as therapeutic target
for diseases like rheumatoid arthritis, atherosclerosis and cancer as the role of this
immune cell is known to be tilted to favour disease development under specific
conditions, particularly due to their induced inflammation (Ponzoni et al., 2018). The
role of macrophages in cancer for instance involves the release of pro-inflammatory
cytokines such as interleukin 1β (IL-1β) and tumour necrosis-α (TNF-α) by tumour
associated macrophages (TAM) within the tumour microenvironment (Fultang et al.,
2019). The release of these inflammatory cytokines like IL-1β can drive endothelial
cell proliferation and secretion of growth factors such as the vascular endothelial
growth actor A (VEGF-A) by the endothelial cells, facilitating angiogenesis (Voronov
et al., 2014). In the same manner, production of IL-1β and TNF-α aids recruitment of
leukocytes that perpetuate inflammation, which facilitates proliferation of synovial
fibroblasts to form pannus that damages the rheumatoid arthritis joint (Kim and
Moudgil, 2017). There is evidence that TNF-α can induce activation of extrinsic
apoptotic pathway through TNF receptors 1 and 2 (TNFR1/TNFR2). Binding of
metalloproteinase cleaved soluble TNF-α or membrane anchored TNF-α to TNFR1 or
TNFR2 respectively. This interaction results in internalisation of the receptor-ligand
complex where they engage FAD associated death domain (FADD) protein and
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Tumor necrosis factor receptor type 1-associated DEATH domain (TRADD) protein
that subsequently activate caspase 8 and 3 to induce apoptosis (Dreschers et al., 2017).
It appears that the exaggerated inflammatory response of these macrophages may in
part be facilitated by the high level of reactive oxygen species that is generated by the
immune cell. There is evidence in the literature that macrophages generate a high level
of reactive oxygen species (ROS) such super oxides and hydrogen peroxides within a
tissue or organ even under minimal perturbation to the normal processes that may
characterise a diseased condition (Bae et al., 2009, Kim et al., 2017).
In support of this notion, ROS generation by macrophages have been documented to
play key role in driving progression of atherosclerosis through NADH oxidase activity
in production of RANTES (regulated on activation, normal T-cell expressed, and
secreted), a chemokine that facilitates the homing of immune cells that boost
inflammation within the atherosclerotic plaque (Virani et al., 2011, Bae et al., 2009).
Macrophages generated ROS also drives progression of cancer through secretion of
TNF-α and IL-1β to drive hyperproliferation and arthritis through downregulation of
regulatory T cells (Canli et al., 2017, Roberts et al., 2015). The ROS generation has
other significant impact as it has been previously demonstrated that ROS can induce
activation of caspase 3 and 9 through TNFR activation (Thakor et al., 2017), indicating
a link between ROS generation and TNF-α signalling. Interestingly, targeting ROS
generated by macrophages has been shown to attenuate the development of
atherosclerosis (Vendrov et al., 2007). Likewise in cancer, liposomal bisphosphonates
or monoclonal antibodies have been employed to directly induce cytotoxic effect on
TAMs to deplete the macrophages, preventing ROS generation or inflammation
(Ponzoni et al., 2018).
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Silver nanoparticles (AgNP) are widely used as an antibacterial in a variety of
applications including wound treatment and food preservation but have also been
investigated as anticancer agent in recent years. AgNP has been shown to induce a
cytotoxic effect on macrophages even at a very low dose (Haase et al., 2011) and may
be effective in treating disease conditions mediated by macrophages as detailed above.
Unfortunately, the main mechanism of AgNP action involves induction of ROS which
effect myriad of intracellular responses such as DNA damage, increased Bax/Bcl-2
ratio, permeabilization of the mitochondrial membrane, degradation of key cellular
protein and subsequent caspase 3/7 dependent apoptosis (Verano-Braga et al., 2014).
While the induction of caspase-dependent apoptosis may facilitate macrophage
depletion within the atherosclerotic plaque, a tumour microenvironment or the arthritic
joint, the induced ROS may result in surge in secretion of inflammatory molecules by
the macrophages themselves further favouring the disease condition.
It has been shown in Chapter 4 that encapsulation of AgNP in a dipalmitoyl
phosphatidylcholine (DPPC) based liposome suppressed ROS generation in
macrophages and that the nanoparticle encapsulation suppressed AgNP-induced ROS
generation, enhanced the nanoparticle cytotoxicity in THP-1 monocytes and
suppressed AgNP-induced inflammation in THP-1 monocytes and THP1 derivedmacrophages (Chapter 6). This Chapter investigated the cytotoxic effect of
encapsulated AgNP (Lipo-AgNP) on THP-1 derived macrophages (TDMs) and
further probed the mechanistic detail of the pathway utilised by Lipo-AgNP in
inducing cell death, highlighting the divergence to the pathway utilised by AgNP.
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5.1
5.1.1

Results
Macrophage cell viability

As stated, the cell viability of TDMs upon exposure to AgNP or Lipo-AgNP was
evaluated by AB assay. The AB assay is routinely used to estimate cell viability based
on the rate at which metabolically active cells reduce resazurin, a non-fluorescent blue
dye to resorufin, to a pink fluorescent product. This chemical reduction of resazurin
occurs in both the mitochondrion and the cytoplasm, thus it gives a broad indication
of cellular viability (Rampersad, 2012). TDMs were exposed to varying
concentrations of AgNP, Lipo-AgNP and AgNO3 (as positive control) ranging from
0.3 µg/ml to 10 µg/ml. As shown in Figure 5-1, the AgNO3 used as a positive kill
control for Ag+ induced a significantly higher reduction in TDMs viability at all
concentrations (p < 0.0001) with a 24 h IC50 of 0.12 µg/ml. In comparison to AgNP
induced reduction in cell viability at concentrations ≤ 5.0 µg/ml while Lipo-AgNP
induced significant reduction in TDMs viability at concentrations ≤ 2.5 µg/ml (p <
0.001) compared to control unexposed TDMs, making Lipo-AgNP to have a lower
IC50 value compared to AgNP (3.98 ± 1.49 µg/ml compared to 5.71 ± 1.09 µg/ml
respectively). In addition, Lipo-AgNP induced a significant reduction in TDM
viability when compared with AgNP at 2.5 µg/ml. As a negative control, TDMs were
also exposed to empty liposome at concentrations equivalent to the liposomes in 2.5
µg/ml and 5 µg/ml Lipo-AgNP. As shown in Figure 5-1B, it was found that the empty
liposomes did not affect the cell viability.
A calcein-AM/PI staining of TDMs was also carried out to confirm the result of the
AB assay at a cellular level via an alternate technique. To evaluate cell viability here,
2 µg/ml was chosen as a test concentration. This concentration was just below that
where a significant difference in both AgNP and Lipo-AgNP toxicity existed. Here
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the exposure of TDMs to Lipo-AgNP resulted in a significant reduction in TDM cell
viability compared with control unexposed TDMs (p < 0.05), which was not observed
for AgNP at the same concentration (Figure 5-2). On the contrary, PI entry into the
cells was similar in all groups. This was likely because the exposure concentration of
the nanoparticles was not toxic enough to cause cell death. To confirm if the liposome
was not cytotoxic on the cell, manifesting as the observed cytotoxicity, the TDMs were
exposed to an equal amount of empty liposome as contained in 2 µg/ml Lipo-AgNP
and it was found that the liposome did not affect the cell viability after 24 h exposure
(Figure 5-2).
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Figure 5-1. Effect of AgNP, Lipo-AgNP and AgNO3 on cell viability of TDMs
(A) TDMs were incubated with 0.3 µg/ml to 10 µg/ml of either of AgNP, Lipo-AgNP
or AgNO3 or (B) equivalent concentration of empty liposome as contained in 2.5
µg/ml and 5 µg/ml Lipo-AgNP for 24 h. Cells were incubated in 10% AB solution in
2% FBS-RPMI for another 2 h. IC50 (24 h) was computed for (C) AgNP (D) LipoAgNP and (E) AgNO3, Y-axis represent arbitrary reading from the spectrophotometer
for AB assay. Data is represented as mean ± SD of 3 independent experiments. *** p
< 0.001 and **** p < 0.0001.
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Figure 5-2. Calcein/PI staining of TDMs exposed to AgNP and Lipo-AgNP
TDMs were exposed to 2 µg/ml of AgNP or Lipo-AgNP or 0.5 µM of Dox or empty
liposome containing DPPC and cholesterol as in 2 µg/ml Lipo-AgNP for 24 h before
staining with 1 µM calcein-AM and 10 µg/ml PI stain for 20 mins. Conversion of
Calcein-AM to fluorescent calcein was measured by detecting the dye MFI in FL-2
channel while PI entry into the cell was detected in the FL-4 of a BD Accuri 6
cytometer. Data is represented as mean ± SD of 3 independent experiments. MFI was
calculated from intensity of 50 individual cells per experiment. ** is p < 0.01
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5.1.2

Lipo-AgNP suppressed AgNP induced redox imbalance in TDMs

One of the known mechanisms of AgNP cytotoxicity responsible for its antibacterial
and anticancer properties is its ability to induce generation of ROS upon entry into the
cell. As such, whether the enhanced cytotoxic effect of Lipo-AgNP was due to its
ability to enhance ROS generation was investigated. TDMs were exposed to either of
2 µg/ml of AgNP or Lipo-AgNP or 0.5 µg/ml of AgNO3 as positive control after
which the ROS generation upon exposure was analysed at different time points using
flow cytometry (Figure 5-3). A negative of the empty liposome at the same DPPC
concentration as in 2 µg/ml Lipo-AgNP was also incorporated. As expected, AgNP
exposure induced significantly higher generation of intracellular ROS at all time
points investigated when compared to the control unexposed and Lipo-AgNP exposed
TDMs. Although, percentage of cells that were positive for DCFDA fluorescence was
comparable in all groups as shown in Figure 5-3A, the MFI readings indicated that
AgNP resulted in stronger intensity of ROS dependent DCFDA signals compared to
other groups. ROS generation was highest for all groups at 1 h post exposure but this
began to decline up until 4 hours. In contrast to AgNP, Lipo-AgNP exposure at all
time points resulted in comparable levels of intracellular ROS generation with the
unexposed control cells (Figure 5-3B). The empty liposome was also found to induce
comparable levels of ROS to the control untreated cells for all time points.
After demonstrating that Lipo-AgNP mediates a time dependent suppression of AgNP
induced intracellular ROS, whether this is associated with the GSH levels in the cells
and thus the redox balance was investigated. This was done by exposing the TDMs to
1 µg/ml and 2 µg/ml of AgNP or Lipo-AgNP empty liposome at the same DPPC
concentration as in 2 µg/ml Lipo-AgNP for 1 h. ROS and reduced glutathione (GSH)
levels were then quantified by spectrophotometry. As observed previously, 2 µg/ml
112 | P a g e

Lipo-AgNP suppressed AgNP-induced ROS generation and in the same manner
contrary to what was expected (Figure 5-4A), Lipo-AgNP also significantly reduced
the level of GSH in the TDMs compared to both AgNP exposed and control unexposed
TDMs (p < 0.05) (Figure 5-4B). As also observed in the confocal microscopy result,
the empty liposome induced comparable levels of ROS and GSH as in the control
untreated groups (Figure 5-4C and D). This observation is indicative of a redox
imbalance due to Lipo-AgNP exposure as a high GSH level is expected due to ROS
suppression and that the empty liposome is relatively non-toxic to the cells.

113 | P a g e

Figure 5-3. ROS generation by TDMs pot-exposure to AgNP and Lipo-AgNP
TDMs were preloaded with 10 µM H2DCFDA for 30 mins before exposure to 2 µM
AgNP or Lipo-AgNP or 0.5 µg/ml AgNO3 or empty liposome containing DPPC and
cholesterol as in 2 µg/ml Lipo-AgNP for up to 4 h. (A) Plot of percentage of cell
population with positive DCFDA fluorescence (B) plot of the MFI of TDMs.
Statistical significance was analysed by One-way ANOVA Turkeys multiple
comparison tests for each time point. Data represents mean ± SD of 3 independent
experiments. * p < 0.05 and ** p < 0.01
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Figure 5-4. Redox balance in AgNP and Lipo-AgNP exposed cells
(A) Cells were treated as previously for ROS and the ROS level in cells at 1 h post

exposure to 2 µM of AgNP and Lipo-AgNP and 0.5 µg/ml AgNO3 or (C) empty
liposome containing DPPC and cholesterol as in 2 µg/ml Lipo-AgNP was measured
spetrophotometrically (B) GSH levels as measured in TDMs by first exposing the cells
to 2 µM AgNP or Lipo-AgNP or 0.5 µg/ml AgNO3 or (D) empty liposome containing
DPPC and cholesterol as in 2 µg/ml Lipo-AgNP for 1 h and then to ThioltrackerTM for
30 mins before measurement. Statistical significance was analysed by Two-way
ANOVA Tukeys test. Data represent mean ± SD of 3 independent experiments. * p <
0.05 and *** p < 0.001.
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5.1.3

Caspase 3/7 pathway activation

ROS is one of the major upstream factors in the caspase 3/7 apoptotic pathway, and
indeed the main mechanism of AgNP induced apoptosis. The above data demonstrated
that Lipo-AgNP induced a higher cytotoxic effect on TDMs compared to AgNP, which
is independent of intracellular ROS generation and was accompanied by reduced GSH
levels. It has been previously shown that this redox imbalance created by suppressed
ROS and GSH levels induced caspase 3-dependent apoptosis (Liu et al., 2014b). Based
on this, activation of caspase 3/7 upon exposure of the TDMs to 2 µg/ml AgNP or
Lipo-AgNP was probed. It was found that AgNP induced significant activation of
caspase 3/7 at 24 h compared to the unexposed (p < 0.0001) which was similar to that
induced by Lipo-AgNP (Figure 5-5). However, exposure of the TDMs to AgNP and
the observed caspase 3/7 activation did not translate to observable cell death as
indicated by fluorescence due to the Sytox AAdvanced stain for dead cells. Contrary
to this, Lipo-AgNP exposure resulted to significant number of dead cells after 24 h
despite inducing activation of caspase 3/7 at similar level with AgNP (p < 0.001).
Bax and Bcl-2 are respectively pro- and anti-apoptotic factors in the intrinsic cell death
pathway that act upstream of caspase 3/7. The protein expression of Bax and Bcl-2
after AgNP and Lipo-AgNP exposure was next investigated. TDMs were exposed to
2 µg/ml of AgNP or Lipo-AgNP for 24 h after which cell lysate was obtained from
the cells. Immunoassay of the lysate indicated that none of the nanoparticles
influenced Bax protein expression when compared with Bax expression in control
unexposed group (Figure 5-6A). On the other hand, Lipo-AgNP was found to
significantly inhibit Bcl-2 protein expression (p < 0.001). Bax to Bcl-2 ratio (Bax/Bcl2) is widely used as an indicator of apoptotic status of a cell (Azimian et al., 2018).
Bax/Bcl-2 analysis carried out showed that Lipo-AgNP exposure exhibited the highest
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ratio compared to AgNP exposure or non-exposure of the control group (p < 0.05),
explaining the observed cell death upon exposure to Lipo-AgNP.
siRNA of Bcl-2 has been demonstrated to make cancer cells sensitive to DNA damage
resulting in apoptosis (Knezevic et al., 2007). Based on this the possibility of LipoAgNP causing DNA damage which in addition to the low Bcl-2 expression might be
the reason for the observed apoptosis was investigated. Activation of H2AX was
evaluated in TDMs 24 h post exposure to AgNP or Lipo-AgNP. This is because
formation of H2AX foci upon phosphorylation signals increased DNA double strand
break (DSB). A significant activation of γH2AX was observed in cells exposed to
Lipo-AgNP while AgNP exposed TDMs showed comparable γH2AX fluorescence
with control unexposed TDMs (Figure 5-6B). Thus, Lipo-AgNP induced DNA
damage in the TDMs may have resulted in apoptosis due to low Bcl-2 expression in
the cells.
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Figure 5-5.Activation of caspase 3/7 and induction of apoptosis by AgNP and
Lipo-AgNP.
TDMs exposed to 2 µg/ml AgNP or Lipo-ANP or 0.5 µM Dox or empty liposome
containing DPPC and cholesterol as in 2 µg/ml Lipo-AgNP for 24 h were stained with
500 µM of CellEvent and 1 µM of SytoxAADvanced stain as describe in methods.
The fluorescence obtained from confocal microscopy (left) was converted into digital
data (right) using imageJ software. Statistical significance was computed using Twoway ANOVA with Tukeys multiple comparison test. Data repesents mean ± SD of 3
independent experimental repeats and ***p < 0.001 and ****p < 0.0001.
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Figure 5-6. Bax/Bcl-2 ratio and DNA damage in AgNP and Lipo-AgNP exposed
TDMs
(A) Lysates from TDMs exposed to AgNP and Lipo-AgNP AgNP or 0.5 µM of Dox
or empty liposome containing DPPC and cholesterol as in 2 µg/ml Lipo-AgNP for 24
h were collected and immunoprobed by ELISA for Bax and Bcl-2 and the Bax/Bcl-2
ratios were computed (B) TDMs exposed as above were incubated in antiphosphoH2AX antibody as described in methods and the H2AX phosphorylation was
analysed by flow cytometry. Statistical significance was carried out by One-way
ANOVA with Dunnet’s multiple comparison test. Data is represented as mean ± SD
for n = 3 independent experimental repeats.
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5.1.4

Effect of liposomal encapsulation on AgNP uptake

A time dependent intracellular ROS generation in the TDMs indicated that ROS
generation was highest for all exposure groups at 1 h after which the level dropped
considerably. This indicates that the AgNP and Lipo-AgNP must have been
internalised by the cells prior to 1 h time point. As such the time course uptake of the
nanoparticles by flow cytometry was investigated, since the nanoparticles will
increase the internal complexity of the cell which can be accurately monitored by the
SSC values. The uptake studies indicated that Lipo-AgNP was significantly
internalised by the TDMs at 30 mins (p < 0.01) while the AgNP was not internalised
at this time point since AgNP exposed TDMs had comparable SSC value when
compared with the control unexposed cells (Figure 5-7). At 45 mins, AgNP and LipoAgNP uptake had significantly increased (p < 0.0001) but Lipo-AgNP uptake was
significantly higher than that of AgNP (p < 0.0001). At 1 h post exposure to the
nanoparticles, there was an observed drop in the SSC values of the TDMs which was
likely due to the degradation of the nanoparticles. This continued up till 24 h when
none of the nanoparticles seem to be in the cells based on the comparable SSC values
with control unexposed cells. This finding indicates that entry of the silver
nanoparticle at 45 mins must have resulted in ionisation of the nanoparticle causing
increased intracellular ROS levels, which may have been suppressed by the liposome
shell of Lipo-AgNP.
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Figure 5-7. Nanoparticle uptake by TDMs
TDMs were exposed to 2 µg/ml AgNP or Lipo-AgNP for 24 h after which cells were
rinsed and analysed by flow cytometry. Statistical analyses were carried out by Oneway ANOVA with Dunnet’s multiple comparison test. Data is represented as mean ±
SD for n = 3 independent experimental repeats.
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5.2

Discussion

In Chapter 4 it was demonstrated in THP-1 monocytes that AgNP encapsulation in
liposome enhances the nanoparticle cytotoxicity through steady release of AgNP and
induced a caspase-dependent and ROS-independent apoptosis. Based on the different
roles of monocytes and macrophages in disease development as well as their varying
responses to different stimuli, this study was carried out to probe the molecular
mechanism utilised by Lipo-AgNP in inducing cell killing effect in TDMs. As
previously observed for THP-1 monocytes, Lipo-AgNP also demonstrated higher
cytotoxicity on the TDMs compared with AgNP. However, the IC50 for Lipo-AgNP
in the TDMs was slightly higher than what was previously recorded for the monocytes.
This may be due to the higher uptake rate of the nanoparticle by TDMs because of
their active phagocytosis compared to THP-1 monocytes coupled with a more
sensitive nature of monocytes. Beduneau et al. (2009) have previously demonstrated
that macrophages exhibit higher uptake rate of IgG coated and uncoated supermagnetic iron-oxide nanoparticles compared to monocytes, although the study showed
the nanoparticle exhibited similar toxicity in both THP-1 and TDMs which was only
after 1 h of exposure. A longer time point might have shown the nanoparticle is more
toxic in TDMs. In support of this, Wu et al. (2018) demonstrated the SPIONs induced
release of pro-inflammatory cytokines after 24 h exposure of macrophages to the
nanoparticles.
ROS generation has been documented to be the main mechanism utilised by AgNP to
induce apoptosis in different cell types (Flores-Lopez et al., 2019). Entry of AgNP into
the cytoplasm results in ionisation of the nanoparticle by the aqueous environment into
silver ions, which subsequently causes generation of intracellular ROS that oxidise
cellular proteins and subcellular structures like the mitochondria or induce DNA
122 | P a g e

damage, culminating in caspase-dependent apoptosis (Mao et al., 2016). Interestingly,
the role of macrophages in diseases such as cancer and atherosclerosis are largely
modulated on the ability of the immune cell to generate or respond to high intracellular
ROS within the tumour microenvironment to suppress anticancer immune response or
the atherosclerotic plaque to induce expression of adhesive molecules that facilitate
plaque build-up (Bae et al., 2009, Roux et al., 2019). TDMs were employed in this
study to investigate Lipo-AgNP effectiveness on macrophages that may be within the
tumour microenvironment, especially since Lipo-AgNP possess an anti-inflammatory
property in these cells (Chapter 6). As expected AgNP exposure of TDMs resulted in
ROS generation supporting findings of other studies (Haase et al., 2014, Haase et al.,
2011). Contrary to this and as was previously shown in THP-1 monocytes, Lipo-AgNP
suppressed AgNP-induced intracellular ROS generation. This indicates that the
encapsulation prevented or delayed the ionisation of the coated AgNP possibly
through the anti-inflammatory action of the DPPC liposome or protection of the AgNP
within the DPPC liposome once in the cytoplasm. However, this does not explain the
enhanced cytotoxicity.
Increased ROS generation is often coupled with reduction in level of GSH. GSH is a
tripeptide of glutamine, cysteine and glycine, a biologically active antioxidant against
the activities of ROS. Oxidation of GSH by increasing level of ROS results in
crosslinking of the two molecules of oxidised glutathione to GSSG causing a drop in
the level of GSH and vice versa under low ROS levels. As expected, it was found that
exposure to AgNP resulted in reduced GSH level. AgNP is known to induce ROS
generation, GSH depletion and activation of caspase 3 (Yin et al., 2013). Interestingly,
Lipo-AgNP exposure also resulted in reduced GSH levels which was unexpected since
the encapsulation prevented AgNP-induced ROS. The reason for this is currently
123 | P a g e

unknown but this redox imbalance has been previously demonstrated to induce
activation of caspase 3/7 dependent apoptotic pathway (Liu et al., 2014b). It is possible
suppression of GSH by Lipo-AgNP is coupled with activity of Bcl-2 since the
inhibition of Bcl-2 protein expression was observed. A previous study showed that
Bcl-2 overexpressing human leukaemia cells have high level of GSH and another
showed that the overexpression of Bcl-2 in a lymphoma cell line aids intranuclear
sequestration of GSH (Wright et al., 1998, Voehringer et al., 1998), which may inhibit
ROS induced activation of caspase 3/7.

Increased expression and activation of Bax causes destabilisation of mitochondrial
outer membrane resulting in release of cytochrome C activating downstream factors
preceding activation of caspase 3 and 7. Bcl-2 as an anti-apoptotic factor binds Bax to
prevent mitochondrial dysfunction. However, an increased Bax expression relative to
a low Bcl-2 expression results in a high Bax/Bcl2 ratio causing Bax to induce
mitochondrial outer membrane permeabilization (MOMP), with release of
cytochrome C and a subsequent activation of caspases 3 and 7 down in the intrinsic
apoptotic pathway (Salakou et al., 2007, Zhu et al., 2015). As such, the Bax/Bcl-2 ratio
has been used as a prognostic factor for survival in different cancers and even as
predictor of cancer cells response to chemotherapy (Kulsoom et al., 2018, Del Principe
et al., 2016, Luo et al., 2015). Interestingly, it has been demonstrated that AgNP
induces expression of Bax increasing Bax/Bcl-2 ratio to induce apoptotic cell death in
male Wistar rats (Ghooshchian et al., 2017).
Based on the above and to establish a link between Bcl-2 expression and the low GSH
level observed in Lipo-AgNP exposed TDMs, Bax and Bcl-2 protein expression in the
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cells in response to AgNP and Lipo-AgNP exposure was investigated. Bax protein
levels was unaffected in all the exposure groups but Lipo-AgNP was found result in
suppression Bcl-2 protein expression. This kept the Bax/Bcl-2 ratio high for LipoAgNP exposed TDMs. A high Bax/Bcl-2 ratio has been reported to be associated with
increased apoptosis in cells due to high Bax expression and a relatively unaffected
Bcl-2 expression in cells exposed to therapeutic agent relative to control cell lines
(Azimian et al., 2018). Although this contradicts the finding here here where the Bax
level is similar in all exposure and control groups, the low Bcl-2 level kept the
Bax/Bcl2 levels high such that there is enough free Bax that will induce mitochondria
dysfunction and caspase 3/7 activation in Lipo-AgNP exposed TDMs.
In Chapter 4, it was shown that Lipo-AgNP induced DNA fragmentation and cell cycle
arrest at the S-phase of THP1 monocytes. This is likely because cells with fragmented
DNA cannot successfully proceed through the S-phase due to replication failure. It
was further confirmed here that Lipo-AgNP induced DNA damage as the exposure of
TDMs to the nanoparticle resulted in significant γH2AX activation. Phosphorylation
of H2AX histone result in formation of γH2AX, which recruits DNA damage repair
proteins, hence its use as a marker of DNA damage. Bcl-2 overexpression has also
been shown to suppress DNA repair, allowing cancer cells accumulate mutations
which result in genome instability, a hallmark of cancer (Wang et al., 2008). Deng et
al. (1999) also demonstrated that Bcl-2 accelerates recovery of prostate cancer cells
from oxidative stress induced nuclear and mitochondrial DNA damage. Taken
together, Lipo-AgNP may have induced DNA fragmentation causing H2AX
phosphorylation and the low level of Bcl-2 could not allow for Bcl-2 mediated survival
of the cell, further making the cells more sensitive to the cytotoxic effect of LipoAgNP just as high Bax/Bcl-2 ratio is known to sensitize cancer cells to
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chemotherapeutic agents (Luo et al., 2015). This coupled with the high Bax/Bcl-2 ratio
could synergistically induce activation of caspase-dependent apoptotic pathway.
It has been shown here that Lipo-AgNP is more cytotoxic than AgNP, inducing a
caspase dependent apoptosis. While AgNP was found to be less cytotoxic than the
Lipo-AgNP, the uncoated nanoparticle also induced a caspase-dependent apoptosis
which was dependent on intracellular ROS generation. This differing mechanism for
Lipo-AgNP and AgNP led to the hypothesis that Lipo-AgNP must have a distinct
pharmacokinetic mechanism when compared with AgNP. In essence, these
nanoparticles must have been metabolised in different ways once they are internalised
by the cells. To test this, the uptake of both AgNP and Lipo-AgNP was monitored by
evaluating the SSC values of the cells at specific time point. Generally, the SSC value
of cells increases with particle uptake due to increase in their internal complexity and
there are studies that have successfully applied this technique to measure nanoparticle
uptake (Claudia et al., 2017, Zucker and Daniel, 2012, Jochums et al., 2017).
Measuring the SSC has several advantages. Firstly, in comparison with fluorescently
probing particle uptake, loss of fluorescent intensity will affect the result of particle
uptake since SSC measurement does not require cell staining. Secondly, this method
is also more valuable in comparison with cell lysis as particles can react with lysis
reagent which may confound data from subsequent quantification. Finally, this method
is cheap and fast. Measurement of Lipo-AgNP and AgNP uptake showed that LipoAgNP was significantly internalised after 30 mins of exposure. AgNP internalisation
was not observed until after 45 mins of exposure, which confirms the encapsulation
of AgNP in liposome resulted in increased and faster uptake of the nanoparticle. This
finding is supported by findings in different studies that reported that liposome
encapsulation of pharmacologically active agents enhances drug uptake and delivery,
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producing better toxicity profile and increased bioavailability (Fuhrmann et al., 2015,
Rafiyath et al., 2012, Ong et al., 2016).
Combining the uptake data with the ROS studies, while Lipo-AgNP were already
internalised at 30 mins, it did not result in any rise in intracellular ROS which indicates
that the encapsulated AgNP had not been exposed to the aqueous surrounding of the
cytoplasm, thus not ionised. In correlation with AgNP uptake by the TDMs, significant
intracellular ROS generation was observed at 1 h which was after 15 mins of detected
uptake and while the ROS level dropped afterwards, it was still significantly higher
than that of other cell groups. While the ROS generated by AgNP would have been
responsible for the cytotoxicity observed in AgNP-exposed TDM, the ROS level was
likely not high enough to suppress Bcl-2 expression or DNA damage. This also
explains why the cell killing effect of AgNP as depicted by Sytox AADvanced staining
was significantly less in AgNP-exposed TDMs when compared with Lipo-AgNP
exposed cells (Figure 5-5). In addition, the caspase activation induced by Lipo-AgNP
must have occurred earlier than that of the AgNP due to the improved uptake causing
cell death earlier than in AgNP. This may be the reason why caspase activation was
comparable between AgNP and Lipo-AgNP at 24 h but AgNP cell killing effect may
occur long after Lipo-AgNP. This is an indication of slower kinetics of AgNP
mechanism compared with Lipo-AgNP. On the contrary, Lipo-AgNP maintained
comparable intracellular ROS levels as the control unexposed TDMs indicating ROS
was not involved in its mechanism. Taken together, it seems the interaction between
the lipid bilayer of the liposome and that of the TDMs facilitated uptake of the
liposome. However, entry of the liposome prevented ionisation of the AgNP allowing
direct delivery of the nanoparticle at concentrations high enough to cause DNA
damage which resulted in phosphorylation of H2AX and suppression of Bcl-2
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expression. The low level of Bcl-2 in the cells did not match Bax levels allowing free
Bax to bind to the mitochondrial membrane causing MOMP and possible release of
cytochrome C and subsequent activation of caspase 3/7 to induce apoptosis
5.2.1

Conclusion

AgNP main mechanism of inducing apoptosis has been reported in different studies to
involve generation of ROS and offset of the Bax/Bcl-2 ratio causing MOMP. Here it
was confirmed that low dose AgNP induce significant generation of intracellular ROS
coupled with depletion of GSH but the no significant cell death. ROS generation and
inflammation are tightly coupled, and this may be responsible for AgNP induced
associated inflammation reported in previous studies. On the contrary, it has been
shown that Lipo-AgNP suppressed ROS generation but depleted GSH level creating
a redox imbalance. This redox imbalance and DNA damage caused by Lipo-AgNP
may be responsible for the suppression of Bcl-2 increasing the Bax/Bcl-2 ration to
cause effective MOMP that can induce caspase 3/7 activation and then cell death.

128 | P a g e

Chapter

6

129 | P a g e

6

“Surface modification of silver nanoparticle (AgNP) by liposomal
encapsulation mitigates AgNP-induced inflammation”

Published: September 2019, Toxicology in Vitro 61: 104641
Silver nanoparticles (AgNP) are widely used as an antibacterial agent and are the
active agent in more than 24% of global nanotechnology driven commercialised
product, in dermal applications, medical apparels and in sterilisation products for
medical equipment (Vance et al., 2015). While the application of AgNP as an
antibacterial agent hold promise in the treatment of bacterial infection, their increased
commercialisation translates to increased and repeated human exposure. There are
reports of skin irritation and permanent discolouration of the eyes and skin as a result
of exposure to AgNP (León-Silva et al., 2016). In support of this, several in vitro and
in vivo studies in recent decades have demonstrated AgNP induced inflammatory
responses. A repeated-dose toxicity assessment carried out on mice that were orally
administered with AgNP showed that the nanoparticle, irrespective of size induced
significant expression of IL-1, IL-6 and TNF-α, among other pro-inflammatory
cytokines in a dose dependent manner (Park et al., 2010b). In primary rat brain microvessel endothelial cells (rBMEC), Trickler et al. (2010) demonstrated that AgNP
induced secretion of interleukin 1β (IL-1β), IL-2 and tumour necrosis-α (TNF-α).
Murphy et al. (2016) also reported that exposure of THP1 and primary human
monocytes to AgNP resulted in increased mRNA expression of IL-1, IL-6 and TNFα. In addition to this, increased inflammasome activation was suspected due to
increased secretion of pro-IL-1β that was observed upon THP1 exposure AgNP.
Inflammation is central to the development and progression of various chronic
diseases including cancer, sepsis, cardiovascular, autoimmune, and neurodegenerative
diseases (Seol et al., 2017, Pianta et al., 2017, Jones et al., 2003, David et al., 2016,
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Mukherjee et al., 2016). Findings in the past decades have shown that IL-1β, IL-6 and
TNF-α are the major pro-inflammatory cytokines with roles central to promotion and
maintenance of systemic inflammation (Mori et al., 2011, Hernandez-Rodriguez et al.,
2004). These pro-inflammatory cytokines effect different cell types by inducing
secretion of other inflammatory cytokines that activate a complex network of
inflammatory pathways especially in disease conditions. Cytokines are mainly
produced by immune cells such as monocytes, macrophages and dendritic cells; and
stromal cells such as endothelial cells and fibroblasts as a means for intercellular
communication in mediating processes like proliferation, differentiation, growth,
immune cell activation and migration (Landskron et al., 2014). The maintenance of
the delicate balance between anti- and pro-inflammatory cytokines, however, is what
defines the line between normal condition and disease state for different chronic
diseases. For example, IL-1β, IL-6 and TNF-α are the main cytokines driving the
damaging inflammatory responses in rheumatoid arthritis (RA), likely through the
perturbation of the balance between anti- and pro-inflammatory cytokines in RA joints
(Mori et al., 2011). This perturbation may arise due to the amplification of
inflammatory response through the activities of IL-1β, IL-6 and TNF-α in inducing
expression of other pro-inflammatory cytokines through activation of transcriptional
factors such as Signal Transducer and Activator of Transcription-1 (STAT-1) and
STAT-3 (Pugazhenthi et al., 2013, Chung et al., 2017). The Janus kinase/STAT
(JAK/STAT) pathway can be activated by IL-6 binding to a receptor tyrosine kinase
(RTK) which transactivates JAK which in turn phosphorylate the RTK facilitating the
recruitment of STAT to the RTK intracellular domain and subsequent phosphorylation
of STAT by JAK. Phosphorylated STAT dimerises and undergo cytoplasmic-nuclear
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translocation where it binds to specific DNA sites to facilitate transcription of cytokine
inducible genes, amplifying inflammation (Morris et al., 2018).
In the same manner, the anti-tumoral response of immune cells like monocytes and
macrophages or pro-tumoral activities of tumour associated macrophages (TAM)
during chronic inflammation are also regulated by the balance between the anti- and
pro-inflammatory cytokine subsets. Chronic inflammation induced and sustained by
expression of IL-1β, IL-6 and TNF-α in TAMs are known to induced tumour
progression and even increase susceptibility of individuals with Crohn’s disease and
ulcerative colitis in developing neoplasia (Poh and Ernst, 2018). During chronic
inflammation, cancer cells are known to also utilise IL-8 and its receptor to facilitate
the recruitment of immune cells with pro-tumoral and immunosuppressive activities
to offset the activities of anti-tumour cytotoxic immune cells (David et al., 2016).
Investigations have shown that AgNP are capable of inducing expression and secretion
of IL-8 to stimulate neutrophil or stem cell activation and proliferation which if left
unregulated may provoke pathogenic inflammation and disease (Fraser et al., 2018,
Jung et al., 2014).
Taken together, repeated human exposure to AgNP may result in chronic
inflammation that may favour autoimmunity or cancer development. In this study, it
was shown that liposomal encapsulation of AgNP suppresses AgNP induced
inflammation in both THP1 monocytes and THP1 cells differentiated into
macrophages and inhibits STAT3 expression possibly suppressing any STAT3dependent perpetuation of inflammatory response in both immune cells.
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6.1
6.1.1

Results
Time dependent release of IL-1β in Pro-THP1, monocytic THP1 and
TDMs

THP1 cells are pro-monocytic cell line that grow in suspension. To induce maturation
to monocytes (monocytic THP1) or TDMs, the pro-monocytic THP1 (pro-THP1) were
stimulated with 100 ng/ml PMA for 24 h or 72 h respectively and then allowed to rest
in a PMA free RPMI medium for another 24 h as recommended by Chanput et al.
(2014). In other to understand the effect of AgNP and Lipo-AgNP on the inflammatory
response of these cells, the cells were primed with LPS from E. coli 0111:B4, which
is known to induce release of pro-inflammatory cytokines in THP1 cells (Lackman
and Cresswell, 2006). The cells (pro-THP1, monocytic THP1 and TDMs) were primed
with 10 µg/mL LPS after which the cells were also stimulated with 5 mM ATP prior
to collection of culture supernatant at 0 h. A time-response analysis of IL-1β release
in cell culture supernatant from pro-THP1 indicated very low release of IL-1β (< 25
pg/ml) in both LPS primed and non-primed cells between 0 and 4 h, except for LPS
stimulated pro-THP1 at 4 h where significantly higher IL-1β concentration was found
(78 pg/ml, p < 0.0001) (Figure 6-1A). At 0 h, both unprimed and LPS primed
monocytic THP1 cells secreted similar but low IL-1β level (14 pg/ml and 12 pg/ml
respectively). This level significantly increased at 0.5 h to 118 pg/ml and 146 pg/ml
for unprimed and LPS primed monocytic THP1 respectively. IL-1β release in the
monocytic THP1 cells continues to rise at 1 hr to 165 pg/ml and 192 pg ml respectively
for unprimed and LPS-primed monocytic THP1. This level peaked at 2 hrs up to 4 h
for both unprimed and LPS-primed monocytic THP1 not increasing above 198 pg/ml
(Figure 6-1C). Unlike the monocytic THP1, the TDMs showed gradual increase in
level of IL-1β secreted from 0 h (9 pg/ml) peaking at 3 h (199 pg/ml) for the unprimed
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cells. This level remained unchanged at 4 h. the same trend was observed for the LPSprimed TDMs which also showed gradual increase from 0 h (15 pg/ml) peaking at 2 h
(213 pg/ml). This level slightly reduced at 3 h and 4 h to 212 pg/m and 206 pg/ml
respectively (Figure 6-1D). At 4 h, both monocytic THP1 and TDM secreted similar
concentrations of IL-1β, which was 25 folds and 3 folds IL-1β release of unprimed
and LPS-primed pro-THP1 respectively. Figure 6-1B shows IL-1β release by proTHP1 on the same scale as those of monocytic THP1 and TDM indicating less IL-1β
release.
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Figure 6-1. Time dependent IL-1β release in unprimed and LPS primed
proTHP1, monocytic THP1 and TDMs:
(A) pro-THP1 (C) monocytic THP1 and (D) TDM were either primed with 10 µg/mL
LPS or unprimed and then challenged with 5 mM ATP. Culture supernatant was
collected at time shown for IL-1β analysis by sandwich ELISA. (B) IL-1β secretion
by pro-THP1 in the same scale as monocytic THP1 and TDMs. Data was presented as
mean ± SD of 3 independent experiments. Statistically significant differences were
analysed by Two-way ANOVA Sidak multiple comparison test. *** p < 0.001, ****
p < 0.0001.
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6.1.2

Role of caspase-1 in release of IL-1β upon ATP and/or LPS challenge of
THP1 and TDMs

Matured IL-1β is produced after proteolysis of pro-IL-1β by the activity of caspase-1
also referred to as interleukin 1 converting enzyme (ICE) in an independent event from
the release of matured IL-1β by immune cells. LPS, used to mimic trigger of
inflammation during infection/sepsis, and ATP, which activates the P2X7 receptor,
are commonly used to trigger release of matured IL-1β in immune cells, both acting
in independent pathways (Stoffels et al., 2015). As such IL-1β release in both
monocytic THP1 and TDMs in response to ATP and/or LPS was investigated and
whether this release was affected while caspase-1 was inhibited. This was necessary
to understand the influence of both AgNP and Lipo-AgNP on LPS-induced and basallevel cytokine release. Both monocytic THP1 and TDMs were cultured in RPMI media
containing 30 µg/ml of polymyxin B for 1 h to inhibit exogenous LPS contamination.
The cells were then primed with 10 µg/mL LPS for 3 h after which they were
stimulated with 5 mM ATP for another 1 h with or without 20 µM ICEinh. As controls,
unprimed monocytic THP1 and TDMs were also subjected to the same conditions. It
was found that ATP stimulation of unprimed monocytic THP1 without caspase-1
inhibition by ICEinh resulted in significantly higher IL-1β release (199.77 pg/ml)
compared to when caspase-1 was inhibited by ICEinh in the presence of ATP (101.62
pg/ml) (p < 0.0001). The IL-1β release consequent of only ATP stimulation was also
significantly higher than the basal IL-1β release (103.85 pg/ml), i.e. when the cells
were neither stimulated with ATP nor exposed to ICEinh. Inhibition of caspase-1, was
found to have no significant effect on IL-1β release (99.75 pg/ml) (Figure 6-2A). This
finding that IL-1β release in monocytic THP1 is not affected in the absence of ATP or
when caspase-1 is inhibited suggests that the role of ATP upstream of caspase-1 is
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solely for stimulation of caspase-1 into activity in THP1 monocytes. Conversely, LPS
priming of the monocytes without ATP stimulation was found to induce significant
increase in basal IL-1β release when caspase-1 was not inhibited (p < 0.0001). Even
when caspase-1 was inhibited, ATP stimulation and LPS priming of the monocytic
THP1 with LPS was found to be sufficient to significantly enhance IL-1β release (p <
0.0001). This may suggest that LPS priming may induce resistance of caspase-1 to the
inhibitory activity of ICEinh (Figure 6-2B).
Contrary to the finding in the monocytes, ATP stimulation of TDMs was found to
significantly enhance IL-1β release (p < 0.0001), irrespective of caspase-1 activity in
proteolyzing pro-IL-1β. IL-1β release in TDMs that were neither stimulated with ATP
nor treated with ICEinh (16.69 pg/ml) was 6-fold smaller than in monocytic THP1 of
the same treatment condition (103.85 pg/ml) ((Figure 6-2C). This suggests that TDMs
do not readily secret IL-1β likely due to low caspase-1 activity and ATM stimulation
only resulted in release of low amount of IL-1β that is proteolyzed by caspase-1 basal
activity. Priming of TDMs by LPS on the other hand, was found to induce significant
enhancement of IL-1β release (p < 0.0001) except in TDMs that were not stimulated
with ATP, which were also exposed to ICEinh (> 185 pg/ml) (Figure 6-2D). This
indicates that TDMs are more responsive to LPS priming in secreting IL-1β except
when pro-IL-1β processing by caspase-1 is blocked and there is no ATP stimulation.
This finding suggests that caspase-1 activity in TDMs is sensitive to ATP stimulation
especially LPS priming even in the presence of ICEinh.
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(A) unprimed monocytic THP1 (B) monocytic THP1 primed with 10 µg/mL LPS (C)
unprimed TDM and (D) TDMs primed with 10 µg/mL LPS were incubated for 2 h
followed by exposure to 20 µM ICEinh for another hour and challenged with 5 mM
ATP in the last hour before collection of culture supernatant for IL-1β analysis by
ELISA. Data was presented as mean ± SD of 3 independent experiments. Statistically
significant differences were analysed by Two-way ANOVA Tukeys multiple
comparison test. *p < 0.05, **** p < 0.0001.
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6.1.3

Inflammatory response in monocytic THP1 exposed to AgNP and LipoAgNP

IL-1β plays a central role in inflammatory responses throughs its involvement in
regulating its own release in addition to that of IL-6 and its crosstalk with TNF-α
during inflammation (Mori et al., 2011, Di Paolo et al., 2015). As such, whether
exposure of the monocytic THP1 and TDMs to AgNP or Lipo-AgNP would provoke
an inflammatory response in these cell types was investigated by evaluating the release
of IL-1β, IL-6, IL-8 and TNF-α upon exposure to the nanoparticles. Prior to
nanoparticle exposure or LPS priming, the cells were exposed to polymyxin B for 1 h
to inhibit any LPS contamination that have occurred in procedures prior to this stage.
After this, LPS-primed and unprimed monocytic THP1 and TDMs were exposed to 1
µg/ml and 2 µg/ml of AgNP or Lipo-AgNP for 3 h after which the cells were
stimulated with 5 mM ATP for another 1 h when supernatant from the cells was
collected for ELISA analysis of IL-1β release. From Figure 6-3A, analysis of IL-1β
measurement in monocytic THP1 indicated that both 1 µg/ml and 2 µg/ml of AgNP
significantly induced IL-1β release compared to untreated and unprimed monocytic
THP1 (p < 0.05 and 0.0001 respectively). While Lipo-AgNP maintained no significant
induction of IL-1β compared to the unprimed and untreated monocytic THP1 at both
1 µg/ml and 2 µg/ml, Lipo-AgNP significantly suppressed AgNP induced IL-1β
release at both concentrations (p < 0.05 and 0.0001 respectively). At 1 µg/ml
concentration, both AgNP and Lipo-AgNP were able to significantly suppress LPS
induced IL-1β release (p < 0.05) but at 2 µg/ml, the nanoparticles showed no effect on
LPS induction of IL-1β release.
Given that IL-1β and TNF-α interact during inflammation to upregulate transcription
and expression of pro-inflammatory cytokines, release of TNF-α upon monocytic
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THP1 exposure to both AgNP and Lipo-AgNP was also investigated following the
same procedure used for measuring IL-1β levels. As observed for IL-1β release, Figure
6-3B shows that exposure of unprimed monocytic THP1 to 1 µg/ml AgNP resulted in
significant induction of TNF-α compared to untreated and unprimed monocytic THP1
(p < 0.05). Coupled with this, exposure of the monocytes to 1 µg/ml Lipo-AgNP did
not induce any rise in TNF-α release compared to the untreated and unprimed
monocytic THP1. This coupled with the observation that both 1 µg/ml and 2 µg/ml
Lipo-AgNP maintained IL-1β levels similar to that of untreated and unprimed
indicates that Lipo-AgNP mediate suppression of AgNP mediated IL-1β and TNF-α
release. At 2 µg/ml concentration, both AgNP and Lipo-AgNP induced similar levels
of TNF-α as that in untreated and unprimed control monocytes. The contrary was
observed for LPS primed monocytic THP1 as exposure to AgNP but not Lipo-AgNP
at 1 µg/ml and 2 µg/ml resulted in suppression of LPS mediated induction of TNF-α
(p < 0.01 and p < 0.0001 respectively). Also, Lipo-AgNP exposure resulted in
significantly higher levels of TNF-α release compared to AgNP exposed monocytic
THP1 at 1 µg/ml and 2 µg/ml in the presence of LPS (p < 0.001).
IL-1β and TNF-α are known regulators of IL-6 release (Palmqvist et al., 2008) and
based on this, the effect of AgNP and Lipo-AgNP on IL-6 release was next
investigated. Findings revealed that IL-6 release was not influenced by LPS priming
of monocytic THP1 cells even in the cells that were exposed to 1 µg/ml AgNP and
Lipo-AgNP alone or with LPS (Figure 6-3C). Conversely, exposure of the monocytic
THP1 to 2 µg/ml AgNP alone or with LPS priming, induced highly significant increase
in IL-6 release in comparison to untreated unprimed THP1 monocytes (p < 0.0001 and
p < 0.001 respectively). An interesting finding here was the suppression of AgNP
induced IL-6 release by Lipo-AgNP both at 1 µg/ml and 2 µg/ml monocytes (p <
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0.0001 and p < 0.01 respectively). It is noteworthy that LPS priming of monocytic
THP1 resulted in suppression of IL-6 release although not significantly (p = 0.5875).
In the same manner, exposure of LPS-primed monocytic THP1 to 2 µg/ml AgNP
resulted in significantly lower release of IL-6 when compared to cells exposed to 2
µg/ml AgNP alone. Taken together, these findings might be indicative of an
antagonistic role of LPS on release of IL-6 in the monocytes.
IL-8 is a pro-inflammatory cytokine with tumour promoting roles (Long et al., 2016).
IL-8 release upon exposure of unprimed and LPS-primed monocytic THP1 to either
AgNP or Lipo-AgNP was investigated. As shown in Figure 6-3D, there was significant
induction of IL-8 release in LPS primed monocytic THP1 (1422.65 pg/ml) compared
with unprimed THP1 monocytes (505 pg/ml) (p < 0.0001). As observed for IL-1β,
exposure of the THP1 monocytes to 1 µg/ml and 2 µg/ml of Lipo-AgNP resulted in
similar IL-8 release profile with those that were untreated and unprimed with LPS
(498.36 pg/ml and 354.48 pg/ml respectively). Conversely, AgNP at both 1 µg/ml and
2 µg/ml resulted in significant induction in released IL-8 levels (1191.17 pg/ml and
1371.61 pg/ml respectively) (p < 0.0001), while Lipo-AgNP significantly suppressed
AgNP induced IL-8 release (p < 0.0001). However, both AgNP and Lipo-AgNP
exposure did not suppress LPS induced release of IL-8 at both concentrations
evaluated.
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Figure 6-3. Lipo-AgNP suppress AgNP mediated secretion of IL-1β, IL-6, IL-8
and TNF-α in monocytic THP1 cells.
Monocytic THP1 cells that were either primed with 10 µg/mL LPS or unprimed were
exposed to 1 µg/ml or 2 µg/ml of AgNP and Lipo-AgNP and incubated for 3 h. The
cells were challenged with 5 mM ATP for 1 h before culture supernatant was collected
for ELISA analysis of (A) IL-1β (B) TNF-α (C) IL-6 and (D) IL-8 release. Data was
presented as mean ± SD of 3 independent experiments. Statistically significant
differences within same exposure group were analysed by Two-way ANOVA Tukeys
multiple comparison test while differences between different exposure groups were
analysed by Sidak multiple comparison test. *p < 0.05, **p < 0.01, ***p < 0.001, ****
p < 0.0001.
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6.1.4

Inflammatory response in TDMs exposed to AgNP and Lipo-AgNP

Following the discovery that Lipo-AgNP was able to suppress AgNP and LPSmediated cytokine release in the monocytic THP1 cells, the cytokine release
experiment was replicated in TDMs upon their exposure to AgNP and Lipo-AgNP.
This was necessary because monocytes and macrophages are both important
components of the innate immune system in processes leading up to inflammation
especially in the release of pro-inflammatory cytokines either during injury, disease
development or infection. As such, release of the same set of cytokines measured in
the monocytic THP1 were examined in TDMs under the same conditions.
Analysis of IL-1β release upon LPS priming of TDMs indicated a significant increase
or enhancement of IL-1β release by TDMs (188.43 pg/ml) compared to the untreated
and unprimed control TDMs (174.45 pg/ml) (p < 0.05). Exposure of the unprimed
TDMs to 1 µg/ml of AgNP and Lipo-AgNP resulted in significant suppression of IL1β release (28.41 pg/ml and 41.28 pg/ml respectively) (p < 0.0001), although AgNP
significantly suppressed the IL-1β release compared to Lipo-AgNP (p < 0.05). In a
similar manner, 2 µg/ml of AgNP and Lipo-AgNP significantly suppressed IL-1β
release in unprimed TDMs (23.73 pg/ml and 48.59 pg/ml respectively) (p < 0.0001).
Unfortunately, both AgNP and Lipo-AgNP did not suppress LPS mediated release of
IL-1β in TDMs (Figure 6-4A).
The effect of the nanoparticles on TDM response in terms of TNF-α release was next
examined. As shown in Figure 6-4B, the first observation was that TNF-α release in
TDMs was more than twice that secreted by monocytic THP1s under all exposure
conditions. It was found that LPS priming of TDM induced significantly high level of
TNF-a release (3458 pg/ml) compared to unprimed TDM (593.33 pg/ml) (p < 0.0001).
Exposure of the TDM to 1 µg/ml and 2 µg/ml of Lipo-AgNP resulted in significant
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suppression of TNF-α release (399.43 pg/ml and 258.33 pg/ml respectively). AgNP
exposure on the other hand only resulted in significant suppression of TNF-α release
at 2 µg/ml (341.9 pg/ml) (p < 0.01). In TDMs that were primed with LPS, exposure to
2 µg/ml AgNP and Lipo-AgNP resulted in significant suppression of LPS induced
TNF-α release in the TDMs (3270 pg/ml and 3068 pg/ml respectively) (p < 0.05 and
p < 0.0001 respectively). Furthermore, 2 µg/ml Lipo-AgNP significantly mediated
suppression of TNF-α release in comparison with AgNP at the same concentration.
As observed in monocytic THP1, LPS priming of TDMs induced significant release
of IL-6 (42.86 pg/ml) when compared with the untreated and unprimed TDMs (0.76
pg/ml) (p < 0.0001). In addition, AgNP and Lipo-AgNP at 1 µg/ml and 2 µg/ml did
not induce further IL-6 release as the TDMs exposed to the nanoparticles maintained
similar IL-6 release as the control. While 1 µg/ml of AgNP and Lipo-AgNP did not
affect LPS induce IL-6 secretion in TDMs, exposure of the LPS-primed TDM to 2
µg/ml AgNP resulted in significantly higher release of IL-6 (54.39 pg/ml) compared
to 1 µg/ml AgNP (42.59 pg/ml) (p < 0.05). The reverse was observed for 2 µg/ml
Lipo-AgNP exposure which induced significantly lower IL-6 release compared to 1
µg/ml Lipo-AgNP (37.86 pg/ml to 49.21 pg/ml respectively) (p < 0.005) (Figure
6-4C). In TDMs, observed IL-8 release upon exposure to 1 µg/ml AgNP and LipoAgNP (1118.51 pg/ml and 1033.22 pg/ml respectively) was significantly higher
compared to control untreated group (566 pg/ml) (p < 0.0001). The same was observed
for the nanoparticles at 2 µg/ml concentration but AgNP induced significantly higher
IL-8 release (1273 pg/ml) compared to Lipo-AgNP (1099.57 pg/ml) (p < 0.01) (Figure
6-4D). LPS priming of the TDMs also resulted in significantly higher release of IL_8
at both 1 µg/ml and 2 µg/ml of both AgNP and Lipo-AgNP (p < 0.0001).
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Figure 6-4. Lipo-AgNP suppress AgNP mediated secretion of IL-1β, IL-6 and
TNF-α in TDMs.
TDMs that were either primed with 10 µg/mL LPS or unprimed were exposed to 1
µg/ml or 2 µg/ml of AgNP and Lipo-AgNP and incubated for 3 h. This was followed
by 5 mM ATP challenge for 1 h before culture supernatant was collected for ELISA
analysis of (A) IL-1β (B) TNF-α (C) IL-6 and (D) IL-8 release. Data was presented as
mean ± SD of 3 independent experiments. Statistically significant differences within
same exposure group were analysed by Two-way ANOVA Tukeys multiple
comparison test while differences between different exposure groups were analysed
by Sidak multiple comparison test. *p < 0.05, **p < 0.01, ***p < 0.001, **** p <
0.0001.
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6.1.5

Cell viability of monocytic THP1 and TDMs at 4 h post-exposure to AgNP
and Lipo-AgNP

It has been shown that Lipo-AgNP exhibit immunosuppressive role, even AgNP to
some extent. To ensure that the suppressed cytokine release was not due to reduced
cell viability or reduction in number of cells that are able to release the cytokine upon
exposure to AgNP and Lipo-AgNP, a cell viability assay was carried out. Both LPS
primed and unprimed monocytic THP1 and TDMs were exposed to 1 µg/ml and 2
µg/ml of either AgNP or Lipo-AgNP for 3 h after which the cells were stimulated with
5 mM ATP for another 1 h, as done for cytokine release. The cell viability by Alamar
blue was then carried out. As shown in Figure 6-5.A and B, exposure conditions for
AgNP and Lipo-AgNP did not affect the cell viability of both monocytic THP1 and
TDM at 4 h when the cytokine release was evaluated.
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Figure 6-5. Cell viability of monocytic THP1 and TDMs.
(A) monocytic THP1 and (B) TDMs that were either primed with 10 µg/mL LPS or
unprimed were also exposed to 1 µg/ml and 2 µg/ml AgNP and Lipo-AgNP for 3 h
followed by 5 mM ATP challenge for 1 h. The cells were then exposed incubated in
10% Alamar blue containing RPMI media for 2 h. Data is presented as mean ± SD.
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6.1.6

Expression of STAT-3 in AgNP and Lipo-AgNP exposed monocytic THP1
and TDMs

Data obtained from this study have shown that AgNP provokes inflammation in both
monocytic THP1 and TDMs. The effect of AgNP on STAT-3 expression was next
evaluated. STAT-3 is a transcriptional factor known to regulate expression of different
inflammatory cytokines, which can result in uncontrolled inflammation (Kasembeli et
al., 2018). Monocytic THP1 and TDMs that were either primed with LPS or unprimed
were exposed to 1 µg/ml of either of AgNP or Lipo-AgNP for 24 h. The lysate
collected was subjected to sandwich ELISA analysis and result obtained showed that
exposure of LPS primed monocytic THP1 to AgNP resulted in significant induction
of STAT-3 expression compared to LPS primed and untreated control monocytes (p <
0.05) (Figure 6-6A). It was also found that AgNP induced significantly higher STAT3 expression when compared with Lipo-AgNP exposure, both in LPS-primed
monocytic THP1 cells (p < 0.01). Contrastingly in TDMs, exposure of the cells to
AgNP induced significant expression of STAT-3 in both LPS primed and unprimed
TDMs when compared to primed and unprimed untreated controls (p < 0.05 and p <
0.001) as well as LPS primed and unprimed Lipo-AgNP exposed TDMs (p < 0.05 and
p < 0.001) (Figure 6-6B). However, Lipo-AgNP exposure did not affect STAT-3
expression in THP1 monocytes or TDMs in both LPS primed and unprimed cells.
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Figure 6-6. AgNP induced STAT-3 expression in monocytic THP1 and TDMs.
(A) Monocytic THP1 and (B) unprimed TDMs or TDMs primed with 10 µg/mL LPS
were also exposed with either of 1 µg/ml AgNP or Lipo-AgNP for 24 hrs. Lysates
were collected and analysed by sandwich ELISA for STAT-3 expression. Statistically
significant differences within same exposure group were analysed by Two-way
ANOVA Tukeys multiple comparison test while differences between different
exposure groups were analysed by Sidak multiple comparison test. *p < 0.05, *** p <
0.001.
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6.2

Discussion

In Chapter 4, it was shown that Lipo-AgNP at very low dose induced significant
caspase 3/7 dependent cell death compared to uncoated AgNP in THP1 cells in a ROS
independent manner (Yusuf et al., 2018). Here, the immunomodulatory role of LipoAgNP was investigated using THP1 monocytes and TDMs as models for human
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monocyte and macrophages respectively. Monocytes and macrophages are central to
the functioning of the innate and adaptive immune system in response to infection,
injury and tissue repair or in autoimmune and inflammatory diseases such as
rheumatoid arthritis (RA) (Roberts et al., 2015, Ogle et al., 2016). As monocytes and
macrophages functions are mainly modulated by inflammatory cytokines in above
conditions, the response of these immune cells to AgNP and Lipo-AgNP in normal
condition and during induced inflammation was investigated.
In this study, pro-THP1 were stimulated with PMA for 24 h to induce maturation into
monocytic cells because THP1 cells, referred to as pro-THP1 here, have been
described to have phenotypic characteristic of pro-monocytes which are the progenitor
cells from which monocytes develop (Daigneault et al., 2010, Li et al., 2013b).
Coupled with this, pro-THP1 are known to secrete significantly less concentration of
inflammatory cytokines such as IL-1β, TNF-α, IL-6 and IL-8 compared to matured
monocytes (Jones et al., 2003, Shalit et al., 2005). This may be indicative of a less
active role of promonocytes during inflammation or tissue repair. The level of cytokine
generated by promonocytes may also be difficult to quantify accurately, subjective to
method of measurement and type of equipment used. This low response was observed
in this study where it was found that pro-THP1 produced significantly less IL-1β
compared to monocytic THP1 and TDMs at all time points (p < 0.0001). This was also
the case for the highest recorded IL-1β release at 4 h post LPS priming of pro-THP1
and was 2.5 folds less than IL-1β release in both monocytic THP1 and TDMs at same
time point. CD14, toll-like receptor 2 (TLR2) and TLR4 are major toll like receptors
expressed by monocytes and macrophages to sense and identify pathogen associated
molecular patterns (PAMPs) to activate pathways for secretion of either cytokines or
chemokines that mediate inflammation or recruitment of more immune cells to either
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fight infection or induce perpetuation of immune response that causes autoimmunity
(Liu et al., 2014d, Mukherjee et al., 2016, Zoccal et al., 2014). Interestingly,
expression of CD14, TLR2 and TLR4 have been reported to be higher in monocytes
compared to pro-THP1 (Parker et al., 2004), which may explain why cytokine
expression in promonocytes is less than in monocytes and macrophages.
Unprimed monocytic THP1 exhibited significant increase in IL-1β release at 0.5 h,
while this type of increase was not observed in unprimed TDMs until at 2 h. During
infection or tissue repair, monocytes are recruited to the site of infection or tissue
damage where they then differentiated into either of macrophages or dendritic cells
(Yang et al., 2014). Upon recognition of microbial PAMP, evidence in the literature
has shown that IL-1β is one of the first set of cytokines that kickstart the differentiation
of monocytes into macrophages (Schenk et al., 2014). This possibly explains the
reason why the monocytic THP1 released high amount of IL-1β upon ATP challenge
which may be sensed by the cells as stimuli to induce inflammatory response,
eventually resulting in either their differentiation into macrophages or phagocytosis of
foreign body. This may also account for the reason why TDMs had slow onset of IL1β release. During hypoxia induced inflammation, expression of IL-1α precursor is
upregulated which is then released by the dying cells. This allows the recruitment of
neutrophils to the site to clear up the cells. Expression of IL-1β precursor and release
of matured IL-1β on the other hand occurs as a late signal for migration of
macrophages (Rider et al., 2011), indicating a time lag in macrophage requirement for
IL-1β.
Release of matured IL-1β is regulated by caspase-1 in both monocytes and
macrophages. Caspase-1 proteolytically cleave pro-IL-1β into the mature IL-1β but
this process is not always spontaneous in vitro especially in THP1 derived cells. In
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vitro, extracellular ATP is thus used to challenge monocytes or macrophages to
activate the P2X7 receptor, a purinergic receptor that mediates huge efflux of
potassium ion (K+). This K+ drives proteolytic activation of caspase-1 by the NLRP3
inflammasome, subsequently influencing the processing and release of IL-1β (Wiley
et al., 2011, Brough and Rothwell, 2007, Amores-Iniesta et al., 2017). This supports
the finding of this study that THP1 monocytes exhibited enhanced IL-1β release after
ATP stimulation except when caspase-1 activity was inhibited. ATP may be acting
upstream of caspase-1 in processing of IL-1β for release. Thus, the inhibition of IL-1β
release when the monocytes were stimulated with ATP while caspase-1 was inhibited
may be as a result of the failure of ATP to stimulate a non-functioning caspase-1. LPS
priming on the other hand, seem to induce a resistance in the monocytes against
caspase-1 inhibition. Consequently, higher ICEinh concentration may be required to
bring about the observed inhibition in unprimed monocytic THP1. LPS binding to
TLR2 and TLR4 induce activation of NF-κβ resulting in increased transcription of
NLRP3 and more pro-IL-1β release (Gaidt et al., 2016). As such, it could indicate that
increased level of NLRP3 available for formation of NLRP3 inflammasome tilts the
steady state kinetics of ICEinh interaction with caspase-1 due to the formation of more
pro-caspase 1 that is activated to caspase-1 molecule at levels significantly higher than
the ICEinh concentration.
Macrophages unlike monocytes do not readily secrete IL-1β based on the finding here
and those from other studies (Carta et al., 2011, Madej et al., 2017), this may be
attributed to the tissue resident role of macrophages which is less involved promoting
inflammation rather than secretion of chemokine required for recruitment of immune
cells (Madej et al., 2017). This line of evidence supports the finding here that TDMs
used in this study secrete significantly higher IL-8 than monocytic THP1. IL-8 is a
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chemokine that facilitates recruitment of immune cells like neutrophils to site of
inflammation and different lines of evidence now exist in the literature for its tumour
promoting role based on its chemokine activities (Turner et al., 2014, David et al.,
2016). the finding here here indicated that AgNP also induced higher release of IL-8
compared to Lipo-AgNP, although both nanoparticles induced release of IL-8 higher
than the basal levels in TDMs. In addition to this, AgNP induction of IL-8 release in
THP1 monocytes was similar to that induced by LPS and this may indicate a possible
contribution of AgNP mediated inflammation that may favour tumour development.
LPS has been demonstrated to induced cancer development and promote tumour
invasion and metastasis (Kurago et al., 2008, Seol et al., 2017), which may be linked
to the IL-8 secretion and the chemokine activity. As such, AgNP stimulation of IL-8
release may facilitate IL-8 chemokine activity in the same manner. This may also
explain the hormetic effect of AgNP in stimulating THP1 cell proliferation (data not
shown) and in HepG2 and A549 cancer cells (Sthijns et al., 2017, Jiao et al., 2014).
Interestingly, HepG2 cell proliferation have been shown in another study to be
inhibited by gallic acid through inhibition of IL-8 secretion (Lima et al., 2016).
Although, IL-1β release in the TDMs was significantly less than in THP1 monocytes,
LPS priming of TDM alone or with ATP stimulation resulted in IL-1β release
comparable to that exhibited by the monocytic cell even under caspase-1 inhibition.
Priming of TDMs might have resulted in much more higher transcription rate of
NLRP3 resulting in no net effect of caspase-1 inhibition of IL-1β release upon ATP
stimulation. Furthermore, monocytes response is heavily reliant on the formation
NLRP3 inflammasome while macrophages utilise AIM2 inflammasome in addition to
NLRP3. As AIM2 pathway has been previously shown to be activated by LPS for
induction of IL-1β release (Turner et al., 2014), this pathway in addition to that of
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NLRP3 may have been activated by LPS to induce activation of caspase-1 to process
release of IL-1β.
Inflammation is tightly associated with activities of reactive oxygen species (ROS).
Excessive generation of ROS such as that generated from the mitochondria during
oxidative stress or even subtle changes in endogenous ROS level can induce cellular
responses that activate redox sensitive proteins like NF-κβ causing inflammation due
to upregulation of NF-κβ target genes such as IL-1β, IL-6 and TNF-α (Mittal et al.,
2014, Forrester et al., 2018, Wang et al., 2007). Likewise, inflammatory response can
induce generation of ROS. Human retinal pigment epithelial cells exposed to TNF-α,
IL-1β and IL-6 exogenously were shown to exhibit increased ROS generation in a time
and dose dependent manner from NADPH oxidase and mitochondrial induced
oxidative stress (Yang et al., 2007). Many studies have documented ROS generation
to be AgNP main mechanism of action as an antibacterial, even as anticancer (Yuan
et al., 2017, Xu et al., 2012, El-Hussein and Hamblin, 2017, Gurunathan et al., 2013),
as such it was hypothesised Lipo-AgNP will suppress AgNP induced inflammation as
it does AgNP ROS generation.
In this study, exposure of the THP1 monocytes to AgNP resulted in significant release
of IL-1β, IL-6, IL-8 and TNF-α but the nanoparticle did not influence inflammatory
response of TDMs except suppression of IL-1β release. In support of this, evidence
that AgNP induce inflammation is largely present in the literature. Sweeney et al.
(2016) showed that AgNP induced secretion of IL-6 and IL-8 in mouse neuronal cells
human alveolar type-I-like epithelial cells. In the same manner, Murphy et al. (2016)
demonstrated increased gene expression of IL-1, IL-6 and TNF-α and increased
secretion of pro-IL-1β upon exposure of THP-1 and primary human blood monocytes
to AgNP. These observations have also been recorded in non-human models. Park et
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al. (2011a) demonstrated that intra-tracheal instillation of silver nanoparticle in mice
resulted in a time and dose dependent increase in release of IL-1, IL-2, IL-6 and TNFα. It was also found that AgNP resulted in upregulation of genes associated with
inflammation and tissue damage. Huang et al. (2015) also showed in mouse nerve cells
that AgNP induced increased release of IL-1β as well as increased gene expression of
CXCL13 chemokine and glutathione synthetase likely due to induced oxidative stress.
Thus, this observed inflammation may be linked to ROS generation by AgNP.
Interestingly, Lipo-AgNP suppressed both AgNP-mediated inflammation and basal
cytokine release by significantly suppressing the release of IL-1β, IL-6, IL-8 and TNFα in THP1 monocyte. In TDMs, Lipo-AgNP suppressed IL-1β and TNF-α release
while maintaining basal level of IL-6 which was aggravated by AgNP. Coupled with
the finding from the previous study that Lipo-AgNP suppresses generation of ROS
(Yusuf et al., 2018), DPPC which is the major component of the liposome
encapsulating AgNP in Lipo-AgNP is known to also possess an immunosuppressive
feature (Murphy et al., 2015b). Sweeney et al. (2016) had shown that a DPPC
containing commercial surfactant prevented release of IL-6 and IL-8 in addition to the
near abolishment of ROS generation in human alveolar type-I-like epithelial cells. As
such, Lipo-AgNP may have suppressed the inflammatory response by preventing
generation of ROS, supporting the finding here that AgNP generated ROS induced the
observed inflammation. The immunosuppressive activity of Lipo-AgNP opens up an
application in treatment of RA and other inflammatory diseases. Involvement of
bacteria and bacterial-induced inflammation have been reported in the development of
RA due to the microbe exacerbation of inflammation and oxidative stress, and
sometimes induced autoimmunity (Pretorius et al., 2017, Olsen-Bergem et al., 2016).
As such, Lipo-AgNP can serve as a double-edged sword to suppress the induced
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inflammation at the joint and to exert its antibacterial effect on the pathogens within
the RA joint.
As a major PAMP responsible for bacterial induced inflammation during infection,
LPS binding to CD14, TLR2 and TLR4 are prominent to initiation of cytokine release.
The application of AgNP as antibacterial is fared to drive inflammation into a chronic
state that may favour development of diseases like cancer and autoimmunity. It was
discovered that AgNP supressed LPS-induced IL-1β (at 1 µg/ml) and TNF-α release
(at both concentration) while Lipo-AgNP (at 1 µg/ml) only suppressed release of IL1β in THP1 monocytes. While AgNP significantly enhanced LPS induced-IL-6
release, Lipo-AgNP exposure of THP1 monocytes did not induce IL-6 release. In
TDMs, only 2 µg/ml Lipo-AgNP mediated suppression of LPS-induced TNF-α. The
reason for suppression of LPS induced IL-1β and TNF-α release by either of AgNP or
Lipo-AgNP in monocytic THP1 or TDM is not known but it could be that LPS
interaction with AgNP modifies the surface chemistry of both AgNP/Lipo-AgNP and
LPS resulting in alteration in interaction between LPS and the TLRs. Thus,
subsequently modulating expected inflammatory response. However, further studies
are required to probe this possibility. Another possible explanation could be that both
AgNP and Lipo-AgNP at the right concentrations can inhibit iNOS (inducible nitric
oxide synthase) which may have resulted in suppression of LPS-induced IL-1β and
TNF-α. In a study by Sarkar et al. (2008), allylpyrocatechol obtained from crude
extract of from piper beetle leaf was shown to inhibit iNOS mRNA expression
resulting in suppression of LPS-induced secretion of TNF-α, COX-2 and IL-12p40 in
RAW 264.7 macrophages. Other compounds such as neocryptotanshinone and
naringenin, which are plant extracts were also shown in different studies to inhibit
LPS-induced mRNA and protein expression of IL-1β, IL-6 and TNF-α in RAW 264.7
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macrophages upon inhibition of iNOS (Kumar and Abraham, 2017, Wu et al., 2015).
A study supporting the activity of AgNP in suppression of LPS induced inflammation
through suppression of iNOS and nitric oxide was that of Haase et al. (2014), who
showed that AgNP suppressed nitric oxide synthesis in human neutrophils and
macrophages. Another study also reported that AgNP attenuated the expression of
iNOS inhibiting production of nitric oxide in Hep-G2 cells (Zuberek et al., 2017).
Although findings of other studies have shown that AgNP can induce expression of
iNOS due to increased ROS generation such as in pancreatic cancer and osteoblastic
cell lines (Zielinska et al., 2016, Barcinska et al., 2018), this may be as a result of
differing cellular responses to AgNP because of the different genetic backgrounds.
It has been demonstrated that AgNP induced inflammatory responses, which is
suppressed by encapsulation in DPPC based liposome. Particular, AgNP induced
release of IL-1β, IL-6 and TNF-α indicating that it may induce persistent inflammation
through STAT-3. To investigate this possibility, the effect of AgNP on the expression
of STAT-3, a transcriptional factor in the JAK/STAT pathway known to be involved
in sustained inflammatory response through its regulation especially by IL-6 family of
protein (Wang et al., 2013b), was examined. It was found that exposure of LPSmonocytic THP1 to AgNP resulted in significant induction of STAT-3 expression. On
the other hand, TDMs exposure to AgNP was found to induce significant expression
of STAT-3 irrespective of LPS priming. This finding in addition to those existing in
the literature suggests AgNP may sustain inflammatory response by at least indirectly
activating STAT-3 expression. For example, IL-1β, IL-6 and TNF-α as found to be
induced by AgNP in this study have been previously shown to induce STAT3
phosphorylation and activation causing prolonged inflammation and joint destruction
in RA mice (Mori et al., 2011). IL-6 binding with its receptor, IL-6R, is known to
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indirectly induce activation of STAT-3 through IL-6R interaction with epidermal
growth factor receptor (EGFR) or activation of janus kinase (JAK) leading to STAT3 activation (Figure 6-7). This STAT-3 activation subsequently results in prolonged
inflammation through continued expression of proteins like the MAP kinase (MAPK)
and interleukin-1 receptor associated kinase binding protein-1 (IRAK1BP1) that play
crucial role in inflammation and cancer (Wang et al., 2013b). The fact that Lipo-AgNP
maintained STAT-3 expression within the level observed in untreated control THP1
monocytes and TDMs may be indicative of the suppressive role of the encapsulation
on AgNP mediated inflammation. Taken together, Lipo-AgNP may be a potential in
treatment of RA and the pannus formation in RA joint. Like a double-edged sword,
Lipo-AgNP may treat the RA killing the often-colonised bacteria and suppressing the
provoked chronic inflammation. In addition, Lipo-AgNP may be useful in treating
other bacterial diseases that are characterised with heightened inflammation like
ulcerative colitis and Crohn’s disease or even cancer like inflammatory breast cancer.
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Figure 6-7. Mechanism of AgNP sustenance of perpetual inflammation.
Entry of AgNP into the cell can result in generation of ROS through mitochondrial
membrane disruption and cytochrome C release or through ionisation of the
nanoparticle by the aqueous milieu of the cytoplasm. The generated ROS could
activate IKKβ releasing it from the IKK complex. IKKβ then activates NFkβ re
pathway which in turns activates IKK which in turns activate NF-κβ facilitating its
translocation into the nucleus to initiate transcription of pro-inflammatory cytokines
like IL-1β, IL-6 and TNF-α. ROS can also activate NFkβ through the MAP kinase
(MAPK) pathway. Release of IL-6 and its subsequent interaction with IL-6R can then
activate the JAK/STAT3 pathway leading to phosphorylation and activation of STAT3
which facilitates transcription of factors like MAPK that can further activate upstream
signaling cascade in the NFkβ pathway further creating a continuous loop of cytokine
release.
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6.3

Conclusion

While AgNP suppression of LPS-induced IL-1β and TNF-α may be indicative of a
somewhat favourable contribution of the nanoparticle during LPS triggered
inflammation, AgNP provocation of inflammatory response in the absence of LPS
indicates otherwise. AgNP is mainly used in preventing bacterial infection which
means human exposure to AgNP is highly likely under sterile conditions such as in
sterilised items like garments, cosmetics and medical equipment that contain AgNP
with intent of preventing rather than treating infection. As such, the increased contact
in such conditions may likely drive inflammation that are favourable for chronic
diseases like cancer and inflammatory diseases. On the other hand, It has been shown
that Lipo-AgNP effectively suppressed AgNP mediated inflammatory responses in
both monocytic THP1 and TDMs. Based on the evidence presented here and that in
Chapter 4, Lipo-AgNP application will not only translate to lower AgNP concentration
required to achieve effective cytotoxicity, but will likely mitigate AgNP-mediated
inflammation, preventing vicious cycle of chronic inflammation that favours disease
development and progression. This will prove especially useful in treating
inflammation induced bacterial disease such as RA and the associated pannus
development, ulcerative colitis and Crohn’s disease, all of which are characterised
with bacterial infection and chronic inflammation since AgNP is an antibacterial
coupled with the immunosuppressive properties of Lipo-AgNP.
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Chapter

7
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7

General Discussion

AgNPs are the most researched and most commercialised nanoparticles primarily
owing to their antibacterial properties against a wide range of bacteria strains (Vance
et al., 2015). The main mechanism of AgNP induced bactericidal effect has been
demonstrated to be due to intracellular ROS generation upon ionisation of the
nanoparticle within the aqueous environment of the cell (El-Hussein and Hamblin,
2017, Abdal Dayem et al., 2017). Furthermore, research has now shifted into the
investigation of AgNP as an anticancer agent since it is now known that AgNP has
some anticancer properties. As an antibacterial, AgNP is present in various everyday
consumable product such as cosmetics, food items and apparels in very high
concentrations (discussed in section 1.1.1), which in addition to the potential
anticancer applications will result in increased human exposure. Not only will this
repeated human exposure to AgNP pose an impending risk of adverse effects
development to human, AgNP that leaches into the ecosystem poses great risk to
marine organisms and wildlife.
Many studies have demonstrated the cytotoxic effects of AgNP in different organisms
ranging from marine organisms such as Daphna magna and Chaetoceros curvisetus
to mammals such mice and Guinea pig as well as several human cell lines (Korani et
al., 2013, Lodeiro et al., 2017, Kawata et al., 2009, Yusuf et al., 2018, Hou et al.,
2017). While there have been no studies directly evaluating the toxicity of AgNP on
human subjects, there are reports in the literature indicating that exposure to high
concentrations of AgNP is linked to cardiotoxicity, hepatotoxicity and nephrotoxicity
(Tacar et al., 2013). In addition, AgNP at high concentration is also linked to less toxic
conditions such as agyria, eye and skin discolouration (Tak et al., 2015). In addition
to the reports on possible AgNP toxicity in humans, several in vitro and in vivo studies
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have reported inflammatory response induced by exposure of specific cells or animals
to AgNP (Murphy et al., 2016, Fraser et al., 2018, Park et al., 2010b, Park et al., 2011a,
Park et al., 2011b).
To circumvent the toxic effect AgNP and the potential of the adverse effect, it was
hypothesised that improving the intracellular delivery of AgNP will enhance its
cytotoxicity and possibly the induced inflammation, resulting in lessened
concentration of the nanoparticle in consumable products and mitigated risk of adverse
effects. This step is also hoped to reduce the amount of AgNP that will eventually be
released into the ecosystem. Unfortunately, there are no studies till date that have
researched the possible ways of enhancing AgNP toxicity as well as mitigating AgNPinduced inflammation. Hence, this thesis aimed to enhance AgNP delivery and
subsequently its cytotoxicity by encapsulating the nanoparticle in a DPPC-based
liposome for improved delivery and suppression of AgNP-induced inflammation
owing to the anti-inflammatory role of DPPC (Sweeney et al., 2016, Murphy et al.,
2015b).
7.1

AgNP encapsulation in DPPC based liposome by extrusion method
produced stable nanocapsules and enhances nanoparticle cytotoxicity

The first step in this thesis was to synthesise AgNP by chemical reduction of AgNO3
by NaBH4 in a cold environment following the equation in section 3.9. Two different
encapsulation methods, which are probe sonication and extrusion techniques, were
then trialled for preparation of Lipo-AgNP to yield PB-Lipo-AgNP and Ex-LipoAgNP respectively. Data from DLS analysis showed PB-Lipo-AgNP and Ex-LipoAgNP to be of 143 nm and 140 nm respectively. However, PB-Lipo-AgNP had a
second peak of agglomerated nanoparticle of roughly 5 µm in size which made up
about 14% of the nanoparticle (Table 3-1) which was also confirmed by SEM and
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STEM. The uptake rate nanoparticles is affected by their sizes (Foroozandeh and Aziz,
2018), giving the first insight into the acceptance of Ex-Lipo-AgNP over PB-LipoAgNP. Contrastingly, Ex-Lipo-AgNP formed distinct population of spherical
liposomes. The STEM showed that AgNP in the Ex-Lipo-AgNP to be [resent within
the liposome but some AgNPs were found on the surface of the PB-Lipo-AgNP. This
indicated free unencapsulated AgNP which was supported by the EE found to be
67.8% for PB-Lipo-AgNP and 86.5% for Ex-Lipo-AgNP. In addition, the UV-Vis
spectra of the PB-Lipo-AgNP was similar to that of uncoated AgNP most likely due
to the free unencapsulated AgNP in the PB-Lipo-AgNP. This was also apparent in the
golden yellow colour of the uncoated AgNP and PB-Lipo-AgNP (Figure 3-2). The
free AgNP on the PB-Lipo-AgNP may be responsible for the drastic increase in the
average nanoparticle size in culture media in a similar fashion to uncoated AgNP.
Nanoparticles such as AuNPs are known to interact with the protein corona in culture
media as a consequence of its reactive surface (Sabuncu et al., 2012). Contrastingly,
this aggregation with protein was not observed for Ex-Lipo-AgNP, likely because
most of the AgNP are present within the liposome causing no net change in the
nanoparticle size from water to culture media.
To further evaluate the applicability of both Lipo-AgNP preparations for biological
studies, the stability and drug release profile of both PB-Lipo-AgNP and Ex-LipoAgNP were carried out. Findings indicated that Ex-Lipo-AgNP was more stable over
a 6-month period with minimal increase in size and reduction in zeta potential
compared with PB-Lipo-AgNP at both 4oC and 24oC (Table 3-2). DLS analysis of
temperature-dependent size change indicated that Ex-Lipo-AgNP was more stable in
RPMI culture media compared with PB-Lipo-AgNP which exhibited a time dependent
increase in size over a 6 h period from 20oC at 0 h to 37oC at 6 h. This reduction in
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size was attributed to the loss of the liposomal water content due to osmosis since the
culture media is of higher osmolarity compared with the aqueous content of the
liposome (Monteiro et al., 2014). This data also supports the finding here that PBLipo-AgNP possess a burst release of content at both pH 6.5 and 7 unlike the Ex-LipoAgNP which showed a steady load release. Based on this, PB-Lipo-AgNP is suggested
to have a less stable liposome resulting in quick loss of liposomal content.
The large size of PB-Lipo-AgNP due to agglomeration, its less stable liposome both
in water and culture media, and the poor drug release profile all suggest that it is of
less biological potential compared with Ex-Lipo-AgNP. A 24 h cytotoxicity profile of
both Lipo-AgNP preparations were then evaluated on THP1 monocytes. Data from
Alamar blue, flow cytometry and confocal microscopy all showed that Ex-Lipo-AgNP
was more cytotoxic than PB-Lipo-AgNP. In fact, PB-Lipo-AgNP had similar
cytotoxicity profile compared with uncoated AgNP which is likely due to high
quantity of unencapsulated AgNP in the PB-Lipo-AgNP. The less cytotoxic nature of
PB-Lipo-AgNP was suggested to be due to the large size affecting endocytosis of the
nanoparticle as larger particles exhibit poor intracellular uptake. The stability of ExLipo-AgNP and the uniform size must have allowed increased intracellular uptake and
delivery of the nanoparticle in a manner that allowed efficiently load release.
7.2

Ex-Lipo-AgNP (Lipo-AgNP) induced ROS-independent and caspase
dependent apoptosis

AgNP mechanism of antibacterial and anticancer activity has been widely investigated
to involve ROS generation, degradation on intracellular structures, lipid peroxidation
and inhibition of bacterial cell growth (Qing et al., 2018, Hsueh et al., 2015, Oves et
al., 2018). However, there has been no study investigating encapsulation of AgNP in
a liposome and the effect this modification will have on the mechanism of AgNP
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antibacterial and anticancer activities. Based on the superior biological activity of ExLipo-AgNP, this Lipo-AgNP preparation was selected for the subsequent studies and
its biological activities were compared with uncoated AgNP to evaluate how the
encapsulation modifies AgNP activities in THP1 monocytes. The rationale behind the
employment of THP1 monocyte in this research is because of the following;
1. THP1 monocytes are a leukemic (cancer) cell line, thus allowing investigation
of the toxicological profile of Lipo-AgNP on a cancer cell line.
2. Monocytes and similar immune cells such as macrophages are important
component of the innate and adaptive immune response to foreign objects
including nanoparticles upon human exposure (Mrakovcic et al., 2014, RuedaRomero et al., 2016, Robbins et al., 2015), making the cell line a perfect model
to also study the effect of the nanoparticle on the innate immune system which
is relevant in the case of nanoparticle induced cytokine release.
The 24 h IC50 of Lipo-AgNP was first estimated for better comparison of the
nanoparticle toxicological profile. Lipo-AgNP was found to have a 24 h IC50 of 3.045
μg/mL compared to AgNP with 4.991 μg/mL. Exposure of the THP1 monocytes to
0.625 µg/mL of either of AgNP or Lipo-AgNP, a concentration that is considerably
lower than the IC50 of both nanoparticles, indicated from flow cytometric data, that
Lipo-AgNP possessed significant cytotoxic effect on the cells compared to unexposed
and AgNP-exposed THP1 monocytes. The possible explanation for this was either the
liposome was toxic, or the encapsulation must have enhanced the toxicity of the
nanoparticle. Exposure of the cells to equivalent concentration of empty liposome of
the same size was found to show no effect on the cell viability, suggesting the
encapsulation must have enhanced the toxic effect of AgNP.
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In determining cell viability upon exposure to toxic agents, analysis of the cell cycle
profile and investigations of apoptotic hallmarks are crucial to the determination of
cytotoxic impact of any pharmacological agent (Orrenius et al., 2010). The cell cycle
profile of THP1 monocytes exposed to 0.625 µg/mL of either AgNP or Lipo-AgNP
showed that Lipo-AgNP induced interruption in the cell cycle at the S-phase causing
less THP1 monocytes progressing to the G2/M phase. Interestingly, the cells that
failed to progress to the G2/M phase were found present in the Sub-G1. Since the SubG1 phase cells are cells with fragmented DNA, these data suggest that Lipo-AgNP
might have induced DNA fragmentation preventing DNA replication in the S-phase
causing the observed cell death.
AgNP ionisation into Ag+ which may cause oxidation of cellular proteins and lipids
releasing ROS which may cause DNA damage (Marnett, 2002). It was thus
hypothesised that Lipo-AgNP might have induced significant ROS generation that
resulted in DNA damage. Investigation into the ROS induction by both AgNP and
Lipo-AgNP showed that while AgNP at 0.625 µg/ml did not cause significant cell
death or interruption of the cell cycle of THP1 monocytes, it induced some level of
ROS. On the contrary, Lipo-AgNP at the same concentration resulted in ROS
suppression, suggesting that ROS generation was not responsible for the DNA damage
in the THP1 monocytes. The activity of ROS upstream of caspase 3 and 7 will suggest
that Lipo-AgNP induced cell death may not involve the executioner caspases.
However, the activation of the executioner caspases 3 and 7 was investigated to
confirm the type of apoptosis involved. Contrary to expectation, it was found that
exposure of the THP1 monocytes to Lipo-AgNP resulted in significant caspase 3 and
7 activation and cell death in comparison to AgNP and control unexposed cells.
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The data here suggested that Lipo-AgNP may have caused significant improvement in
the intracellular uptake of the encapsulated AgNP which must have remained within
the liposome and protected the nanoparticles from ionisation by the aqueous
intracellular environment. The entry via the endo-lysosomal pathway may have caused
nuclear delivery of the AgNP resulting in DNA damage and subsequent activation of
the executioner caspases causing ROS independent cell death.
7.3

Lipo-AgNP improved intracellular nanoparticle delivery and causes redox
imbalance to induce cell death

It has been established that Lipo-AgNP can induce significant cytotoxic effect on
THP1 cell at very low concentration and the induced cell death is ROS independent
but caspase dependent. The mechanistic detail of Lipo-AgNP cytotoxicity was further
probed in TDMs obtained from THP1 monocytes. As stated earlier, both monocytes
and macrophages are important to the functioning of the innate immune response. In
addition, macrophages play important role in development and progression of chronic
diseases such as cancer and arthritis (Lameijer et al., 2013), making them a potential
therapeutic targets in treatment of these diseases. Cell viability studies carried out on
the TDMs post-exposure to AgNP and Lipo-AgNP showed a similar toxicological
profile for both nanoparticles to what was observed in the monocytes, although the
IC560 in the TDMs were higher than in the monocytes. The 24 h IC50 values of AgNP
and Lipo-AgNP was found to be 5.71 µg/ml and 3.98µg/ml respectively indicating a
higher dose requirement in the TDMs to achieve same toxicity levels as in the THP1.
This differential response of THP1 monocytes and TDMs to AgNP and Lipo-AgNP
may be dependent on the nanoparticle uptake rate of the cells which is known to be
different for monocytes and macrophages. Unlike monocytes which only uptake
particles by endocytosis, macrophages are specialised cells for phagocytosis in
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addition to endocytosis (Lunov et al., 2011), causing the TDMs to exhibit higher
nanoparticle uptake.
Based on the higher IC50 of the nanoparticles in TDMs, a higher working concentration
was implemented in the TDMs. While 0.625 µg/mL was used in THP1 monocytes, 2
µg/mL was used in the TDMs for all biological studies. Cell viability studies by
confocal microscopy aided with calcein-AM stain showed that AgNP at 2 µg/mL
resulted in considerable but non-statistically significant reduction in cell viability after
24 h. On the contrary, Lipo-AgNP induced significant reduction in cell viability (p <
0.01). Investigation of ROS generation in the TDMs after exposure to the
nanoparticles revealed that not only did Lipo-AgNP significantly suppressed AgNPinduced intracellular ROS generation for the 4 h period considered, it maintained the
ROS level at level similar to that in control untreated cells. Macrophages are known
to generate significant levels of intracellular ROS and the ROS induction plays is an
important mechanism in their roles in diseases such as cancer and cardiovascular
disease (Roux et al., 2019, Bae et al., 2009).
Data obtained here for cell viability and ROS studies were similar to that observed in
THP1 monocytes (section 4.1.5). This led to the investigation of the GSH level in the
TDMs after nanoparticle exposure. It was expected that high ROS would result in a
low GSH level and vice versa. This was true for AgNP, as the high ROS level led to
significant reduction in the GSH level. Unexpectedly, a significantly low GSH level
which interprets to a redox imbalance was observed in the TDMs exposed to LipoAgNP. Conventionally, the only specific function attributed to intracellular ROS
accumulation has been known to be damage to cellular structures and subsequent
cellular dysfunction as seen in chronic pathologies such as cancer, neurodegenerative
diseases and premature ageing (Sena and Chandel, 2012). Furthermore, ROS has been
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considered to be a waste from aerobic metabolism and consequence of cellular
toxicity. However, studies in the last decade have shown that low ROS level acts as
redox activator to signal proliferation and cellular differentiation (Zhu et al., 2012,
Hernández-García et al., 2010). On the contrary, the finding here and that of Liu et al.
(2014a) showed association between low ROS level and cellular apoptosis post
exposure to cytotoxic agents. Liu et al. (2014a) demonstrated that the survival of
HepG2 cancer cell was dependent on a balance between the ROS and antioxidant
level. The sharp reduction in ROS level induced by the dihydromyricetin used in the
study resulted in imbalance redox state perturbing the ROS signalling further resulting
in apoptosis. The low ROS level induced by Lipo-AgNP may have used the same
mechanism.
The cellular redox state is also often used to describe the GSSG/GSH level and under
normal physiological condition, the this is maintained within narrow range just as pH
is regulated. In pathological conditions, the redox state can be abnormally high or low
(Flohé, 2011, Liu et al., 2014a). Low GSH levels have been shown to be associated
with mitochondrial dysfunction and apoptosis, which can sensitize tumour cells to
chemotherapy (Nie et al., 2009). The data indicated that Lipo-AgNP dose dependently
decreased GSH levels in the TDMs with activation of caspase 3 and 7. The low GSH
level as such may have resulted in mitochondrial dysfunction, release of cytochrome
C and the observed caspase 3 and 7 activation, causing apoptosis. Bax and Bcl-2 are
pro- and anti-apoptotic proteins regulating cell death and survival respectively, both
of which maintain mitochondrial stability. A balanced Bax and Bcl-2 level is required
for cell survival and high Bcl-2 expression results in inhibition of caspase-dependent
apoptosis while high Bax expression induces apoptosis and vice versa (Luo et al.,
2015). Bax binding with the mitochondrial membrane causes MOMP and release of
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cytochrome C then caspase-dependent apoptosis. But this is prevented by inhibition
of Bax through its binding with Bcl-2. In this study, the data showed that Lipo-AgNP
caused suppression of Bcl-2 protein expression while Bax expression was unaffected.
This tipped the Bax and Bcl-2 balance towards Bax causing it to exert its apoptotic
effect on the TDMs through induction of MOMP. MOMP coupled with the low GSH
level led to a possible release of cytochrome C and subsequent activation of caspase 3
and 7 dependent apoptosis (Figure 7-1).
Both AgNP and Lipo-AgNP induced caspase activation at 24 h but only Lipo-AgNP
caused significantly higher cell death in comparison with the control untreated TDMs.
This was an indication of difference in the kinetics of the nanoparticle uptake by the
TDMs. To confirm this, the uptake of both AgNP and Lipo-AgNP were monitored for
4 h by flow cytometry and it was found that Lipo-AgNP had been internalised by the
TDMs by 30 mins while AgNP internalisation was detectable after 45 mins. The
improvement in Lipo-AgNP uptake can be attributed to the similarity between the cell
membrane and the liposome shell of the Lipo-AgNP. Coupled with this, the 15 mins
difference in uptake coupled with the redox imbalance may have enhanced the
cytotoxic effect of Lipo-AgNP making it exert a more deleterious effect which was
not observed for AgNP. In essence, improved uptake of AgNP within the liposome
and the protection of the liposomal content form the cytosol changes the overall
pharmacokinetic of the nanoparticle, thus altering the pathway utilised from that which
AgNP would activate. From this, AgNP ionisation was prevented early on in the
cytosol and the entry of Lipo-AgNP through the endo-lysosomal pathway must have
provided a way for delivery of the AgNP content close to the nucleus for interaction
with the DNA causing the observed cell death.
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Figure 7-1. Proposed mechanism of action of Lipo-AgNP.
Lipo-AgNP is endocytosed and within the endosome which prevents early release of
AgNP within the liposome preventing AgNP from ionisation in the cytosol. The AgNP
from the liposome is thus released in the late endosome where it undergoes nuclear
translocation to cause DNA fragmentation. This signals activation of ATM which
phosphorylates CHK2 and subsequently activate p53. P53 in addition with the redox
imbalance caused by suppressed ROS and GSH level prevents interaction of Bcl-2
inhibition and Bax causing Bax to form a membrane pore on the mitochondria
resulting in cytochrome C release. This is followed by APAF1 oligomerisation and
interaction with cytochrome C to form the apoptosome which proteolytically activate
pro-caspase 9 forming caspase 9 that then induce activation of caspase 3 and 7
(Galluzzi et al., 2018).
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7.4

Lipo-AgNP mitigates AgNP-induced inflammation

While AgNP and Lipo-AgNP has both been shown to activate caspase 3 and7, LipoAgNP was found to significantly higher apoptosis when compared with AgNP at the
same concentration after 24 h. Here, it was shown that AgNP induced ROS generation
as previously demonstrated in several other studies (El-Hussein and Hamblin, 2017,
Xu et al., 2012, Lodeiro et al., 2017). However, Lipo-AgNP with its enhanced
cytotoxicity at the same AgNP concentration exhibited a ROS suppressive activity
both in THP1 monocytes and TDMs. Intracellular ROS generation that is induced by
internal factors such as metabolic processes or external factors such as
pharmacological agents is tightly coupled to inflammation, playing crucial role in
inflammatory diseases such as atherosclerosis, arthritis, diabetes and cancer (Forrester
et al., 2018). AgNP has been reported and demonstrated in various studies to induce
inflammation (Murphy et al., 2016, Fraser et al., 2018, Trickler et al., 2010),
implicating AgNP-induced ROS in the nanoparticle mediated inflammation. Although
there have been no human studies directly linking AgNP exposure to development of
inflammatory disease, AgNP-induced inflammation is still a cause for concern.
Suppression of ROS generation by Lipo-AgNP led to the hypothesis that Lipo-AgNP
may also suppress AgNP mediated inflammation. To test this hypothesis, THP1
monocytes and TDMs were exposed to AgNP and Lipo-AgNP. Monocytes and
macrophages are important component of the innate and adaptive immune system in
response to cellular invasion by pathogens and foreign particles. Upon recognition of
a pathogen or foreign particle, monocytes and macrophages secrete pro-inflammatory
cytokines which aids clonal expansion of specific subset of the immune system like
lymphocytes, recruitment of inflammatory cells like T-cells or activation of others
such as neutrophils to facilitate endocytosis, phagocytosis and cell killing of such
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pathogens (Arango Duque and Descoteaux, 2014). Macrophages generate high level
of ROS during chronic inflammation and in inflammatory diseases such as cancer and
the ROS generation is implicated in the release of cytokines seen in these diseases
(Kamp et al., 2011). Based on this, THP1 monocytes and TDMs were exposed to either
of AgNP or Lipo-AgNP to study the effect of these nanoparticles on cytokine release.
In THP1 monocytes, findings showed that AgNP induced significant release of IL-1β,
IL-6, IL-8 and TNF-α in comparison with control unexposed THP1 monocytes. On
the contrary, Lipo-AgNP maintained cytokine release level that was similar to that of
control untreated THP1 monocytes for all cytokines. This is an indication that LipoAgNP was able to suppress AgNP mediated release of the cytokines in a similar
fashion to what was observed in the ROS studies. Furthermore, AgNP and Lipo-AgNP
did not influence LPS-induced cytokine release except Lipo-AgNP inhibition of LPSinduced IL-6 release which was maintained at the level of control unexposed
monocytes.
In TDMs, both AgNP and Lipo-AgNP exposure resulted suppression of IL-1β and
TNF-α when compared to the control untreated cells, but it was found that IL-1β
release was more suppressed in AgNP exposed TDMs while TNF-α was more
suppressed in TDMs exposed to Lipo-AgNP. It is interesting to note that TNF-α
interaction with TNFR is a known activator of the extrinsic cell death pathway (Rauert
et al., 2011). As such, TNF-α dependent apoptosis induction is unlikely the pathway
activated by Lipo-AgNP especially as the endocytosis of Lipo-AgNP may have also
resulted in endocytosis of TNFR death receptor preventing activation of this pathway.
Unfortunately, the limitation of ELISA used in determining expression of these
cytokines in this study prevent determination of their cellular localisation.
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For IL-6, while the release was not significantly higher, AgNP exposure caused a
considerable release of the IL-6 in TDMs (p = 0.5875). Just as observed in the
monocytes, AgNP exposure cause enhanced the release of IL-8 in comparison to LipoAgNP exposure which caused similar release levels as that in control untreated cells.
As observed in the monocytes, both AgNP and Lipo-AgNP did not suppress LPS
induced cytokine release in the TDMs. Monocytes generally require cytokines like IL1β for activation and maturation, while macrophages produce IL-1β to recruit immune
cells to cite of inflammation. The difference in cytokine release pattern in the
monocytes and TDMs may thus be attributable to difference in functional cytokine
requirement and protein expression pattern of both cell lines. In addition, method by
which the TDMs were obtained via PMA differentiation may also impact the cytokine
release profile of the TDMs.
Lipo-AgNP successfully inhibited AgNP-induced release of IL-8 both in THP1
monocytes and TDMs. IL-8 is a chemokine that serves as chemoattractant for immune
cells towards site of infection or inflammation, and it also has a tumour promoting role
(David et al., 2016). Not only was AgNP induced IL8 release higher than that of
control unexposed cells, it was similar to the levels both in THP1 monocytes and
TDMs, suggesting AgNP might enhance both favourable and unfavourable chemokine
activities of IL-8.
IL-1β, IL-6 and TNF-α play central role in chronic inflammation especially in tissue
injury, cancer and inflammatory diseases like arthritis and atherosclerosis (Mori et al.,
2011, Poh and Ernst, 2018). IL-1β, IL-6 and TNF-α may activate NF-κβ or STAT-3,
transcriptional factors that activate transcription of inflammatory genes, thus
perpetuating inflammation. In fact, there is evidence that TNF-α induced activation of
NF-κβ can induce IL-6 secretion which in turn activates STAT-3 and induce
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expression of STAT-3 target genes (McFarland et al., 2013). There is also a report of
NF-κβ interaction with STAT-3 to induce expression of myriad of inflammatory
cytokines such as IL-1β and IL-6 as well as transcriptional factors like STAT-3 and
JAK-2 creating a feedback loop for STAT-3 activities in the IL-6/STAT-3 pathway
(Ji et al., 2019). It was demonstrated here that exposure to AgNP in both TDMs and
THP1 monocytes correlates with STAT-3 expression while Lipo-AgNP exposure did
not affect STAT-3 protein expression. Put together, it is not implausible that repeated
AgNP exposure may favour chronic inflammation and subsequent disease
development or progression due to activities of IL-6/STAT-3 pathway. On the other
hand, the inhibitory effect of Lipo-AgNP on the cytokine release both in THP1
monocytes and TDMs highlights the potential of the nanoparticle in suppression of
chronic inflammation preventing progression of inflammatory diseases. Due to the
limitations of the ELISA methods as to its indifference in identifying the different
forms of STAT-3 (active and inactive), an overestimation of STAT-3 expression might
have resulted.
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8

Conclusions

This thesis has demonstrated that AgNP can be successfully encapsulated within
DPPC-based liposome using both probe sonication and extrusion methods. However,
data from characterisation studies carried out on both encapsulates obtained by both
preparation methods indicated the extrusion method produced a more stable liposomal
AgNP, which also exhibited a significantly more cytotoxic effect on THP1 monocytes
in comparison with that obtained by probe sonication method or the free unmodified
AgNP in very low concentrations. A probe into the mechanistic detail of Lipo-AgNP
revealed that low concentration of Lipo-AgNP unlike AgNP as employed in this study
suppressed ROS generation but activated caspase-dependent cell death in both THP1
monocytes and TDMs. From the data obtained in this study, the observed ROSindependent caspase activation was believed to be caused by DNA damage, Bcl-2
inhibition and redox imbalance caused by suppression of GSH upon exposure to LipoAgNP. While Lipo-AgNP was found to be more cytotoxic on both THP1 monocytes
and TDMs, findings into the effect Lipo-AgNP on AgNP-dependent cytokine release
indicated that Lipo-AgNP suppressed AgNP induced inflammation especially in
THP1 monocytes. In TDMs however, Lipo-AgNP generally suppressed cytokine
release but only AgNP-dependent release of IL-6 and IL-8 were suppressed by
encapsulation while both AgNP and Lipo-AgNP suppressed IL-1β and TNF-α release
in the TDMs.
In summary, this study has demonstrated Lipo-AgNP could be used to enhance AgNP
cytotoxicity while at the same time suppress AgNP induced inflammation in THP1
monocytes and TDMs. Considering the role of macrophages for instance in cancer and
arthritis, Lipo-AgNP may serve as a potential therapeutic that not only target
inflammation induced within the tumour microenvironment and the inflamed pannus
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of rheumatoid arthritis. In addition, Lipo-AgNP has an established antibacterial
activity on wide range of bacteria as alluded to in earlier chapters. As such, LipoAgNP may be a novel way of treating inflammatory diseases aggravated by bacterial
infection such as ulcerative colitis and Crohn’s disease tackling both the bacterial
colonisation as well as the chronic inflammation.
One major limitation of the methods and approach of the studies in this thesis was
identification of the possible mechanistic processes involved in Lipo-AgNP and AgNP
mode of action within the cell, but not sorting to proof these processes. For instance,
IL-1β, IL-6 and TNF-α were investigated based on the suspicion of the inflammatory
roles of AgNP which might involve these inflammatory cytokines. It is quite possible
that other cellular factors might be involved in the mechanism of action of AgNP and
Lipo-AgNP which may be further probed within the context of various experimental
models to yield an in-depth information on the possible biological role of this
nanoparticle in health and disease state.
8.1

Future studies

One of the main aims of this thesis was to encapsulate AgNP in a DPPC-based
liposome to improve its delivery and enhance its cytotoxicity and study the mechanism
of action of Lipo-AgNP. A probe into the mechanistic detail of Lipo-AgNP action
revealed that exposure to Lipo-AgNP concentration lower than the IC50 caused
significant DNA damage to interrupt the cell cycle progression, inhibited Bcl-2
expression and suppressed ROS and GSH levels subsequently causing activation of
caspase 3 and 7. Lipo-AgNP was also found to suppress AgNP induced inflammation
in the same manner as the ROS. One of the things to further investigate might be to
investigate if AgNP induced ROS is directly responsible for the inflammation by
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exposing Lipo-AgNP exposed cells to an ROS inducer such as hydrogen peroxide and
evaluate the cytokine release.
This thesis highlighted some factors in the intrinsic apoptosis pathway that were
modulated by Lipo-AgNP. It was shown here that Lipo-AgNP suppressed ROS, a key
stimulus of caspase dependent apoptosis, followed by inhibition of Bcl-2 indicating
possibility of a compromise of mitochondrial integrity leading to cytochrome C
release. As such, the effect of Lipo-AgNP on mitochondria integrity need to be
evaluated by examining the mitochondrial membrane and evaluating cytochrome C
release in addition to apoptosome formation. While the GSH level of exposed cell was
evaluated in this thesis, there is need for caution in interpreting the results. Evaluating
the GSSG to GSH ratio in combination with the ROS levels may paint a more accurate
picture of the redox status of the cells.
Lipo-AgNP has been demonstrated to have anti-inflammatory properties, it’s in vivo
efficacy needs to be studied. Several animal models of RA have been developed
(Fischer et al., 2017) and these can be utilised to investigate anti-inflammatory
properties of Lipo-AgNP. For example, Lipo-AgNP could hypothetically be targeted
at the inflamed joint especially RA joint that has formed pannus where aggressive
macrophages and other inflammatory cells have localised. Lipo-AgNP could therefore
exert its cytotoxic effect on the immune cells while at the same time suppress the
inflammation.
Cytotoxicity of Lipo-AgNP was only tested on THP1 monocytes and TDMs as such
there is a need to test Lipo-AgNP on a panel of cancer cell lines to investigate if it
possesses enhanced activity and efficacy on the cancer cells in comparison to AgNP
especially using cells which AgNP has been tested on. In addition, in vivo potential of
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Lipo-AgNP need to be evaluated as different animal models are available for cancer
studies (Cekanova and Rathore, 2014). Lipo-AgNP can be administered locally at
tumour site to assess resection in tumour size. One major setback in the in vivo
application of Lipo-AgNP will be the lack of specificity during systemic
administration, making the nanoparticle potentially cytotoxic to normal cells. Here, it
will be worth considering improving Lipo-AgNP to a targeted delivery system. This
may involve conjugating moieties such as ligands like peptides or antibodies against
receptors highly expressed on cancer cells or macrophages known to be present within
the tumour microenvironment or RA joint. Furthermore, Lipo-AgNP can be trialled
on a tumour model for targeted delivery to the tumour tissue.
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Appendices
Appendix A1: Table of materials and reagents
CAS/Cat Number

Manufacturer

Storage
Temperature
(oC)*

Dilution
factor#

7761-88-8

Sigma
Aldrich/Merck
(Dublin, Ireland)

RT

-

sodium borohydride
(NaBH4)

16940-66-2

Sigma
Aldrich/Merck
(Dublin)

RT

-

dipalmitoyl
phosphatidylcholine
(DPPC)

63-89-8

Sigma
Aldrich/Merck
(Dublin, Ireland)

-80

-

57-88-5

Sigma
Aldrich/Merck
(Dublin, Ireland)

-20

-

25535-16-4

Sigma
Aldrich/Merck
(Dublin, Ireland)

4

-

sodium azide (NAN3)

26628-22-8

Sigma
Aldrich/Merck
(Dublin, Ireland)

RT

-

Phorbol 12-myristate
13-acetate (PMA)

16561-29-8

Sigma
Aldrich/Merck
(Dublin, Ireland)

-20

-

IL-1β
converting
enzyme
(ICE)
inhibitor, Ac-YVADCMK

178603-78-6

Sigma
Aldrich/Merck
(Dublin, Ireland)

-20

-

lipopolysaccharide
(LPS) from E. coli
0111:B4

LPS25

Sigma
Aldrich/Merck
(Dublin, Ireland)

-20

-

Polymyxin B

1405-20-5

Sigma
Aldrich/Merck
(Dublin, Ireland)

-20

-

67-66-3

Fischer
Scientific
(Dublin, Ireland)

RT

-

Reagent

Silver
(AgNO3)

nitrate

cholesterol

propidium
(PI)

Chloroform

iodide
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Human IL-1β ELISA
kit

HUFI00164

ELISAGenie
(Dublin, Ireland)

4

-

Human
ELISA kits

HUFI00262

ELISAGenie
(Dublin, Ireland)

4

-

Human IL-6 ELISA
kit

HUFI00180

ELISAGenie
(Dublin, Ireland)

4

-

FIRELISA Human
BCL-2 ELISA kit

ELISAFNHU00475

ELISAGenie
(Dublin, Ireland)

4

-

Human Bax ELISA
Kit

HUFI00482

ELISAGenie
(Dublin, Ireland)

4

-

Human
STAT-3
ELISA Kit

HUFI00437

ELISAGenie
(Dublin, Ireland)

4

-

613408

Bio-Legend UK
through
MSC
(Dublin Ireland)

4

1:100

DAL1025

ThermoFischer
Scientific,
through
Biosciences
LTD
(Dublin,
Ireland)

4

1:10

C400

ThermoFischer
Scientific,
through
Biosciences
LTD
(Dublin,
Ireland)

-20

-

C10740

ThermoFischer
Scientific,
through
Biosciences
LTD
(Dublin,
Ireland)

-20

-

Calcein-AM dye

1475337

ThermoFischer
Scientific,
through
Biosciences
LTD
(Dublin,
Ireland)

4

-

Human IL-8 ELISA
MAX™ Deluxe

431504

Biolegend,
London, UK.

4

-

Thiol TrackerTM

T10095

ThermoFischer
Scientific,

-20

-

TNF-α

Alexa Fluor® 647
anti-H2AX Phospho
(Ser139) antibody

Alamar blue

Carboxy-DCFDA
dye

CellEvent Caspase3/7 Green Detection
Reagent and SYTOX
AADvanced
Dead
Cell Stain

206 | P a g e

through
Biosciences
LTD
(Dublin,
Ireland)

Phosphate
saline tablet

buffer

P4417

Sigma
Aldrich/Merck
Dublin, Ireland

RT

T75 flask

VWR,
Ireland

5 ml, 10 ml amd 25
ml pipettes

VWR, Dublin
Irelaand

-

35 mm Confocal dish

VWR,
Ireland

-

Adenosine
triphosphate (ATP)

A2383

Dublin

1 tablet per
200
ml
distilled
deionsed
water
(ddH2O)
-

Dublin

Sigma
Aldrich/Merck
Dublin, Ireland

-20

-
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